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The absorption, metabolism and elimination of
paracetamol was investigated in healthy subjects after
therapeutic doses and also in patients with paracetamol
overdosage, some of whom developed liver damage. Paracet¬
amol disposition was also studied in rela.tion to treat¬
ment with N-acet.ylcysteine (NAG),cysteamine and methionine,
which were used to prevent paracetamol hepatotoxicity.
Sensitive, specific and reproducible analytical
methods were developed for the estimation of paracetamol
and its sulphate, glucuronide, mercaoturic acid and cyst¬
eine conjugates in plasma and urine. These methods, which
employed high-performance liquid chromatography, were
significant improvements on existing procedures, especially
in terms of simplicity and total assay times. N
Following a therapeutic dose, absorption and metabol¬
ism of paracetamol was rapid and essentially complete.
Paracetamol metabolism showed wide but reproducible individ¬
ual variation. NAC had little appreciable effect on
paracetamol elimination after a therapeutic dose but may
have delayed absorption.
The renal clearance of paracetamol was very low,in¬
dicating extensive renal tubular reabsorption whereas that
of the sulphate and glucuronide conjugates was high ,
suggesting active tubular secretion. The mercapturic
acid and cysteine conjugates were probably also actively
secreted since they were not measureable ( <C 1 fig/ml) in
plasma. Renal clearance of paracetamol and its conjug¬
ates wan not appreciably altered at high plasma concentrat¬
ions following overdosage.
Following overdosage, paracetamol elimination was
rapid but prolonged relative to therapeutic dosage,
particularly in patients who developed severe liver
damage. The proocrtions of overa.ll drug recovery excreted
as the sulphate and glucuronide conjugates were lower
and higher respectively, indicating saturation of sulphate
conjugation. Also, the proportion excreted as the mercap-
turic acid and cysteine conjugates was increased in
patients who developed severe liver damage.
Early treatment of paracetamol overdosage with NAG
was associated with reduced hepatotoxicity, enhanced
formation of paracetamol sulphate, increased excretion
of the mercapturic acid and cysteine conjugates and
decreased plasma paracetamol half-life. Cysteamine
treatment also resulted in reduced toxicity and enhanced
formation of paracetamol sulphate but decreased
excretion of the mercapturic acid and cysteine conjugates.
Methionine had little appreciable effect on the metabolism
of paracetamol and was the least effective treatment.
NAG probably protects the liver by "unsaturating"
sulphate conjugation and assisting removal of the toxic
intermediate metabolite of paracetamol by direct conjug¬
ation and/or repleting hepatic glutathione. Cysteamine
apparently inhibits the microsomal oxidation of
paracetamol to its toxic intermediate metabolite.
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The analgesic and antipyretic activity of
acetanilide, phenacetin and paracetamol (Fig. I) was
first recognised towards the end of the last century.
Paracetamol was little used as an analgesic until after
it was discovered to be the major metabolite of both
acetanilide and phenacetin (Brodie and Axelrod 1948aT
1949).This suggested that the analgesic effect of these
two drugs may have been due to the paracetamol (Greenberg
and Lester 1946; Brodie and Axelrod, 1949). The
haematotoxic effects of acetanilide and phenacetin are
not shown by paracetamol and this has led to its
increasing use over the last 20 years as an alternative
to salicylates, which have considerable toxicity
(Prescott and Thompson, 1971; Prescott, 1975, 1977, 1979).
The "over-the-counter" availability of paracetamol
and growing public awareness of the gastro-intestinal
side-effects of aspirin have resulted in declining
consumption of aspirin while paracetamol takes an
increasing share of the market for mild analgesics
(Prescott, 1979). Paracetamol either alone or in
combination with other drugs accounted for about half
the sales of "over-the-counter" mild analgesics and more
than double the quantity of aspirin prescribed in
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Fig* 1 Structural similarities between Phenacetin (l)r
Acetanilide (2) and Paracetamol (3).
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England and Wales during 1973/74 (Spooner and Harvey,
1976).
With the increased use of paracetamol there have
"been increasing reports of overdosage, from which the
mortality rate is about 2 - 3$ (Volans, 1976). Death
usually results from fulminant hepatic failure following
massive hepatic necrosis (Davidson and Eastham 1966).
Thus paracetamol, a remarkably safe drug at low doses,
is potentially lethal after a large overdose. With
large doses paracetamol is converted to a reactive
metabolite which binds covalently to liver cell
macromolecules (Mitchell et al 1973a; Jollow et al
1973).
The treatment of paracetamol overdosage has included
attempts to remove the drug by dialysis, enhance
excretion by diuresis and reduce covalent binding
with agents which bind the reactive metabolite of
paracetamol. (Farid et al, 1972; Maclean et al, 1968;
Prescott et al, 1974, 1979 ; Crome et al, 1976).
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( 2 ) Pharmacology
Paracetamol exhibits antipyretic, analgesic, and
to a much lesser extent, anti-inflammatory actions
(Beaver,1965, 1966). It is ineffective against severe
pain but useful against headache, musculo-skeletal
pains and, to a.lesser extent, rheumatic complaints.
The mechanism of action of some ahtipyretic
analgesics appears to be inhibition of prostaglandin
synthesis (Perreira and Vane, 1974). This inhibitory
action varies greatly for different drugs at different
sites (Flower,1974) and probably explains the
variability in pharmacological action of these drugs.
The relative lack of anti-inflammatory action of
paracetamol was attributed by Flower and Vane (1972)
to the fact that paracetamol inhibits prostaglandin
synthesis strongly in central nervous tissues, eg
the hypothalamus,where whole body tempere.ture is regulated,
but weakly in peripheral tissues where local inflammation
may be generated (Ferreira. and Vane, 1974). Salicylates,
which are effective anti-inflammatory agents, strongly
inhibit prostaglandin synthesis at both sites.
Prostaglandins are widely accepted as being associated
with inflammation, pyrexia and pain (Ferreira and Vane,
1974).
The dose-resoonse of paracetamol as an analgesic
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antipyretic in humans is well established. Plinn and
Erodie (1948) investigated the effect of paracetamol
on the threshold of pain produced by heated needles.
They demonstrated that 325 mg taken orally increased
the threshold significantly for about 3 hours and
that a dose of Ig was not much more effective.
Wallenstein and Houde (1954) used a subjective
estimation of "relief scores" in patients with cancer
pain and showed 600mg paracetamol orally to be as
effective as aspirin and significantly more effective
than placebo and salicylamide. A similar study by
Moertel et al (1972) showed aspirin to be more effective
than paracetamol but the differences were not
statistically significant. Batterman and Grossman
(I955)» studying the long term use of paracetamol
in subjects with musculo-skeletal pain, demonstrated
the analgesic effect of 300 - 600 mg doses four times
a day for periods of up to 25 weeks. Thus tolerance
does not appear to occur with paracetamol. They also
noted the lack of effect in rheumatic patients and this
was confirmed by Hajnal et al (1959).
The antipyretic action of paracetamol was invest¬
igated by Colgan and Mintz (1957) in children with
temperatures above 102°P due to various conditions.
A comparison using age-related doses was made with
aspirin showing that both drugs were effective anti-
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pyretics with maximum effect after about three hours.
Anti-diuretic action has been demonstrated in
patients with diabetes insipidus using normal doses of
paracetamol (Nusynowitz and Forsham, 1966). The
mechanism of action is unclear but paracetamol was
found to increase the rate of water transport across
toad bladder (Nusynowitz et al, 1966).
(3) Contra-Indications and Adverse Reactions
Paracetamol is generally well tolerated in thera¬
peutic doses. Doses of up to 3.6g daily for periods
of up to 116 weeks were better tolerated than aspirin
and produced no evidence of blood, kidney or liver
disturbances in patients with musculo-skeletal complaints
(Batterman and Grossman, 1955). In febrile children
receiving "therapeutic" doses of paracetamol four
times daily for two weeks a similar lack of side-effects
was noted (Colgan and Mintz, 1957). Methaemoglobinaemia
occurs with acetanilide and phenacetin but has not
been described with paracetamol (Prescott and Thomson,
1974; Prescott, 1975)- Agranulocytosis, a much more
serious haemotoxic effect, has been described in a
single patient taking paracetamol regularly for some
months (Lloyd, 1961).
The term "Analgesic Nephropathy" has been
ascribed to toxic effects on the kidney after chronic use
3
of excessive doses of mild analgesics, usually with
particular reference to phenacetin (Murray and Goldberg,
1975; Mitchell et al, 1977). Prescott (1965) compared
the effects of paracetamol,phenacetin, aspirin and
caffeine on the urinary excretion of renal tubular and
blood cells. There was some evidence of mild
nephrotoxicity with all the drugs but particularly
aspirin. Paracetamol appeared to be the least toxic.
No adequately documented case of analgesic nephropathy
has yet been attributed to paracetamol alone
(Prescott, 1979). In a study of the chronic use of
paracetamol in middle-aged subjects, Edwards et al
(1971) discovered no correlation between renal
impairment and ingestion of amounts up to 30 kg
over a period of years.
Paracetamol rarely causes allergic reactions but
a case of fixed drug eruption attributed to paracetamol
has been described (Wilson, 1975). In contrast to
aspirin, paracetamol does not cause gastric irritation,
erosions and bleeding or effects on platelet aggregation
(Mielke and Britten, 1970).
Paracetamol is not extensively bound to plasma
protein at therapeutic concentrations (Gazzard et al,
1973) and will therefore be unlikely to cause interactions
by displacing other extensively bound drugs.
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Ea.de end lasagna (1967) studied subjective side-
effects of paracetamol and phenacetin in relation to
effects on mood, energy and mentation in healthy
volunteers. Paracetamol produced the least number
of unwanted secondary actions and ws.s almost equiv¬
alent to placebo.
4) Absorption, Distribution, Metabolism and Excretion.
Absorption: Paracetamol is taken orally as tablets
or elixir and is normally rapidly absorbed from the
gastro-intestinal tract. In 8 fasted healthy subjects,
mean plasma paracetamol concentrations of 17.8 - 87.7
jug/ml were obtained 30 minutes after ingesting 2g of
6 commercial preparations on different occasions
(Richter and Smith, 1974). Nimmo et al (1975) found
peak concentrations of 20.0 - 1.8 jug/ml 15 - 30 minutes
after administering 20 mg/kg of paracetamol in
aqueous solution to healthy subjects.
Most drugs are absorbed by passive diffusion in
the unionised state (Levine, 1970). Paracetamol is a
very weak acid with a pKa of 9-5, and therefore exists
almost totally unionised in the gastro-intestinal
tract, where the pH varies from I - 2 in the stomach
to a maximum of about 6 - 7 in the duodenum and 8
towards the large intestine. Weikel and lish (1959)
found that the rate of paracetamol absorption in rats
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was dependent on the gastric emptying rate since the
major absorption site was the small intestine. This
pattern was verified in man by Heading et al (1973).
McGilversy and Mattok (1972) found a similar
delay in reaching peak levels (which were also lower)
when comparing oral doses in fasting and non-fasting
subjects. No difference was found in the total
amount of drug absorbed. Paracetamol absorotion can
also be influenced by the co-administration of other
drugs. Nimrao et al (1973a) showed that propantheline
(which inhibits gastric motility) and metoclopramide
(which stimulates gastric peristalsis) slow and enhance
respectively the rate of absorption. The implications
may be important in relation to paracetamol toxicity
after overdosage.
Distribution: In dogs given 2.7g of phenacetin orally,
paracetamol, its major metabolite, was found to be
fairly evenly distributed throughout the tissues with
the highest concentrations to be found in the kidneys,
blood and liver (Brodie and Axelrod, 1949)• Gwilt et al
(1963) confirmed these results in dogs given 300 mg/kg
paracetamol orally and noted that fat contained much
lower concentrations than other tissues. In man,
paracetamol was distributed between red blood cells and
plasma in a ratio of 1.06 for concentrations between
1 and 25 jug/ml. Glynn a^d Bastain ( 1973) found a
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good correlation "between levels of paracetamol in
plasma and saliva and. Gazzard et al ( 1973) observed
no binding to human plasma proteins at concentrations
below 80 jug/ml and only 15% binding at 280 p.g/ml.
Intracellular distribution has been studied in
animals with regard to toxic effects on the kidney
(Duggin and Mudge, 1976; McMurtry et al, 1976) and
the liver (Jollow et al,1973).
Metabolism: For most drugs, the primary sites of
elimination are the liver (metabolism end biliary
excretion) and kidney (excretion). Drugs absorbed from
the gastro-intestinal tract pass directly to the liver
and thence to other organs and sites of action. Thus
many drugs taken orally will undergo considerable
hepatic metabolism before reaching the systemic
circulation. This "first-pass" metabolism of paracetamol
in rats removes up to half the paracetamol delivered
to the liver, depending on the rate of its delivery
(Cohen et al, 1974). The fraction of paracetamol normally
removed by first-pass metabolism in man was estimated
by Chiou ("1975) and Forrest et al (1977) to be
0^102 and 0.15 respectively. Rawlins et al (1977)
observed incomplete bioavailability of paracetamol
after oral administration to volunteers and concluded
that "first-pass" metabolism was likely to account for
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this.
Large amounts of giucuronvl transferases and
sulphotransferases together with their cofactors
UDP-glucuronic acid and active sulphate (PAPS) are
present in the gut and liver. These enzymes convert
paracetamol to its phenolic glucuronide and sulphate
conjugates. The mixed function oxidase system is
also principally located in the liver and performs
a variety of oxidative actions, including the addition
of oxygen to aromatic molecules to form epoxides and
the hydroxylation of aromatic amino groups. Both
these actions are potentially damaging to the cell
since the products can be highly reactive and bind
covalently to macromolecules leading to cell necrosis
(Judafa et: alr 1970)aThis occurs with paracetamol (Mitchell
et al,1973a) and will be discussed further in the
following chapter on toxicity.
However, other enzyme systems such as the
glutathione-S-transferases may deactivate these toxic
metabolites (Boyland and Chasseaud, 1969). Addition
of glutathione to the substrate results in a non-
reactive conjugate from which glycine and glutamic
acid are often lost to form the cysteine conjugate.
Acetylation of the amino group of cysteine results in
the formation of mercapturic acid conjugates.
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The above reactions account for the metabolism
of most of a dose of paracetamol in animals and man
(Fig. 2). In humans, the amounts of paracetamol sulphate
and giucuronide conjugates recovered in urine normally
account for 20 - 30$ and 45 - 60^ respectively of a
therapeutic dose. Only 5$ or less is recovered as
free drug (Cummings et al, 1967; Jagenburg et ai, 1968;
Levy and Yamada, 1971). The cysteine and mercapturic
acid conjugates, normally together account for up to
10$ of the dose (Jagenburg et al, 1968; Mitchell et al,
1974). Other minor metabolites include 3-hydroxy and
3-methoxy paracetamol sulphates and glucuronides
(Mrochek et al, 1974; Andrews et al, 1976) and
3-methylthioparacetamol (Klutch et al, 1978).
The relative amounts of each metabolite excreted
in urine differ considerably after overdosage and
normal dosage. In overdosage, Prescott and Wright
(1973) found that about 15$ was excreted as unchanged
drug. Howie et al (1977) observed that in patients
with severs liver damage after overdosage,proportionally
less was excreted as the sulphate and more as the
cysteine and mercapturate conjugates. Knox and Jurand
(1977, 1978) reported the presence of considerable
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Cystei'" e Merc CLpturate
Pig. 2 Metabolism of Pax*acetamol in Man. (Modified from
Mitchell et al, 1974; Andrews et al, 1976).
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Much attention has "been foeussed on N-cxidation
of paracetamol an^ similar aromatic amino- and acetyl&mino-
compoands. Such oxidation by cytochrome P-450 - depen¬
dent mixed function oxidases is thought to be the
first step in the cytotoxicity often associated with
aromatic amino compounds, including paracetamol
(Potter et si, 1973? Thorgeirsson et al, I973» 1975;
Hinson et al, 1974).
Urinary Excretion:
The elimination half-life of paracetamol after
therapeutic doses in normal subjects is ii - 3 hours
with a mean value of about 2 hours (Neuson and Morioka,
1963; Cummings et al, 1967; Prescott et al, 1968, 1971).
Cummings et al (1967) found a parallel relationship
between semilogsrithmic plots of the urinary excretion
rate versus time after dose for paracetamol and its
sulphate and glucuronide conjugates. Thus paracetamol
elimination appears to be limited by the rate of
formation of its conjugates. The rate constants of
excretion of the sulphate and glucuronide conjugates
were considerably greater than for their formation
and the excretion rate constant for unchanged drug
was very small (Cummings et al, 1967; Prescott and
Wright, 1973).
Prescott and Wright (1973) showed in man that the
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renal excretion of unchanged paracetamol was dependent
on urine flow rate whereas the sulnhate and glucuronide
conjugates were actively secreted and renal clearance
was therefore indeoendent of flow. This was confirmed
by Duggin and Mudge (1975) in dop-s. The unchanged drug
a.poeared to he filtered and reabsorbed by passive
diffusion so that the excretion rate was low and dependent
on urine flow rate. Changes in urine pH had no effect
on excretion. These findine-s are exclaimed bv the
lipid solubility of paracetamol and the fact that the
molecule is practically unionised over the physiological
range of urine pH. The conjugates are actively secreted
and, due to their high water solubility, are not
extensively reabsorbed. Thus their renal clearance was
s-reater than the glomerular filtration rate (Prescott
and Wright, 1973).
5") Toxicity of Paracetamol:
Introduction
Paracetamol hepato-toxicity was first described in
cats (Eder, 1964) and later in rats (Boyd and Bereckzy,
1966) and at about this time the earliest reports of
severe liver damage after overdosage in man appeared
(Davidson and Eastham, 1966; Thomson and Prescott, 1966).
Subsequent reoorts confirmed these findings (Rose,
1969? Proudfoot and Wright, 1970; Prescott et al, 1971;
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Clark et si, 1973). Histological examinetion of the
liver showed acute centrilobulsr hepatic necrosis. In
severe cases necrotic areas coalesce, sometimes
resulting in total liver failure and death. In less
severe cases regeneration begins soon after overdosage
and normal structure and function is usually restored
within 7-28 days. Acute renal tubular necrosis may
occur but is less common (Prescott, 1978).
Individual susceptibility to paracetamol toxicity
varies widely (Mitchell, 1977)» Complete recovery has
been claimed after a dose of 75g but there was no
biochemical evidence that paracetamol had been taken at
all (Chakrabarti and Lloyd, 1973). On the other hand
Wilson et al (1978) reported the death of an adolescent
after an estimated dose of only 6 - 9 gt (confirmed by
plasma paracetamol concentrations) taken together with
phenobarbital.
Mechanisms of Toxicity;
a) Covalent Binding and Cell Necrosis:
The mechanism of paracetamol toxicity was elucidated
by Mitchell and his co-workers (Mitchell et al, 1973a,
1973b; Jollow et al,1973; Potter et al, 1973). They
demonstrated the role of paracetamol metabolism by
cytochrome P-450-dependent mixed function oxidases
and implicated an intermediate metabolite as the
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indirect csusp of centrilobular hepatic necrosis. The
extent of damage was dose-dependent and could "be
altered by modifying the activity of the cytochrome
P-450-deDendent oxidation system. Animals pre-treated
with phenobarbital, (which induces this enzyme system)
showed significantly greater liver damage with paracetamol
compared with non-pretreated animals. The reverse was
found with a mixed-function oxidase inhibitor
(piperonyl butoxide) and an inhibitor of cytochrome
P-450 synthesis (cobaltous chloride).
Jollow et al (1973) showed that administration of
■^H-labelled paracetamol to mice resulted in the covalent
binding of a small proDortion of radio_activity to cell
macromolecules. The metabolite was bound almost entirely
in liver cells although later work showed similar
affinity for liver and kidney cells (Mitchell et al,
1977). Within the cells binding is localised particularly
to the endoplasmic reticulum. Mudge and Duggin (1976)
and McMurtry et al (1976) have shown that dose-dependent
covalent binding of a. paracetamol metabolite can occur
in the kidney in response to cytochrome P-450-dependent
enzyme induction.
The relationship between reactive metabolite
toxicity in the liver and other tissues has been discussed
from a pharmacokinetic viewooint by Gillette (1974).
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Covalent "binding which causes loss of metabolic activity
in the liver may switch activity to other sites, such
as the kidney, thus setting uo a new site for covalent
binding and cell necrosis. A second possibility is
the migration of reactive metabolite to other sensitive
sites. This was thought to be unlikely in the case of
paracetamol (Jollow et al, 1973; Mudge and Duggin, 1976;
Mitchell et al, 1977) although recent studies suggest
otherwise (Healey et al, 1978; Gemborys et al, 1978).
b) Role of Glutathione
Hepatotoxic doses of oaracetamol deplete hepato¬
cellular glutathione and, when stores are reduced by
about 70$, covalent binding and cell damage increase
dramatically (Mitchell et al, 19731)• A similar
relationship was found in kidney cells (McMurtry et al,
1976). Mitchell et al (19731) also showed that mice
pretreated with diethyl maleate (which depletes
-glutathione) are more sensitive to the hepatotoyicity
of paracetamol. Conversely pretreatment with
cysteine, a glutathione precursor, orotects against
covalent linding and liver damage (Mitchell, 19731;
Strulelt et al, 1971).
Davis et al (1974) investigated species differences
in susceptibility to paracetamol toxicity. They found a
direct correlation between the rate of hepatic glutathione
20
deDiet ion end the rote of covalent "binding end severity
of necrosis oroduced "by similar dose levels in mice and
hamsters (susceptible) and rats, guinea nigs and rabbits
(relatively resistant). Jollow et el (1974) compered
the metabolism of paracetamol in mice, hamsters e^d rats
and found larger orooortions excreted as the mercapturic
acid conjugate in species highly susceptible to paracetamol
toxicity, such as hamsters. Increasing the dose
resulted in increasing excretion of paracetamol
mercaoturic acid conjugate until a plateau was reached,
indicating maximum depletion of glutathione stores. A
similar plateau in paracetamol sulphate excretion was
%
also found, suggesting the dependence of both pathways
on the same precursors.
The relevance of glutathione depletion to the
hepatotoxicity of paracetamol in humans was demonstrated
by Mitchell et al (1974) who showed that with increasing
doses of paracetamol the proportions of glutathione-
derived metabolites excreted in urine increased corr¬
espondingly. The toxic dose of paracetamol in mice
was extrapolated to man and it was estimated that a
dose of I5g was likely to produce hepatotoxicity in
humans. Thus the remarkable safety of paracetamol in
therapeutic doses is attributable to the ability of the
glutathione-conjugating system to ina.ctivate the toxic
arylating metabolite.
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c) Time Course of Toxicity:
Maximal covalent "binding of paracetamol to macro-
molecules occurs within two hours in mice, well after
peak olasma paracetamol concentrations and after
glutathione stores have been depleted (Jollow et al,
1973; Mitchell et al, 1973b). However, biochemical
a^d histological evidence of cell damage is not apparent
in mice for at least 3 hours (Mitchell et al, 1973a)
and in man for 12 - 72 hours after a hepatotoxic dose
(Prescott, 1975; Davis et al, 1976).
d) N-hydroyylation:
Of the variety of oxidative reactions involving
cytochrome P-450-dependent enzymes, N-hydroxylation is
the most likely to be responsible for paracetamol
toxicity. Thorgeirsson et al (1973) demonstrated that
N-hydroyylation of 2-acetylaminofluorene, a carcinogen,
is dependent on this enzyme system and Davis et al (1974)
noted that hamsters, which are very susceptible to
2-acetvlaminofluorene toxicity, produce large amounts
of the N-hydroxy derivative. However, guinea pigs
are resistant to 2-acetylaminofluorene toxicity and
produce little N-hydroxy compound. Thorgeirsson et al
(1975) found that mice with genetic loss of the ability
to increase cytochrome P-150-denendent enzymic
oxidative capacity were less susceptible to paracetamol
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2-a.cetylaminof luorene toxicity than nonsl nice.
Also, pretreatrnent with enzyme inducers produced no
effect on N-hyd roxy-2-acetylamiri of luorene excretion.
More indirect evidence in favour of N-hydroxyoaracetamol
as a precursor to cytotoxicity is the low toxicity of
the N-methvl analogue of paracetamol (Jollow et al, 1974;
Nelson et al, 1978) which must he demethylated before
N-oxidation can occur.
A complex scheme implicating N-hydroxylation as
the first step in oaracetamcl toxicity was suggested by
Gemborys et al (1978). N-hydroxyparacetamol probably
rearranges to the highly reactive N-acetyl-p-benzoquin-
oneimine with loss of water (see Figs 2 and 3) and this
may explain why glutathione conjugates of paracetamol
are substituted in the 3-aosition (Calder et al, 1971).
The 3-DOsition carbon will exhibit electroohilic
orooerties and attract nucleophiiic divalent sulphur,
such as in sulphydryl compounds and nucleophiiic centres
of macromolecules (Fig 1).
Mulder et al (1977, 1978 ) suggested that
N-hydroxylation may be only the first steo towards
toxicity . Other enzymic reactions such as sulphstion
or deacetylation may be involved before covalent
binding to macromolecules occurs. Recently, Hinson et al
(1979) found that N-hydroxyparacetamol can be formed
from phenacetin by microsomal oxidation but evidence for








(4) Detoxification of (3) with sulphydryl
compounds (RSH) eg Glutathione
Fig. 3 : Suggested fate of paracetamol following
N-Hydroxylation (after Gemborys et al, 1978).
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Key Ac = CH^CO
(1) N-Acetyl-p-benzoquinoneimine
(2) Glutathione or Macromolecule
(X = CH^ or H)
(3) 3 - Substituted Paracetamol
Fie;. 4: 3-Substitution of Paracetamol in glutathione
conjugation and covalent binding to
macromolecules.
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e) Toxic Dose and Liver Function:
Paracetamol hepatotoxicity results in changes in
the ability of the liver to carry out its normal funct¬
ions. This can be assessed bv standard clinical tests
of liver function such as for hyperbilirubinaemia
arid prolongation of the prothrombin time. Also, marked
increases in the plasma concentrations of enzymes such
as alanine aminotransferase (ALT), aspartate
aminotransferase (AST) and lactate dehydrogenase (LDH)
occur as a result of leakage from damaged liver cells.
The toxic dose-response relationship in animals is
less easily identifiable in humans. The observation of
Proudfoot and Wright (1970) that about I5g appeared to
be the threshold toxic dose was confirmed with the
similar biochemical estimate of Mitchell et si (1974).
However, a single dose of 5.85g, not much above the
therapeutic dose, was said to produce severe liver
damage in one subject ( Femand ez & Feroand ez-Brito, 1977)
whereas 15.3g apparently produced no signs of damage in
another (Prescott and Wright, 1973) and 6 - has becn
fatal (Wilson et el, 1978).
There is an apparent wide variation in the individual
susceptibility to paracetamol toxicity. Unreliability
in reporting the actual dose ingested (Matthew, 1971)
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ard the common occurrence of vomiting after ingestion
both co*!"•""ih'ite to the uncertainty in correlating dose
with toxicity. The only way to check the amount said
to have been taken is by measurement of oaracetamol or
its metabolites in body fluids. The recovery of
osracetamol and its conjugates in urine has been used
as s measure of the dose ingested (Prescott et si, 1974.
1976; Davis et al,1976). A positive relationship
between the severity of liver damage and urinary recovery
of drug was found by Davis et al (1976). Prescott et
al (1971) found that the plasma paracetamol concentration
at 4 and 12 hours after ingestion could provide a useful
indication of the likelihood of liver damage and con¬
cluded that levels above 200 jig/ml at 4 hours and
50 qg/ml at 12 hours were usually associated with
hepatotoxicity. Concentrations of less than 120 jug/ml
et 4 hours and 25 jig/ml at 12 hours were never associat¬
ed with serious toxicity. Paracetamol concentrations
at these times correlated with abnormalities of liver
function tests carried out subsequently. However, the
dependability of this correlation rests on accurate
knowledge of the time of paracetamol ingestion. A more
reliable guide was the plasma paracetamol half-life,
which indicated probable liver damage if greater than 4
hours (Prescott et al, 1971). An increase in the half-
life reflected the general impairment of liver function
caused by hepatic necrosis. These findings were
confirmed by Stewart and Simpson (197^).
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f) Factors Affectin? Toxicity:
Th<= effect of enzyme induction on toxicity in
animals has already "been mentioned (p. 18). Self
poisoning often involves more than one drug, frequently
including known enzyme inducers such as etharol and
barbiturates. Wright and Prescott (1973) studied the
effect of possible enzyme induction in paracetamol
overdosage and found increased severity of liver
damage in potentially-induced patients. Evidence for
increased production of the toxic metabolite in such
patients was provided by Mitchell et al (1974) who
found that volunteers pre-treated with phenobarbital
produced more paracetamol mercspturie acid conjugate
than non-pretreated subjects.
Nutrition influences paracetamol toxicity in rats
(Mclean and Day, 1975). low protein or yeast diets
produced lower hepatic levels of cytochrome P-450 but
an even greater reduction in glutathione levels. Enzyme
induction and negative nitrogen balance have been
implicated as potentiators of hepstotoxicity with the
chronic use of paracetamol (Barker et al, 1977).
Competition for glucuronide and sulphate conjugation
with paracetamol may also potentiate hepatotoxicity.
Oxazepam and ascorbic acid compete with paracetamol
for glucuronidp (Dybing, 1076) and sulphate conjugation
respectively (Houston and levy, IQ76). In subjects
ingesting- I - 4g of paracetamol, the amount of drug
excreted as the sulphate conjugate tended to plateau
with increasing dosage , indicating saturation of the
sulphate conjugation pathway (Davis et al, 1976).
Young children are more resistant to the
heoetotoxicity of paracetamol than adults , which could
reflect their relatively greater production of paracetam¬
ol sulphate (Miller et al, 1976). The elimination half-
life of paracetamol may be longer in young children
and neonates (levy et al, I975; Miller et al, 1976)
suggesting that the. overall metabolism of paracetamol
is. slower than in adults.
Other factors such as the ability to repair damaged
tissue may also be important in determining the extent
of liver damage after paracetamol overdosage.
g) Effect of Toxicity on Paracetamol Elimination.
Hepatotoxicity after paracetamol overdosage
affects the metabolism of paracetamol (Prescctt and
Wright, 1973). The elimination half-life of paracetamol
was prolonged within a few hours of the ingestion of
toxic doses indicating early onset of liver damage and
impairment of paracetamol metabolism. This was
confirmed bv the low ratio of conjugated to free drug
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in the olasma of patients with liver damage compared
to those without. Patients with liver damage who had
previously taken enzyme inducers such as phenobarbital
and ethanol showed similar reductions in the rate of
paracetamol elimination (Wright and Prescott, 1973).
Comparison of the kinetics of elimination of
therapeutic and toxic doses revealed that elimination
was rapid in the absence of liver damage, but was
progressively impaired with increasing severity of
liver damage, and significantly more paracetamol was
excreted unchanged in patients with severe liver
damage. Urinary excretion of paracetamol and its
metabolites was rapid whether liver damage was
present or not, provided that kidney function was
unimpaired.
6) Treatment of Paracetamol Overdosa.ge:
The hepatotoxicity of paracetamol depends on its
absorption, distribution, metabolism end excretion.
Attempts have been made to modify each of these
processes in the hope of preventing toxicity. It may
be possible to remove the drug before absorption is
complete, haemodialvsis has been used to enhance its
removal from the blood and its metabolism may be
modified to prevent formation of the toxic metabolite
and its covelent binding (Prsecott and Matthew, 1971:
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Farid et al, 197?; St rube It et al, 1971; "~c rvey and
Ievitt, 1976).
Time is an important factor since treatment must
"be instituted "before glutathione depletion and
irreversible covalent binding occurs. Some "treatment"
is potentially harmful, especially if given too late
(see below). To aid the early recognition of pote^ t i!73
toxicity and the need for treatment, Prescott et al
(1974) constructed a nomogram of plasma paracetamol
concentration against time after ingestion (Fig 5).
Patients with plasma paracetamol concentrations above
the line joining 200 pg/ml at 4 hours and 50 pg/ml
at 12 hours were considered to be at considerable risk
of liver damage and therefore likely to benefit from
treatment. With values below the line, treatment
would be unnecessary.
a) Prevention of Absorption:
Gastrin aspiration and lavage are normally carripd
out in patients admitted not later th; n 4 hours after
ingestion (Matthew, 1971; prescott and Matthew, 1971)
since absorotion is usually comnlete within this time.
Dordoni et al (1973) recommended the administration of
activated charcoal or cholestyramine to hind unabsorbed
oaracetamol and therefore prevent its absorotion.
Although paracetamol absorotion was considerably
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Ingestion to treatment interval:-
(A) Continuing absorption likely ud to 4 hrs -
_ paracetamol concentration not diagnostic.
£§) Time limit for maximum efficacy of treatment,
(£) Limited efficacy up to 10 hrs; no protection
beyond 15 hrs after ingestion.
Treatment is indicated if the paracetamol con¬
centration is above the lower line.
Fig. 5 ; Paracetamol "Treatment Lines"
(modified from Prescott et alr 1974).
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reduced when dm/? end edsorbent were taken together,
reduction was insignificant when adsorbent was given
one hour or more after the oaracetamol. Very few
self-poisoning cases are admitted to hospital within
such a short time of ingestion.
b ) Removal from Blood:
Haemodialysis was used by Farid et al (1972) who
stated that such treatment might be valuable up to
12 hours after ingestion. Subsequent analysis of their
data by Prescott (1972) revealed that potentially
tovic quantities of paracetamol had been taken by
o^ly 3 out of 15 patients dialysed and that liver
damage had occurred in all three. Most oatients were
dialysed unneccesssrily and only very small amounts
of paracetamol were removed in this way, even in the
more severely poisoned patients.
Haemoperfusion through coated charcoal columns has
been proposed as a more rapid means of removing
paracetamol from the circulation (Willson et al,
1973). However, in a controlled trial by the same
workers (Gazzard et al, 1974b) haemoperfusion was of no
clinical benefit. The treatment was probably given too
late and only small quantities of paracetamol were
removed. The authors stated that possible harm may
have bean done by the treatment.
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Forced diuresis does rot enhance elimination
sign ificantly. Although urinary excretion of paracetamol
is dependent on urine flow rate, elimination by
conjugation is far morp important, even when liver
damage is present (Prescott and Wright,1973)•
Furthermore, paracetamol has antidiuretic oroperties
(Nusynowitz and Forsham, 1966) and. renal failure
sometimes occurs after o^erdosage. Attempts at
forced diuresis in such circumstances could be harmful.
c) Sulohydryl Compounds;
The major role of glutathione conjugation in
protecting against paracetamol toxicity was elucidated
by Mitchell et al (I973h, 1974). Intravenous
administration of glutathione in high doses was shown
to protect mice aga.inst paracetamol toxicity (Strolin-
Benedetti et al, 1975) but Gazzard et al (1974a) obtained
no protection in rats. Glutathione does not enter cells
easily. Other compounds such as cysteamine, methionine,
cysteine and dimercaorol have been shown to be much
mo^e effective protective agents in animals (Mitchell
et al, I973"b, 1974; Mclean and Nuttall, 1978;
Strubelt et al, 1974).
Cysteamine may act by inhibition of microsomal
oxidation, since it reduces the amounts of divalent
sulphur conjugates produced in isolated, perfused rat
liver (Harvey and Levitt, 1976). Cyst©amine end the
other compounds are vpry effpotive in restoring
depleted heoatio glutathione (Strubelt et al, 1974)
and may act as glutathione precursors or substitutes.
Mitchell et a.1 ( 1974) proposed that cysteamine
and similar nucleophiles should prevent liver damage
after paracetamol overdosage in man, even when given
many hours later. Of several sulphydryl compounds
tested, D-penicillamine appeared to aggravate the
nephrotoxicity of paracetamol (Prescott et al, 1976)
and dimercaprol was not particularly effective
(Hughes et al, 1976). Intravenous cysteamine has been
widely used in man since Prescott et el (1974) reported
its first successful use in preventing severe liver
damage in patients with severe paracetamol poisoning.
However, cysteamine produces unpleasant side
effects and therefore alternatives were sought. Oral
L-methionine has since been shown to afford some protect
ion in man without unpleasant side effects (Crome et
al, 1976) although Prescott et al (1976) considered
cysteamine to be more consistently effective. It is
now recognised that all treatment should be given with¬
in 8 -10 hours of ingestion since effectiveness
decreases dramatically beyond this time (Prescott et al,
1979 ). In addition, large doses of sulphydryl compound
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nay bp dp^pprous if severe livpr damage has already
occurrp^. Methionine in particular aggravates
ore-existing liver diseasp (Phpar et ai, 1956).
Prpscott and Matthew (T974) suggested the widely-
available mucolytic '^-acetylcysteine as a possible
alternative to cysteamine. Subsequently Piper^n and
Eerssenbruegge (1976) demonstrated its effectiveness
in mice up to 4^ hours after paracetamol ingestion,
ie after the first sig^s of liver damage had occurred.
Since theo Prescott et al (1977, 1978, 1979 ) have
reported its effectiveness and lack of side-effects i71
man and further experience has shown it to be more
effective thee cysteamine and methionine. The time
limit for maximum effectiveness with all three compounds
is 8 hours after paracetamol ingestion (Prescott et
si,1978, 1979 ).
d) Other Methods:
Mepyramine and hydrocortisone were recommended
by Maclean et al (1968). However subsequent studies
showed that this treatment greatly increased mortality
from paracetamol in rats (Nimmo et al, 1973b).
Walker et al (1974) showed that vitamin E protects rats
against paracetamol hepatotoxicity, possibly by en
antioxidant effect on cell membrane lipids which would
otherwise be damaged by the toxic metabolite of
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paracetamol. It has been suggested that incorporation
of vitamin E, methionine or N-acetylcysteine, into
oaracetamol tablets would provide "built in"
protection against liver damave after overdosage









Outline and Purpose of the Present Study,
Previous investigations into the metabolism and
pharmacokinetics of paracetamol in .man were limited
owing to the difficulty in measuring metabolites and the
small numbers of subjects generally used. Usually only
therapeutic dosage has been studied and often drug and
metabolite estimation's were based on non-specific
analytical methods. The results of these studies do not
always agree and. more nrecise information, particularly
following overdosage, is necessary to gain a better
understanding of the fate of paracetamol in man and its
effects on the liver.
1) Estimation of Paracetamol and its Major Metabolites
Studies by many workers have demonstrated widely
varying metabolite patterns and overall recovery of
paracetamol (Mrochek et al, 1974' Davis et al,1976;
Andrews et alt1976). With the advantages of High
Performance Liquid Chromatography (HPLC) and careful
quantitation procedures for estimating paracetamol and
its metabolites, it is possible to obtain more reliable
data. Three such procedures were developed and
evaluated -
a) Estimation of paracetamol and its major metabolites,
the sulphate, glucuronide, cysteine ar.d merca.pturic
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acid conjugates in urine.
b) Estimation of paracetamol alone in plasma.
c) Estimation of paracetamol and its sulphate and
glucuronide conjugates in plasma.
2) Studies in Healthy Subjects
Control data were obtained from healthy subjects
taking a therapeutic dose of paracetamol. A similar
study was carried out with the simultaneous administration
of N-acetyl-L-cysteine (NAC) in an attempt to elucidate
the mechanism whereby NAC protects the liver from dam¬
age after paracetamol overdosage.
%
3) Hepatic Damage after Paracetamol Overdosage
There have been many clinical reports concerning the
damaging effects of paracetamol on the liver (Davidson
and Eastham, 1966; 'Paracetamol Hepatoxicity,' lancet,
1975). In this study paracetamol metabolism and
elimination was investigated in overdosage patients,
comparing those who subsequently developed liver damage
with those who did not.
A) Effects of Treatment on Paracetamol Metabolism and
the Prevention of Liver Damage
In the last 6 years L-methionine, cysteamine and
N-acetyl-L-cysteine (NAC) have been used in the
Edinburgh Regional Poisoning Treatment Centre to prevent
liver damage after paracetamol overdosage. The protective
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actions of these compounds were investigated in relation
to their effect on the metabolism and elimination of




ESTIMATION OP PARACETAMOL AND ITS METABOLITES
IN URINE AND PLASMA
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ESTIMATION 0? PARACETAMOL AND ITS MAJOR MITABOLITES IN
URINE AND PLASMA
Chapter I Review of Analytical Methods
Various methods have been developed to rapidly and
reliably estimate plasma concentrations of paracetamol
with minimum interference from other materials. This is
important since the prognosis after overdosage may be
greatly improved if an early estimation of the plasma
paracetamol concentration can be made, thus allowing
specific therapy to be given when such treatment will
be most effective (Prescott et al, 2976)- Specific
procedures are necessary because about 25$ of self-
poisoning attempts are made with mere than one drug
(Chambers, 1976) and some methods ere liable to interference
by other drugs.
The earliest methods were colorimetric (Greenberg
and Lester, 1946; Brodie and Axelrod, 1948) , employing an
acid hydrolysis of paracetamol to p-aminophenol. This
was followed by a coupling reaction with c<-naphthol to
produce a blue colour which was measured at 620nm. Other
procedures broadly based on these methods are numerous
(reviewed by Wiener, 1978), the advantage being that
spectrophotometers ar° in wide use and are simple to
operate. They must be used with care when specificity for
free paracetamol is important since p-aminophenol is
also produced by hydrolysis of the sulphate and glue-
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uronide conjugates of paracetamol. A rapid method not
susceptible to metabolite interference is that of
Glynn and Kendal (1975)- Paracetamol is nitrated and the
resulting orange-yellow colour in alkaline solution is
measured. Free paracetamol may be assayed directly by
its ultra-violet absorbance after solvent extraction
(Routh et al, 1968).
With the colorimetric and UV absorba^ce assays,
interference from unrelated compounds can occur (Wiener,
1978) and none of the methods are particularly suitable
for measuring therapeutic concentrations of paracetamol.
Several direct gas chromatographic methods have been
reported which overcome some of these problems (Grove,
1971; Windorfer and Rottger, 1974-; Stewart and Willis,
1975). However, paracetamol is chromatographed as the
fr°e drug and considerable adsorption losses are liable
to occur using this approach due to the polar nature of
the drug. Most workers favoured dprivatisation to
improve chromatography, particularly at very low
concentrations (Prescott, 1971 a and b; Thomas and
Coldwell, 1972; Street, 1975; Dechtiaruk et al, 1976;
Garland et al, 1977;- Evans and Harbison, 1977). The
major problem with gas chromatography is the need, to
concentrate and derivatise the extracts,which adds to
the total analysis time. Also, some methods are still
liable to interference (Street, 1975; Dechtiaruk et al,
1976; Kalra et al, 1977).
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All the above procedures can measure either free
paracetamol or total paracetamol after enzymic or
acid hydrolysis. Fstimation of the individual conjugates
was laborious and unsatisfactory. Jagenburg et al (1968)
employed column chromatography with Sephadex G10 to
separate paracetamol and its sulphate, glucuronide,
cysteine and mercaoturic acid conjugates. Separation
and quantitation was a very lengthy process requiring
large quantities of urine. Simpler, more rapid
separations were achieved using Thin layer Chromatography
(TIC) with either one or two dimensional systems
(Cummings et al, 1967; Davis et al, 1976; Andrews et al,
1976 ). Quantitation was attempted by UV absorbance
after elution from the silica gel or by scanning
densitometry. None of these techniques was found to
be satisfactory for routine use in this laboratory
(Howie, 1977). The ion exchange system of Mrochek et al
(1974) provided excellent separations but took between
one and two days per analysis.
Analysis of polar compounds was greatly facilitated
with the advent of High Performance liquid Chromatography
(HPLC), allowing fast separations of many compounds on
short columns. It is now possible to separate many
components of complex mixtures in a single analysis on
columns as short as 100 mm or less. Another major advan¬
tage of HPIC is the ease of sample preparation. Analysis
can be performed in an aqueous, organic or mixed mobile
45
phase and the sample needs only to be miscible with this
elating phase before chromatography is performed.
However, many drags and metabolites are not easily
detectable at the low concentrations often encountered
in untreated biological fluids. Detection is no problem
with paracetamol since the free drag and its conjugates
all have adequate UV extinction coefficients and can
be quantified in plasma and urine without concentration
after therapeutic doses. Paracetamol alone has been
analysed using HPLC by many workers, mostly after an
extraction stage (Wiener, 1978).
The divalent sulphur-containing conjugates of
paracetamol were measured by Buckpitt et al (1977) in
liver microsomal preparations. Quantitation was
achieved using ~^C - labelled paracetamol and three
mobile-phase systems were required to separate the
compounds of interest. Knox and Jurand (1977, 1978)
have described the separation of paracetamol and its
metabolites in urine using HPIC from a theoretical
viewpoint and they identified at least one previously
unknown metabolite. Quantitation was not attempted but
useful guidance was given in the formulation of suitable
systems for separating compounds of widely varying
physico-chemica-L characteristics.
Howie, Adriaenssens and Prescott (1977) first
described the quantitation of paracetamol and its major
conjugates in urine. The only sample preparation
46
required was the addition of aqueous internal standard
solution. Free paracetamol in plasma was measured after
the addition of internal standard in aqueous trichlor¬
acetic acid, which served to remove plasma proteins
prior to analysis. Columns dry-packed with octadecyl
silica (Spherisorb-ODS 10 /am) were used in each case.
Modifications of these procedures were used in subsequent




h) Development of HPLC Methods for the Estimation of
Paracetamol and its Metabolites in Plasma and Urine
a) Reference Compounds
Paracetamol was obtained from BDH, Poole,Dorset
and was assumed to be 100# pure. Paracetamol sulphate
potassium salt monohydrate, paracetamol glucuronide,
paracetamol cysteine and paracetamol mercapturate were
kindly donated by Dr R S Andrews, Sterling-Winthrop,
Research and Development Division, Newcastle-upon-Tyne,
England and Dr W Madison, McNeil Laboratories Inc.,
Port Washington, USA. The conjugates were obtained
either synthetically or from natural sources.
Purity was determined by UV spectrophotometry of
aqueous solutions and HPLC. The figures obtained were:
Paracetamol sulphate - 91#
Paracetamol Glucuronide - 96#
Paracetamol Cysteine - 93.7#
Paracetamol Mercapturate - Not determined at source.
The purity of paracetamol mercapturate as determined by
Raney Nickel reduction followed by GLC was 41.7# (Howie,
1977).
The internal standard, N-prooionyl-4-aminophenol was
synthesised and purified as described below. Analytical
grade reagents were used for HPLC solvents without
further purification. 4-fluorophenol was obtained from
Aldrich Chemical Co, Gillingham, Dorset. 60# W/V
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Perchloric acid end Trichloracetic acid were analytical
grade and obtained from BDH, Poole, Dorset.
b) Internal Standard
The original internal standard used in the method
of Howie, Adriaenssens and Prescott (1977) was
4-fluorophenol. This compound is hygroscopic and its UV
absorption is relatively poor at the optimum wavelength
for detecting paracetamol and its conjugates (2^2 nm).
A new internal standard, N-propionyl-4-aminophenol (NPA)
was synthesised and evaluated.
Synthesis of N-propionyl-4-aminophenol (NPA)
Reagents: 4-aminophenol (BDH, reagent grade); propionic
anhydride (BDH,, 97^ min. containing about 3% propionic
acid); methanol (James Burrough, reagent grade);- diethyl
ether (May and Baker analytical grade).
Method: 2g of 4-aminophenol was vigorously shaken with
10 ml of methanol to remove dark brown impurities present
in the reagent grade material. The mixture was then
filtered and the colourless crystals remaining were
washed with a further 10 ml of methanol and dried,
1.09g (10 millimole) of 4-aminophenol was dissolved
in 30 ml of methanol in a 100 ml round bottomed fla.sk
with gentle warming and a reflux condenser fitted.
1.43g (1.42 ml, 11 millimole) of propionic anhydride,
diluted in 20 ml of diethyl ether was added slowly over
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about 2 minutes to the methtnolic solution of 4-amino-
phenol. The mixture was refluxed for 15 minutes, cooled
and then evaporated under vacuum to remove the diethyl
ether at room termperature and then the methanol on a
water bath at 60°c. When about 3 ml remained, 30 ml
of distilled water was added and the product was allowed
to crystallise at 4°c for about 30 minutes.
The faintly-pink crystals were filtered and washed
successively with 20 ml of distilled water, 2 x 10 ml
of 3/k aqueous sodium bicarbonate and 20 ml of distilled
water. The washed product was redissolved in the minimum
volume of hot methanol, 30 ml of hot water ws.s added and
the solution allowed to recrystallise at 4°c for 1 hour.
After filtration and drying, 0.86g of a colourless,
odourless, non-hygroscopic crystalline product was
obtained, equivalent to a 52.1#- yield. The reaction
scheme is shown in Fig. 6., Chromatographic purity was
determined in the HPLC systems used for urine and plasma
analysis. A single peak was obtained at 212 and
254 nm (Fig.6). The UV spectrum of an aqueous solution
was practically identical to that of para.cetamol (Fig 7 ;
molar extinction coefficient 0.-99 relative to paracetamol
at 242 nm).
c) Apparatus
The HPLC system consisted of an Orlita model AE10 -














































COLUMN: 90 x 4.9 mm ODS-Hypersil. MOBILE RiASE: 0. 1 M potassium
dihydrogen phosphate: 98% formic acid : isopropanol (100: 0.1: 1.7 v/v/v); 1.3 ml/min.
WAVELENGTH: 254 nm.
COLUMN: 170 x 4.f mm Spherisorb 5-ODS. MOBILE PHASE: water: glacial
acetic acid: isopropanol ( 98: 1: 1 v/v/v); 1. 5 ml/min. WAVELENGTH: 242 nm.
Above - Reaction scheme for the preparation
of N-propionyl-4-aminoohenol (NPA) from
4-aminophenol a^d propionic anhydride.
Below - Chromatographic parity of NPA.
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Wavelength (nm)
Fig. 7 UV absorbance spectra of paracetamol and
N-propionyl-4-aminophenol (TIPA) in water.
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septum injector to the stainless steel, internally-
polished analytical column (90 - 180 mm long and 4.5 or
1.9 mm internal diameter). A pressure gauge was included
to monitor solvent delivery. The eluate fhom the column
passed through a short length of PTFE tubing ( JD05" int.
diameter) into an 8 or 10 gil flow cell mounted in a
UV absorbance detector (Cecil 212 variable wavelength
or Waters model 440 fixed wavelength). Peak areas were
integrated using either a Hewlett-Packard model 3370 -
A integrator or a Spectra-Physics Minigrator. A perm¬
anent trace of each chromatogram was obtained using a
suitable strip chart recorder connected to the integrator
(Pig.8 ). The Orlita pump is of the diaphragm type and
delivers the solvent in pulses which were damped to
avoid excess noise in the signal output to the integrator.
In practice,the Bourdon tube of the pressure gauge acted
as an expansion chamber which, coupled with the flow
resistance of the column itself, provided adequate pulse
dampening.
Two types of column and injector were used. In
both designs solvent is introduced into the injector and
passes concentrically around its central shaft and onto
the column. The two designs are shown diagrammatically
in Pig. 9 .
Sample injection was performed using a high-pressure
micro-syringe (SGE types 5 and 25 B1-RD-50NG), the needle
tip being placed within the glass beads, just touching
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Fig 8 HPLC Assembly
Key:- S - Solvent reservoir and solvent;
F - Solvent filter;
ST - Type 316 stainless steel tubing (1/16" or
1/8" O.D);
P - Solvent delivery oump;
V - On-off valves:
G - Pressure Gauge;
I - Septum injector assembly;
C - Analytical column;
T - Microbore tubing;
D - UV detector;
E - Eluate reservoir;
Int - Peak area integrator;
R - Strip chart recorder.
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Type A Type B
Fig 9 : Analytical Column and Septum Injector Assemblies.
key:- 1 - Upper syringe needle guide; 2 - Septum;
3 - Lower syringe needle guide; 4 - Solvent
inlet; 5 - Glass beads (30-100 mesh); 6 - Woven stain¬
less steel gauze; 7 - Packing material; 8 - Column tube
(internally polished); 9 - Packing retaining gauze (woven
stainless steel); 10 - Microbore outlet tubing; 11 - Steel
ferruue; 12 - PTFE ferrule; 13 - PTFE 'O'-ring;
14 - PTFE insert.
* Type A according to Bristow, HETP Ltd, Macclesfield,
Cheshire.- Type B according to Knox and Wall, V/olfson
Liquid Cromatography Unit, University of Edinburgh.
"the stainless steel gauze above the packing (Fig. 9).
In this way the sample is placer! directly onto the
packing with the minimum of spreading. This makes
possible the "infinite diameter effect" (Knox and
Parcher, 1969) where sample components never touch the
column walls during separation, ensuring maximum
chromatographic efficiency. In practice, some band
spreading and wall effects are probably introduced by
too-large sample volumes and the disturbance caused
by the syringe needle during sample injection
(Majors, 1973; Bristow et al, 1977).
&)Column Packing Material
Octadecyl silica. has been shown to be the most
appropriate stationary phase material for the separation
of weakly acidic small molecules (Twitchett and Moffat,
1975) and this was proved to be so for paracetamol and
its metabolites also (Howie, 1977; Knox and Jurand, 1977,
1978)» Separation efficiency is inversely related to
stationary phase particle size (Martin and Synge, 194-1;
Majors, 1972,1973; Knox, 1973) and improved chromatog¬
raphy was obtained by substituting the 10 jum material
used earlier (Howie, Adriaenssens and Prescott, 3977)
with 5 /um material. Spherisorb-ODS (5 nm) was used in
urine analyses and for paracetamol alone in plasma., and
ODS-Hypersil (5-6 /um) was used for analysis of para¬
cetamol and its conjugates in plasma.
e) Column Packing Procedure
Early columns were packed by the 'tap-fill' method
of Snyder (1967). Packing material was poured into the
oiumn in small amounts and the column was then tapped
at the sides and bottom between each addition until no
further settling occurred. When the column was
adequately filled, the high-pressure pump was connected
to the top of the column and about 100 column volumes
of the appropriate mobile phase were passed through at
high pressure. The column was then disconnected, a
stainless-steel gauze was fitted, and this was covered
with a 5 mm layer of glass beads (80 - 100 mesh,
Pig.9 ). The column was then ready for use.
The more efficient columns using 5 pun particles
were slurry packed for optimum performance, using two
procedures shown diagramatically in Pig. 10. The
balanced density technique (Kirkland,1971} Majors,
1972; Cassidy et al,1974) was employed using an 8 - 12$
w/<r suspension of the packing material in a mixture of
iodomethan&/ethyl acetate (4:Iv/v)* This slurry was
first briefly ultrasonicated to disperse particle
agglomerates and the column tube, with the packing-
retaining gauze and the outlet fitting attached, was
connected to the slurry reservoir tube. Both tubes
were filled with slurry (total volume about 15 ml),
topping up with more solvent if necessary. The reservoir
























Fig 10 : Column packing apparatus and methods
key:- S - Column packing solvent and reservoir
F - Filter (7 or 30 jiM)
P - Solvent delivery pump
V - on/off valve
G - Pressure gauge
R - Reservoir for packing slurry
(25 cm long x 3/8" QD.)
U - Reducing union ( 3/8" to 1/4")
C - Column
E - Eluate reservoir.
Apparatus) via a length, of 1/16" o.d. stainless steel
tubing and packing commenced with a flow rate of
8-10 ml/min, using ethyl acetate and the driving
solvent. About 50 column volumes were passed through
the packing tube and column. The solvent was then
changed to a 1;1 v/v mixture of methanol: ethyl acetate
for about 20 column volumes, followed by methanol alone
for another 20 column volumes. The column was then
detached from the slurry reservoir and inspected to
check that the packing had bedded down evenly. The
weight of packing used was sufficient to fill the
whole length of the column (about 1.5g/l00 mm). The
reservoir tube was then reconnected and solvent flow
re-started. The methanol content of the solvent was
then progressivley reduced with water oVer about 50
column volumes, ending up with water alone for another
20 column volumes. The flow rate was adjusted during
this sequence so that solvent viscosity changes did not
overburden the pump and pressure gauge.
The packing apparatus was dismantled and enough
packing removed from the top of the column to allow
for insertion of a stainless steel gauze directly on
top of the remaining packing, followed by 80 - 100 mesh
glass beads (about 5mm depth). The column was now
ready for connection to the injector assembly. Before
use each column was tested with standard mixtures of
paracetamol metabolites to ensure that performance and
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solute retention were adequate and stable.
In the second procedure, a more polar, unbalanced
slurry was used (Kirkiand, 1971; Bristow et al, 1977; .Sheldon
Southern Products technical note). An 8 - 12$ w/v
suspension of packing material was prepared in a solvent
consisting of 85:15 v/v methanol/water. Particle
agglomeration was clearly visibxe in this medium and
was minimized by brief ultrasonication and vigorous
shaking before packing. The reservoir tube and
column were connected and filled with slurry as in the
first method. The solvent delivery tube was attached
and the reservoir and column vigorously shaken before
commencing solvent flow.
A flow rate of 8 - 10 ml/min of 8p:15 v/v methanol:
water was used and the column and reservoir were
inverted: so that packing proceeded upwards. Eluate
was collected via a flexible outlet tube (Pig. 10).
Upward packing ensured a uniform column bed with a
minimum of radial particle siz-ing, since sedimentation
of larger particles and agglomerates occurs in the
opposite direction to the laying down of the column
bed. Longitudinal particle sizing (where larger
particles pack last) does occur but is unlikely to
affect column performance (Bristow.et al,1-977). After
about 80 column volumes had passed, the water content
of the solvent was progressively increased to 100$
over 50 column volumes. The rest of the procedure was
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as for the first method.
The two methods appeared to produce eq.uivaj.ent
chromatographic results with similar column efficiencies,
as determined by the number of theoretical plates per
column (Martin and S.ynge, 1941) with a mixture of
standards (paracetamol, its metabolites and toe
internal standard). The number of theoretical plates
R2(N) was determined from the equation N - 16 —«■ where
W
R r peak retention time and W 1 baseline peak width
(in the same units as R) for tangents extrapolated to
the baseline from the inflection at each side of the'
peak. The most efficient column produced about 6000
theoretical plates for N-propionyl-4-aminophenol in a
90 mm long column after using the balanced density
method.
f) HPIC Systems for the Analysis of TJrine Samples
With the use of a new internal standard, different
mobile phases relative to that of the earlier method
(Howie, Adriaenssens and Prescott, 1977) were required
for optimum separations. It was found that changing the
mobile phase from 1% aqueous acetic acid with 15%
methanol end 0.1% ethyl acetate(V,/V) to 1% acetic acid
containing 1 - 2%eech(V/V) of methanol end/or
isoorooenol, with the more efficient, 5 Soheri sorb-OPS
provided better separations. The columns used were 120
to 180 mm long and 1.4 to 4.9 mm diameter.
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Resolution of poorly-retained peaks close to paracetamol
sulphate and glucuronide conjugates was improved.
Chromatograms obtained from drug-free urine, urine
collected 3-4 hours after a therapeutic dose of
paracetamol (20 mg/kg) and urine collected 9-23 hours
after an overdose of paracetamol are shown in Pig. 11 .
A chromatogram of standards is shown for comparison
(Pig. 12a). Components of interest are well resolved
from each other and endogenous compounds. Other drugs
commonly ingested with paracetamol in overdosage
(eg barbiturates, salicylates, benzodiazepines) did
not interfere although the possibility of interference
from metabolites of these drugs cannot be ruled out.
Para.cetamol and its major conjugates could still
be measured 24 hours after a therapeutic dose and
sometimes up to 5 days after an overdose using the
system described.
g) HPLC Systems for the Analysis of Plasma Samples
i) Free Paracetamol Only: The system used was as
described by Howie, Adriaenssens and Prescott (1977)
using a Spherisorb 10-0DS column (90 mm long x 4.5 mm id)
and a mobile Dhase composed of 1°j> aqueous acetic acid
and ethyl acetate (99:1 v/v),UV detection was at 253 nm.
The system described below for paracetamol and its conj¬
ugates could also be used . Fig.13 shows chromatograms











































Fig,12:HPLCofreferencecompoundsonthsyst msusedfothanal isfurine( ) andplasma(b). (a)COLUMNSpherisorb5-ODS(170x4.9mm);MOBILEPHASEwater:glacial aceticid:methanol:isopropanol(96.5:1.0:5.v/v/v/v)at1.8ml/min. WAVELENGTH242nm.(b)COLUMODS-Hypersil(90x4.9mm);MOBILE PHASE0.1Mpotassiumdihydrogenphosph t:98%formicaci:isopropanol (100:0.1:1 7v/v/v)at0.9ml/min.WAVELENGTH:-254nm.
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Fig. 1?: HP1C of paracetamol alone in plasma





Colamn - 90 x mm Spherisorb-lO-OPS.
Mobile Phase - 1°jc aqueous acetic acid:ethvl acetate
(99:1 V/V).
Flow rate - 3nl/min.
Wavelength - 2^3 nm.
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cetamol and also from drag-free plasma.
ii) Paracetamol and its Conjugates: The columns were
either 90 or 120 mm, 4.9 or 4.5 mm internal diameter,
packed with Hypersil-ODS. The mobile phase was 0.1M
ootassium dihydrogen phosphate,. 98% formic acid and
isopropanol (100: 0.1: 1.7 V/V/V). Chromatograms of
drug-free plasma, plasma taken 2 hours after a therapeutic
dose of paracetamol and plasma taken 60 hours after a
severe overdose are shown in Pig. 14. Standards
alone are shown for comparison in Pig. 12b. Most
endogenous compounds eluted early in this system.





























Fig.14:HPLCofparacetamolanditsc nju atesipl m . (a)Plasmacollected2hoursft r0mg/kgparacetamolor ly,(b)Drug-fr epl sm(ab v )andplasmaco e t d 60hoursafterparacetamolove dos gewithseverlivdam gandre alfailu(bel w). (Column:90x4.9mHypersil-ODS.MobilePhas:p tas umdihydr genph sphate:98%formicacid:isopr panol, 100:0..7v/v/v,flowrate.9ml/min.Wavelength254nm)
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Chapter 3
UV Absorbance of Paracetamol Metabolites Relative to
Paracetamol.
It has been assumed in the past that paracetamol
and its major conjugates have essentially equal molar
UV extinction coefficients and that their UV spectra
are superimposahle (Mrochek et al, 1974). Howie (1977)
calculated the extinction coefficients at " ^ max 242 ma"
and found that the values for the sulphate and
glucuronide conjugates were about 8^ higher than
for free paracetamol, this difference was ignored
in subsequent quantitation procedures. Both
Mrochek et al (1974) and Howie (1977) made measure¬
ments at wavelengths below the absorbance maximum
and presumably assumed that the spectra were
superimposable. However, these assumptions are
not warranted.
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a) TJV Absorbance Spectra
Dilate solutions (15 - 20 /ag/ml) of paracetamol, its
sulphate and glucuronide conjugates and NPA were
prepared in the solvents used for HP1C. The UV soectra
were determined against reference cells containing
solvent alone, using a Pye-Unicam model sp 1750
spectrophotometer. The spectra appeared almost identical
but there were slight differences around the absorbance
maxima. The maximum absorbance of paracetamol in each
solvent was at 243 nm. The sulphate and glucuronide
conjugates both peaked within 1 nm below the paracetamol
peak and NPA peaked at about 244 nm.
The relative changes in the absorbance spectra and
hence in the extinction coefficients at other wavelengths
likely to be used for the measurement of paracetamol
were also studied.
Method.
Five wavelengths in the region 240 - 254 nm were
chosen and six absorbance measurements were taken at
each wavelength using the solutions described above in
aqueous acetic acid plus a solvent blank. The 3P1750
spectrophotometer wavelength setting dial was placed
manually at the desired wavelength then moved away and
reset for each of the six readings. This was done to




The results are shown in Table 1. The absorbance
of the conjugates dirt not change at the same rate as
that of paracetamol. This wa.s obvious when the absorbance
of the solution of each compound at each wavelength was
compared to its maximum absorba'".ce ( A ^ + A max, Table 2).
Each compound exhibits maximum absorbance at around
242 nm and the sbsorbance is maintained above 99^ of
maximum for at least one nanometer either side of ^raax.
The absorbance of each compound was considerably
reduced at 254 nm, the wavelength most commonly used by
other workers in TJV measurements of paracetamol and
other aromatic compounds. The absorbance of paracetamol
and its sulphate and glucuronide conjugates dropped by
23, 37 and 29-5 per cent respectively relative to their
absorbance at 242 nm. The decrease in absorbance for
N-propionyl-4-aminophenol was 19.3$.
The data was further analysed to determine the change
in absorbance for each compound relative to paracetamol
A
_ A
from the relationship P - — - where P is~
X'P Ap X'P
the fractional change in absorbance of the compound x
relative to paracetamol. A is the absorbance of this
x
compound at the wavelength in question relative to its
absorbance at 2^2 nm (A^ + A max in Table 2). Ap is the
absorbance of paracetamol at this wavelength relative to its
absorbance at 242 nm. The results (Table 3) show that
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TABLE 1
Change in Absorbance with wavelength for Paracetamol, its
sulphate and glucuronide and N-propionyl-l+-aminophenol (KPA)
(Absorbance ±S.D, n = 6 readings; Solutions were 10-20 vg/ml




























































Change in Absorbance with Wavelength











2l+0 VD CO CO • 997 • 991+ • 976
2l+2 1.000 1.000 1 .000 • 996
21+3 1.000 • 991+ • 997 1.000
21+9 • 927 .890 .890 • 91+9




Change in Absorbance with Wavelength relative to
Paracetamol for paracetamol sulphate and paracetamol








240 0 +0.009 +0.006 -0.012
21+2 0 0 0 -0.002+
22+3 0 -0.006 -0.003 0
2U9 0 -0.083 -O.OI4O +O.O2I4
25b 0 -0.182 -0.081; +0.02+8
* For calculation see text , p 69
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the absorbance of the sulphate and glucuronic!e conjugates
decreased more rapidly than th; t of free paracetamol
with increased wavelength (18.2% and 8.1% relative to
paracetamol on changing from 242 to 254 nm). The
absorbance spectrum of N-propionyi-4-aminophenol followed
that of paracetamol very closely, the discrepancy being
less than 5$ at 254 nm. Accurate measurement of extinc¬
tion coefficients relative to paracetamol are therefore
required for each compound before results obtained at
different wavelengths can be compared.
b) Absorbance of the sulphate and glucuronide conjugates
relative to paracetamol, determined by enzvmic hydrolysis
The sulphate and glucuronide conjugates can be
easily hydrolysed to paracetamol enzymically, and the
process can be monitored by direct HPLC of the reaction
mixture. Neither the purity nor the actual amount of
conjugate in the sample taken for hydrolysis needs
to be accurately known before incubation with the
enzymes.
Method
Aqueous solutions of paracetamol and its sulphate
and glucuronide conjugates were prepared containing
1.0, 1.0, and 1.2 mg/ml respectively. An aqueous
solution containing 2 mg/ml N-propionyl-4-aminophenol
(NPA) was also prepared. 200 jul of the paracetamol sulp¬
hate solution and 100 /zl of the NPA solution were mixeH with
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200 /til of 0.-2M sodium acetate buffer (pH 57 0). Three
150 jul aliquots of this mixture were pipetted into 3 ml
polypropylene tubes. To the first was added 2 ;ul
Glusulase (Endo Laboratories, Garden City, USA), to the
second was added 2 ;ul S. Helix Pomatia extract (Industrie
Biologique Prancaise, Gennevilliers, Prance), and to
the third was added 20 /ul of reconstituted dried
S. Helix Pomatia extract (Sigma Chemical Co, Poole,
England). These three enzyme preparations contained
a.rylsulphatase 47,800, 800,000 and unspecified units per
ml and ^-glucuronidase 145,500, 100,000 and 129,000
units per ml respectively. The samples were mixed and
incubated at 37°c for three hours together with the
remaining control mixture without enzyme.. This procedure
was repeated for the paracetamol glucuronide and
paracetamol solutions.
After incubation, 2.5 jul aliquots of each sample
were injected directly into the HPIC column, the
paracetamol samples served a.s controls. The samples
were analysed at 242 nm and 254 nm with the HPIC system
used for analysis of paracetamol and its conjugates in
plasma.The 3 mixtures without added enzyme were analysed
similarly .
Results
Table 4 shows the peak area ratios obtained for each
solution: without adding enzyme divided by the ratio
obtained after enzyme addition (using NPA as internal
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TABLE 1+
Relative absorbance of solutions of paracetamol sulphate















Glusulase 21+2 1.199 1.291 1.000
S. Helix




21+2 1.199 1.299 0.997
Mean 21+2 1.201 1.291+ 0.999
Glusulase 251+ 1.116 1.01+9 1.000
* Equivalent to extinction Coefficients Relative to paracetamol,
E E
i.e. ^"/E , ^/E - see text for explanation, pp 74, 76.
psi pst
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standard). These values ere equivalent to the extinction
coefficients of each compound relative to paracetamol.
The three enzyme preparations produced almost equal res¬
ults which showed that the absorbances of the paracetamol
glucuronide and sulphate solutions at 212 nm are higher
by 20.1 and 29.4$ (mean values) respectively relative to
the equivalent amount of paracetamol released after
hydrolysis (ie relative extinction coefficients of
1.201 and 1.294). The absorbance cf the control
paracetamol samples did not change under the 3ame cond¬
itions. A single series of measurements at 254 nm
showed that the glucuronide and the sulphate absorbed
%
respectively 11.6$ and 4.9$ more light than the equivalent
amount of free paracetamol at this wavelength.
The extinction coefficients of the glucuronide and
sulphtte conjugates relative to oaracetamol at 254 nm
may also be calculated by multiplying the value at 242 nm
(see Table 4) by the relative absorbsnce change from 242
to 254 nm (Fx,p, Table 3). The appropriate value for
paracetamol glucuronide is 1.201 x (1 - 0.084) = 1.100
and for paracetamol sulphate, 1.294 x (1 - 0.182)- 1.058.
These two values agree well with those obtained directly
at 254 nm, ie 1.116 and 1.049 respectively (Table 4).
c) Ahsorbance ef the Cysteine and Mercapturic Acid
Conjugates Relative to Paracetamol
Since the sulphate and glucuronide conjugates showed
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considerable differences in their extinction coefficients
relative to paracetamol, it was possible that the
cysteine and mercepturic acid conjugates did likewise.
These two metabolites cannot be simply hydrolysed to
release paracetamol and they generally contribute only
a few per cent each to the total recovery of paracetamol
in urine. Their extinction coefficients relative to
paracetamol were estimated on the basis of the peak
area ratios obtained for weighed concentrations of each
conjugate and paracetamol relative to the internal
standard (NPA) after HPLC analysis. This procedure has
the advantage over direct spectral analysis of indepen¬
dence from interference produced by impurities known to
be oresent in the reference materials . However, only
very small quantities of each compound were available
and reliable values for relative extinction coefficients
depend on accurate knowledge of the percentage purity
of each compound.
Method
Stock aqueous solutions of paracetamol and its
cysteine and mercapturic acid conjugates were prepared
containing 0.42, 1.18 and 1.07 mg/ml respectively. 500 jul
of the paracetamol solution was pipetted into each of
four 3 ml tubes followed by 100 p.1 of the paracetamol
cysteine solution into two of the tubes and 100 p.1 of
the paracetamol mercspturate solution into the other two.
After thorough mixing,the solutions were analysed by
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HPLC using the system described for plasma . Relative
extinction coefficients at each wavelength were calculated
from the equation
Ecy
_ Acy Coa Mcy PpaX X X
Spa Apa Ccy Mpa Pcy
Ecy.
where Epa is the extinction coefficient of the cysteine
conjugate relative to paracetamol at the appropriate
wavelength. A is the peak area, C the concentration,
M the molecular weight and P the purity of each compound
(Pa = paracetamol, Cy = paracetamol cysteine conjugate).
This equation also holds for paracetamol mercapturate
hut since its purity was known to he low, the correspond-
E
T!1G
mg wr— could not he found. However, the fractional
'pa
-p
change in absorbance ( me) of paracetamol mercapturate
relative to paracetamol between 242 and 251 could be
found since this depends only on the peak area., ratio
A







( 2 42nm)/ Apa (25Anm)




at 242 nm, 249 nm and 254 nm are shown in
pa
Table 5, together with the fractional absorbance changes
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TA33LE 5
Extinction Coefficients and Fractional Absorbance Changes for the













21+2 1 .32 - -
21+9 1.31 0.995 1.002
29b 1.35 1.025 1.037
pa = paracetamol
cy = paracetamol cysteine
me = paracetamol mercapturate
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for the cysteine and mercapturic aci'^ conjugates relative
to paracetamol from 24-2" nm to 249 nm and 24.2 nm to 254 nm
F F
( me and cy). The mean value of the duplicate samples
was taken in each case. The results suggest that the
extinction coefficient of the cysteine conjugate is about
30$ higher than that of paracetamol and that it changes
little relative to paracetamol at the wavelengths studied.
The fractional absorbance changes for the mercapturic
acid conjugate relative to paracetamol are very similar
to those erf the cysteine conjugate (Table 5). However,
since the mercapturic acid and cysteine conjugates
account for only a small proportion of the total
quantity of paracetamol and its metabolites excreted,
the extinction differences relative to paracetamol were
ignored.
Summary
The UV extinction coefficients of paracetamol and
its major conjugates differ significantly according to
wavelength. Thus in order to estimate the conjugates,
absorbance calibration factors ere required to correct
for the extinction differences relative to paracetamol.
At 24.2 nm the extinction coefficients of the sulnh-
ate and gluouronide conjugates relative to paracetamol
were 1.294 and 1.201 respectively. The corresponding
calibration factors were therefore ■=?—ikmr and ■=?—1.294 1.201
respectively. At 254 nm, the corresponding factors
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werc 1 0^8 and 1 100 :for "biie and glacuronide
conjugates respectively..
Correcting factors for the cysteine and mercapturic
acid conjugates were not used.
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Chanter 4
Stability of Paracetamol Conjugates
Howie (1977) showed that the sulphate, glucuronide,
cysteine and mercapturic acid conjugates of paracetamol
were stable in urine for at least seven months
stored at -20°c. No losses were observed with repeated
thawing and freezing. This stability study was
continued and the same batch of samples was assayed
three years later. The original procedure of Howie
(1977) was used.
Method
Pour sets of urine samples (designated A, B, E
and F), each sample containing the sulphate, glucuronide,
cysteine and mercapturic acid conjugates of paracetamol,
were stored at -20°c. The pH of A and B was adjusted
to 5.3 and E and P to 7.2 before freezing. Samples
A and E were used once only and discarded, whereas B
and P were refrozen after thawing and re-analysed
later, together with "fresh" once-frozen samples of
A and E. Thus the effect of pH, as well as thawing
and refreezing could be determined.
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Duolicate samples of A, B, E and F were thawed and
0.2 nil of each sample was pipetted into 3 nil polyprop¬
ylene tabes. 50 /il of internal standard solution
(4 mg/ml aqueous 4-fluoroohenol) was added to each tube
and the samples were mixed. A set of standards was
prepared containing 25 > 50, 100, 150 and 200 p.g/m.1
aqueous paracetamol and these were treated in the same
way as the urine samples. 1 - 3 jul aliquots of all the
solutions were injected into the HPLC column (170 x 4.9 mm
Spherisorb ODS-5Am)• The solvent was 1% aqueous acetic
acid, methanol, ethyl acetate (90:15:0.2 V/V/V), flow
rate 1.6 ml/min. UY detection was at 250 nm and peak
areas were measured using a Spectra-Physics Minigrator.
Peak area ratios of the conjugates to internal standard
were related to those of the paracetamol standards. The
resuxts (expressed as pig/ml paracetamol equivalent) are
shown in Table 6 together with the original data obtained
by Howie (1977).
Results: In all but two cases the concentrations obtained
in the present study were within two standard deviations
of the values obtained during the first 7 months
(maximum deviation 7.97°). The two exceptions were the
concentrations of cysteine conjugate in samples A and E
which were 15.1% and 7.7% high respectively. The resuuts
suggest that decomposition of paracetamol conjugates in
urine stored at -20°c occurs slowly, if at all#.
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TABLE 6
Stability of Paracetamol Conjugates in




pH 5-3 pH 7-2





























































Samples A and E were analysed and discarded after being frozen once only.
Samples B and P were thawed, analysed and refrozen a number of times.
*
analysed 3 years after initiating study, mean of 2 samples.
"f* mean and standard deviation of 5 analyses over 7 months.
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Chapter 5 Analytical Procedures
Paracetamol and its conjugates in urine and plasma
were estimated after the addition of a measured quantity
of aqueous internal standard to a measured volume of
urine or plasma. Estimation in plasma was only
different in that the internal standard solution contained
a protein precipitant, thus plasma proteins were removed
prior to chromatography.
a) Collection of Samples
The volume and pH of urine samples was recorded and
duplicate aliquots stored at -20°c. Blood samples were
separated immediately and the plasma stored at -20°c.
b) Apparatus and Materials
Reference compounds, internal standard, apparatus
and analytical columns were as described previously
( Chap. 2 ) . Solvents were analytical grade and
water was glass distilled; aqueous components were
vacuum degassed before use.
c) Sample Preparation and Analysis
i) Urine
Aliquots of 100 - 500 jul of urine were pipetted
into 3 ®1 polypropylene tubes and 100 - 500 /il of
internal stands,rd solution (2 mg/ml NPA) was added.
The amount of internal standard depended on the
anticipated drug and metaboiit° concentrations in the
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sample. A set of three standards was prepared with each
batch of unknowns by mixing aliquots of 1.0 mg/rnl
aqueous paracetamol (P) and the internal standard
solution (NPA) in the ratios 200 jul P: 100 p.1 NPA,
100 pi! P: 100 Ml NPA, and 100 Ml P: 200pl NPA.
The chromatographic system was as described on
pp. 60—61» 0.5—1 m1 aliquots of each samole were injected
onto the HPLC column. The concentration of unknown
samples was calculated from the relatiohship
Ax 1 VNPA
C (mg/ml) = Hp x x x
A P V
NPA x, p u
Cx is the concentration of the compound of interest
(paracetamol or its conjugates expressed as paracetamol
equivalent), A is the peak area of this compound and
x
_1
Ait-t)a is the area of the internal standard peak. ENPA ^ x,p
is the absorbance calibration factor (reciprocal of the
relative extinction coefficient) of the compound
relative to paracetamol at the appropriate wavelength
( see pp 80 - 81 ). and ere the volumes of
internal standard solution and urine sample respectively.
Hp is the standardisation factor calculated as the
reciprocal of the slope of the line obtained from the
three paracetamol stands,rds run with each batch of the
unknowns.
It was considered unnecessary to prepare more than
three paracetamol standards with each batch of unknowns
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since the peak ares, ratios (end hence Rp values) were
very reproducible ov?r many months of use (Rp = 1.813 -
0.043 over 19 months). The only sources of variation
were the preparation of standard solutions of paracetamol
and NPA.- There is no extraction step and any variation
in solvent and column characteristics is minimised by
the use of peak areas rather than heights for quantitation.
ii) Plasma - Paracetamol Alone
Two stock solutions (A and E) were prepared contain¬
ing the internal standard 4-Fluorophenoi (4FP) in aqueous
trichloracetic acid (TCA). Solution A contained 5 mg/ml
4FP in 25$ W/W aqueous TGA and solution B contained
7 mg/ml 4FP in 75$ W/W aqueous TCA,
1.0 ml aliquots of plasma containing paracetamol
after overdosage were pipetted into 10 ml glass tubes
and 1.0 ml of solution A was added slowly while the
tubes were held on a vortex mixer. The tubes were
centrifuged for 5 minutes at about 1200 g to separate
the precipitated protein from the clear supernatant.
Up to 5 jul of this supernatant was injected into the
HPIC column. For plasma samples containing low
concentrations, such as after therapeutic dosage, 100 p.1
of solution B was added slowly to 1.0 ml aliquots of
plasma and up to 25 jul of the clear supernatant was
chromatographed. The chromatographic system was as
described on p 61.
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Quantitation was by peak height ratio, overdose
samples were related to olasma standards containing 50
and 200 /ig/ml paracetamol and therapeutic samples were
related to plasma, standards containing 5 and 20 pig/ml
paracetamol. The standards were treated in the same
way as unknown samples. The limit of measurement was
about 0.1 p.g/ml.
iii) Plasma - Paracetamol and Metabolites
Sample preparation was identical to (ii) above
except that solution A (for overdose concentrations)
contained 360 pig/ml NPA in 6$ W/V aqueous perchloric
%
acid and solution B (for low concentrations) contained
300 jug/ml NPA in 30$ W/V aqueous perchloric acid. Up to
5 gil aliquots of the clear supernatant were chromato-
grsohed using the HPLC system described on p 65-
Peak areas of paracetamol and its suxphate and
glucuronide conjugates were related to standards
containing 5 and 20 pig/ml paracetamol (low concentration
range) and 25 and 250 pig/ml paracetamol (overdose range).
The limit of measurement of each compound was less than
1 jug/ml. Appropriate correction factors relating
concentrations of paracetamol sulphate and glucuronide
to paracetamol in plasma were determined as described
below. The mercapturate and cysteine conjugates were
seldom seen in plasma except in severe overdosage,
usually accompanied by renal failure. Therefore it was
considered unnecessary to determine similar factors for
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these compounds and calibration considerations
(ie linearity and absorbance factors) were assumed to
be equivalent to those already described for the urine
assay.
d) Correction Factors for the.Sulphate and Glucuronide
Conjugates
Estimations of paracetamol and its sulphate and
glucuronide conjugates in plasma produce different
peak area ratios relative to internal standard when
compared to estimations of the same concentrations in
water (or urine). Paracetamol alone was used for
standardisation therefore appropriate correction
factors were required to account for these differences
and the differences in molar absorptivity relative to
paracetamol. The correction factors were calculated by
comparing the peak area- ratios of measured concentrations
of paracetamol and its sulphate and. glucuronide conjugates
in plasma and water taken through the procedures
described above. The values obtained are shown in Table 7.
e) linearity of the Assay Procedures .
The Linearity of each assay for concentrations found in
therapeutic and overdose situations was assessed as
follows
Urine: Urine from a patient who had taken paracetamol in
overdosage was diluted serially with water.
This provided concentration ranges
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TABLE 7
Correction Factors for the quantitation of
Paracetamol sulphate and glucuronlde conjugates
in plasma using Paracetamol only for
standardisation.
Conjugate Wavelength Correction Factor
(nm) Therap. Overd ose
Assay Assay
Sulphate 242 0.84 0.76
254 1.03 0.93
Glucuronide 242 0.77 0.77
254 0.84 0.84
of 1.6 - 1600, 28 - 28000, 2.0 - 1P80, 13 - 1^00 e~d
9-8 - 980 /ig/ml of paracetamol and its glucuronide,
sulphate, mercaoturic a old and cysteine conjugates
respectively. The dilutions were assayed according to
C (i) above.
Plasma - Paracetamol Alone: Serial dilutions of plasms
containing 500 /ug/ml paracetamol were prepared using
drug-free plasma to cover the range 0.5 - 500 jig/ml.
The dilutions were assayed in two ranges (0.5 - 50 and
25 - 500 p.g/ml) according toc(ii) cllo CV6 «
Plasma - Paracetamol and Metabolites: Plasma containing
4-20, 239 ond 51.5 )ig/ml of paracetamol and its glucuronid
and sulphate conjugates respectively was serially diluted
with drug-free plasma d o?m to one-tenth of the stock con¬
centrations. These dilutions covered typical concentrati
ons of the three compounds after overdosage. Dilutions o
plasma containing 25, 28 and 10 jug/m1 of paracetamol and
its glucuronide and sulphate conjugates respectively,
covering tvpical therapeutic concentrations, were pre¬
pared similarly. The two concentration ranges were
assayed according toc(iii) above.
Peak height or peak area ratios were plotted against
concentration for the plasma assays and the measured
concentrations of each compound were clotted against
dilution for the urine assay.
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Resuuts: The plots ere shown in Rig. 15 (urine),
Fig. 16 a and. h (paracetamol alone in plasma), ana
Fig. 17 a and b (paracetamol and metabolites in plasma).
Linearity was maintained throughout each concentration
range for each assay and the plots obtained for the
plasma assays passed through the origin in each case.
f) Precision and Accuracy
Batches of six replicate samoles of urine and plasma
containing typical concentrations of paracetamol and
its metabolites at therapeutic and overdose levels were
assayed by the appropriate procedures already described
to assess the precision and accuracy of each method.
Concentrations are all paracetamol equivalent, corrected
for purity.
Urine: Paracetamol and its glucuronice, sulphate,
cysteine and mercaoturic acid conjugates were dissolved
in drug-free urine at concentrations of 0.63, 2.30, 1.22,
0.40 and approximately 0.35 mg/ml respectively. Portions
of this solution were diluted 1 in 4 and 1 in 30 with
drug-free urine to provide three concentration levels
wdich were then assayed according toc(i) above.
Plasma - Paracetamol Alone: Plasma samples containing
2, 10 and 30 p.g/ml were assayed on six separate occasions
according to the therapeutic level procedure inc(ii)
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using samples containing 25f 100 and 300 jug/ml.
Plasma - Paracetamol and Metabolites: Concentrations
assayed using the therapeutic range procedure inc(iii)
above were 2.5> 2.8 and 1.0 jug/ml and 20.0, 22.8 and
8.1 /ig/ml of paracetamol and its glucuronide and
sulphate conjugates respectively.
For the overdose range assay, the concentrations
were 42, 24 and 5.2 p.g/ml and 252, 143 and 31 Ms/^l of
paracetamol and its glucuronide and sulphate conjugates
respectively.
Results: Means, standard deviations, coefficients of
variation and percentage accuracy for each assay are
shown in Tables 8 - 10.
Urine: For the. urine assay (Table 8), coefficients of
variation were less than 2$ at all concentrations for
paracetamol and its sulphate and glucuronide conjugates
whereas the mercapturate and cysteine conjugates, which
chromatographed as broader peaks, showed somewhat
greater variability (maximum 1.2%). Accuracy was within
6 percent at all levels for paracetamol and its sulphate
and glucuronide conjugates. The high values obtained
for the cysteine conjugate reflect the difference in
its UY extinction coefficient relative to paracetamol.
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plasma (Table 9)> coefficients of variation ranged from
1.1 to 5.7#. Measured concentrations were within 2#
of weighed-in values for all but the 25 samples
in the overdose range (within 7#).
Plasma-Paracetamol and Metabolites: The ranges of
values obtained for precision were 0.3 - 1.9# (paracetamol)r
0.3 - 2.0# (paracetamol glucuronide) and 0.4 - 2.4#
(paracetamol sulphate, Table 10). The higher values
were all at the low therapeutic level. Accuracy was
within 4# for all compounds at each level except for





Comparisons with other Methods
The above procedures were compared with published
methods for estimating "total" paracetamol in urine
and plasma and free paracetamol in plasma.
(i) Urine
Aliquots of urine samples collected from 10
patients after paracetamol overdosage were pooled
and assayed by HPLC ats in chapter 5. same
pooled samples were assayed following enzymic
hydrolysis of the sulphate and glucuronide conjugates
to free paracetamol which was then estimated by
gas-liquid chromatography (Prescott, 1971a,b). The
total free paracetamol obtained after hydrolysis
and gas-liquid chromatography (T&) was plotted
against the corresponding total of paracetamol and its
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sulphate and glucuronice conjugates obtained by HP1C
(T^). There was a highly significant correlation
between the values obtained by the two methods
(r = 0.995; p<.001) and the slope of the regression
line was close to unity (T^ = 0.95T^ - 0.56; Pig. 18).
(ii) Plasma - Paracetamol Alone;
125 plasma samples collected from poisoned patients
and healthy subjects, with concentrations ranging from
1.3 to 14.0 jug/ml were assayed as in Chapter 5 and by
the gas-liquid chromatographic (GLC) method of Prescott
(1971 b). Values obtained by HPLC were plotted against
those measured by GLC(Fig 19). A highly significant
correlation was obtained (r = 0.997; pc.OOl). The
equation of the regression line was C-^ = 1.02 - 0.21,
where C-^ and are concentrations measured by
HPLC and GLC respectively.
(iii) Plasma - Paracetamol and Metabolites:
Twenty-four samples collected from patients after
paracetamol overdosage and containing a. wide range of
paracetamol concentrations were assayed by the following
method s:-
a. Glynn and Kendal (1975)> which measured free paracet¬
amol only. After protein removal with trichloracetic
acid, paracetamol was nitrated in acid. This was
103
Paracetamol +sulphate &glucuronide
conjugates by HPLC (g)
. 13 Comparison of methods for the estimation of
paracetamol and its sulphate and glucuronide
conjugates in urine using gas-liquid chrom¬
atography (GLC; Prescott 1971a,. b) and
high performance liquid chromatography
(HPLCf Chapter 5 ).
The line denotes 1:1 relationship, n = 10 sample
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PLASMA PARACETAMOL (yug/ml)-GLC
Fig. 19: Comparison of methods for the estimation
of paracetamol alone in plasma by high
performance liquid chromatography (HP1C;
Chapter 5 ) and gas-liquid chromatography
(G1C; Prescott, 1971b).
The line denotes 1:1 relationship
n = 125 samples.
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followed by addition of base to produce and orange-yellow
ion which was read at 450 nm (Mace and Walker, 1976).
b. Wilkinson (1976), which involved protein removal
and hydrolysis using perchloric acid. Hydrolysis was
carried out at 100°c for 40 minutes. The p-aminophenol
released was coupled with o-cresol in the presence of
aqueous ammonia and the resulting blue colour was read
at 615 nm.
c. Smith et a.l (1978), in which protein was first
removed with trichloracetic acid followed by hydrolysis
in 4 N hydrochloric acid at 100°c for one hour. The
p-aminophenol released was coupled with phenol in
alkaline bromine water and the blue colour obtained was
read at 620 nm (Welch and Conney, 1965).
d. By HPLC, as already described in Chapter 5«
Each method was standardised with the same set of
weighed-in paracetamol standards in horse serum. The
"paracetamol" concentrations measured using methods (a),
(b) and (c) were plotted against those obtained by HPLC.
The extents of hydrolysis using method (b) and the
modification advocated by Love (1977) were also assessed.
Plasma (0.5 ml) containing added paracetamol and its
sulphate and glucuronide conjugates was treated with
0.33M perchloric acid (4.5 ml) to precipitate the
proteins and the supernatant was removed for hydrolysis.
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An aliquot (0.5 ml) was removed "before commencing
hydrolysis. Further aliquots (0.5 ml) were removed
after hydrolysis for 10 minutes at 100°c (according to
Love 1977) and after 40 minutes at 100°c (according to
Wilkinson 1976). Equal amounts of internal standard
(50 /il of aqueous NPA, 2.0 mg/ml) were mixed with each
aliquot prior to chromatography as in method (d).
Results
Good correlation coefficients were obtained in each
case (Figs. 20 and 21) but onxy with the method of
Glynn and Kendal (1975) was the slope of the regression
» line close to unity (m = 1.01; Fig. 20 a), indicating
that values were essentially equivalent using this
method and the HPLC procedure. With the methods of
Wilkinson(1976) and Smith et al (1978) the slope values
were 1.20 and 1.87 respectively (Figs. 20b and 21 a),
suggesting that more than .just free paracetamol was
being measured by these two methods. When the paracetamol
concentration measured according to Smith et al (1978)
was plotted against the total paracetamol concentration
by HPLC (ie equivalent to the free drug plus its sulphate
and glucuronide conjugates)r the relationship obtained
suggested that the former method was measuring total
paracetamol in plasma (Fig. 21 b).
Further investigation of the methods of Wilkinson
(1976) and Love (1977) by HPLC showed that paracetamol
sulphate completely disappeared after both hydrolyses
(a)y=l.Olx-1.9;r0.99b.20x+266
«




(b) Paracetamolnditssulphateand glucuronideconj gates(ug/ml)byHPLC
(a)y=1.87x+3 ;r0.98(b)=1. 2x-17;r 0.99
Fig21:Comparisonfplasmaparaceta olconcentrationsobtainedusi gHPL(seechapt r5)and themethodofSmiteal(1978). (a)concentrationofpara etamolonlybyHPLCcomp edwith"para etamolconcentrati n"obtained usingthemethodofSmiteal(1978). (b)concentrationofpara etamoltogeth rwii ssulph teandgluc ron deconj gateobtainedby HPLCcomparedwith"para etamolconcentration"obtainedusi gthemeth dof Smitheal(1978). (n=24;regressionlin ;lidescribing1:1relationsh p).
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(Pig. 22) but even after 40 minutes at 100°c considerable
amounts of free paracetamol and its glucuronide con¬
jugate were present. Thus the "paracetamol" concen¬
tration measured by these methods did not reflect either
free or total paracetamol in plasma. Clinical
interpretation would be mere difficult using these



























10 -I I.S. I
L_
Fig.22:HPLCofparacetamol( )anditsglucuroni e(G)andsu h tS)conj gatesipl smbef rea d afterhydrolysisinpe chloricacid. (a)beforehydrolysis;( )aftehydrolysifor10min(L v ,977);cafthydr lysisfo40min (Wilkinson,1976). IS=internalstandard(N-propionyl-4-aminophe ol).
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Chapter 7 Summary and Discussion
HP1C methods were developed and evaluated for the
estimation of paracetamol and its four major conjugates
in urine and plasma. These methods were shown to be
significant improvements on existing procedures,
especially in terms of simplicity and total assay times.
The 5 A® p&rticle-size spherical reverse-phase column
stationary phase materials now available were particularly
suitable for the analysis of paracetamol and its
conjugates. Fast, efficient separations were achieved
with simple column/injector assemblies at relatively
low pressures and solvent flow rates. Mobile phase
composition could be easily modified to improve peak
detection and separation from endogenous materials.
An internal standard (N-propionyl-4-arninophenol,.
NPA) was prepared and shown to be suitable for quantit¬
ation at different detector wavelengths, owing to its
chemical similarity to paracetamol. The assay procedures
each required only simple one-step sample preparation
(basically addition of internal standard) followed
by chromatography. Peak area or height ratios of each
compound to the internal standard could be related to
standards containing paracetamol only, linearity,
reproducibility and accuracy were demonstrated for each
method over all concentrations likely to be encountered
in practice.
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Each HPIC method was shown to correlate well with
appropriate alternative methods for measuring either
free paracetamol or paracetamol plus its sulphate and
glucuronide conjugates. Also,, more information
concerning the pattern of metabolism could be
obtained more quickly by HPLC due to the specificity
and speed of these methods.
Urine samples containing paracetamol conjugates
were shown to be stable at -20°c for at least 3 years,
an important finding since samples were collected over
a period of years.
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SECTION IV
PARACETAMOL DISPOSITION IN HEALTHY SUBJECTS
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PARACETAMOL DISPOSITION IN HEALTHY S'T"FJ~CTS
Introduction
Thp metabolism of paracetamol was studied after a
single oral dose in 8 healthy subjects. In addition,
the effect of oral N-acetylcysteine, the current treat¬
ment of choice for paracetamol overdosage (Prescott et
al, 1979) on paracetamol metabolism was investigated.
Chapter 1s Subjects and methods .
a) Paracetamol Alone;- Eight healthy male laboratory
and clinical staff volunteered for the study. None had
received any other medication for at least one week
beforehand and each subject fasted overnight before
taking 20 mg/kg paracetamol B.P dissolved" in 400 ml
"Coca-cola" over 10 minutes. The ages and weights of the
subjects and doses administered are shown in Table 11.
The bladder was emptied and an in-dwelling cannula was
inserted into a suitable forearm vein prior to paracetamol
administration- The subjects refrained from smoking and
fluids during the first 2 hours and lunch was allowed"
a hours after dosing. 10 ml blood samples were collected
into heparinised tubes at 0, 15, 30, 45", 60 and 90
minutes and 2, 3, 4, 6 and 8 hours after dosing. The
plasma was separated immediately and stored at -20°c
prior to analysis. Urine samples were collected hourly
for the first 12 hours and from 12 - 24 hours. The
volume and oH of each sample was measured a^d duplicate
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TABLE 11
Paracetamol and healthy subjects - ages
weights and doses administered*
Subject Age Weight Dose
(yr) (kg) (mg)
PA 28 67 131+0
AB 28 70 11+00
JP 3b 75 1500
IK 21 62 121+0
AP 29 68 1360
JP 32 67 131+0
LP b2 75 1500
BE 32 63 1260
* All subjects were male; dose 20mg/kg Paracetamol BP
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aliquot? '"erp stored at -20°c orior to analysis.
b) Paracetamol with N-aeretylcvsteine: The protocol
was identical to (I) above exceot that
(a) 75 mg/kg N-acetylcysteine*was added to the oaracetamol
solution in "Coca-cola". This was followed by two
further doses of 37.5 rag/kg each in 100 ml "Coca-cola"
at 2 and 4 hours after the first dose.
b) In five subjects no blood ssmnles were taken and
urine was collected at 0-2, 2-4, 4-8, and 8 - 2A
hours.
* Supplied as a 20*% W/V solution buffered to pH7 ("Airbron",
Duncen-Flockhart Ltd.)
c) Analytical Methods
Plasma concentrations of paracetamol and its sulphate
and glucuronide conjugates and urine concentrations of
oaracetamol and its sulphate, glucuronice, cysteine and





The absorption, distribution and elimination of
most drugs are usually first-order processes (Gibaldi,,
1971). Thus the rate of delivery of drug to the body
is proportional to the amount present in the gastro¬
intestinal tract and the rate of elimination is
proportional to the amount present in the body. It
follows that the rate of change in the plasma concent-*
rations of the drug and its metabolites is proportional
to the total amount of each present in the body*
assuming that the volumes in which they are distributed
remain constant. Based on these assumptions the
following can be estimated
(a) Apparent Plasma Elimination Half-Life; When
absorption and distribution are complete the plasma
-fit
concentrations decline such that = (Const.) e ....(
(Gibaldi and Perrier, 1975) where C^ is the plasma
concentration at time t and jS describes the elimination
rate of the drug.
Therefore lnC^ = In (Const.) - pt ...»(2)
A plot of lnC^ against time gives a straight line with
slope -J3 .
The apparent plasma elimination half-life (t^) is the
time taken for the concentration to fall by one half
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and is obtained from the formula
The method of least squares was used to estimate p from
semilogarithmic plots of di*ug concentration against
time. Similar relationships also hold for metabolites.
(b) Area under the Plasma Concentration - Time Curve (AUC):
The AUC is a measure of the amount of drug reaching the
systemic circulation (Gibaldi,. 1971).
Areas were calculated by the trapezoidal rule from
points on a linear plot of plasma concentration against
time after ingestion*
(c) Urinary Excretion: Assuming that the urinary
excretion of drugs and metabolites is proportional
to their plasma concentration, a plot of In (excretion
rate) against time gives a linear terminal phase with
slope equal to the apparent elimination constant ,.
as in equation (2).
The excretion rate was estimated from plots of the
hourly excretion of paracetamol and its conjugates at
the mid-point of each urine collection period. The
urinary elimination half-life was estimated according
to equation (3) above, using the method of least squares
to estimate the slope.
(d) Benal Clearance; The renal clearance of paracetamol
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and its sulphate and glucuronide conjugates were
calculated as follows:-
Totsl compound excreted in each
urine collection period
,it (4)
Renal Clearance = Area, under plasma concentration-
time curve in the same period
Values were calculated from the hourly urinary excretion
of each compound and its plasma concentration at the
sampling times described on p 114 ► Plasma
concentrations at 5 and 7 hours were interpolated
semilogarithmically from the 4 and 6 hour concentrations
and the 6 and 8 hour concentrations respectively. This
enabled areas under the plasma concentration-time
curves to be calculated for each hourly urine collection
up to 8 hours after paracetamol ingestion.
(e) Recovery of Paracetamol and its Metabolites in Urine:
The urinary recovery of paracetamol and its
sulphate,, glucuronider cysteine and mercapturic acid
conjugates was determined up to 24 hours after
paracetamol ingestion. Amounts of the metabolites were
expressed as the paracetamol equivalent.
(f) Statistical Analysis: Mean values are given with
the standard deviation (S.D) except where stated other¬





1) Ingestion of Paracetamol Alone
a) Plasma Concentrations of Paracetamol and its
Conjugates
(i) Paracetamol: Table 12 and Figure 23 show
the mean plasma concentrations of paracetamol and
its sulphate and glucuronide conjugates after
ingestion of 20 mg/kg of paracetamol in the
eight subjects. The cysteine and mercapturic
acid conjugates were not measurable ( < 1/ag/ml).
Individual values for peak concentrationsr times
to reach peak concentrations and apparent




Mean Plasma concentrations of Paracetamol and, its Sulphate and
Glucuronide Conjugates following oral ingestion of 20 mg/kg Paracetamol












0.25 15.7 ± 5.1 2.3 4 0.8 1.5 ± 1.3
o.5 18.7 ± 3.1 1+.1+ ± 1.0 3-7 ± 2.3
0.75 18.7 ±3-1 5.1+ ± 1.0 6.1 ± 3-9
1.0 18.0 ±1.9 6.1 ± 1.1 8.2 ± 1+.9
1.5 15-3 ±1-3 6.0 ± 1.3 11.2 ± 5.8
2.0 13-7 ±2.0 5.7 ± 0.8 12.3 ± 5.1
3.0 10.0 ± 1.8 1+.8 ± 1.0 11.8 ± I4.. 6
2+.o 7.5 ±1.6 b-3 ± 0.9 10.7 ±3-3
6.0 3-9 ±1.3 2.8 ± 0.9 6.8 ± 1.9
8.0 2.5 ±0.9 1.8 ± 0.7 24.-6 ±1.1+























PjL£_2Ji: Plasma concentrations of paracetamol and its
sulphate and glucuronide conjugates following
a 20 mg/kg oral dose of paracetamol in 8 healthy
subjects.






Paracetamol and its Sulphate and Glucuronide conjugates in
plasma - individual peak concentrations and time to reach
peak concentrations in 8 healthy subjects after oral ingestion













PA 0.75 19-2 1 6.03 0c~-CM
AB 0.5 l8.ii. 2 5.92 2 1.1+.5
JP 0.75 23.0 1 7.26 3 9.73
IK 1.0 15.3 1.5 6.30 1+ 7* 66
AP 0.75 21.0 1 1+. 21 3 16.1+
JP 0.5 21.6 2 5.91 2 13.3
LP 0.25 23.1 1 6.99 1.5 23.7











Apparent elimination half-life of Paracetamol and its Sulphate
and Glucuronide conjugates from plasma in 8 healthy subjects










PA 2.67 5.03 2.70
AB 2.03 2.51 2.71+
JE 2.22 3.85 3.05
IK 2.56 1+.1+6 3.60
AP 2.31 1+.11 3-78
JP 2.32 3.1+1 3-51+
LP 1.1+7 2.1+0 2.1+5










Paracetamol absorption was rapid with a mean
individual peak concentration of 19.7- 3.0 fig/ml
occurring at 0.66 + 0.23 hours after ingestion. There¬
after levels appeared to decline monophasically in all
subjects with a mean apparent elimination half-life of
2.30^0.41 hours.
(if) Metabolites: Paracetamol sulphate and glucuronide
conjugates were present in plasma in all subjects at
15 min.. The peak concentration of the sulphate
conjugate generally occurred within an hour of the
peak concentration of the parent drug (mean 1.4-0.4
hours after ingestion) but occurred somewhat later
(mean 2.4^0.7 hours) with the glucuronide. The
concentrations of paracetamol sulphate were considerably
lower than those of the free drug. In contrast,
paracetamol glucuronide concentrations usually rose
steadily, eventually exceeding those of the free drug
(between 0.8 and 5 hours). In one subject (PA)
paracetamol glucuronide concentrations were particularly
low throughout. The mean individual peak concentrations
of paracetamol sulphate and paracetamol glucuronide
were 6.34—1.15 fig/ml and 12.81 5.5 jag/311 respectively.
The apparent elimination half-lives of the conjugates
were longer than those of the free drug, being 3.67lto.90
hours and 3.19lto.51 hours for-paracetamol sulphate and
glucuronide respectively. Both conjugates were easily
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measurable at 8 hours, (mean concentration of 1.8 ±
0.7 /ig/ml and 4.6 ± 1.4 /ig/ml for paracetamol sulphate
and glucuronide respectively).
(b) Urinary Excretion of Paracetamol and its Conjugates
The mean urinary excretion rates of paracetamol and
its major conjugates in collections up to 24 hours after
paracetamol ingestion are shown in Table 19 and Pig. 2-4 ..
The mean urinary elimination half-lives calculated from
individual plots are shown in Table 20.
(i) Paracetamol: Urinary excretion rates of paracetamol
were low in all subjects with a mean peak value of
11.3 ±3 .5 mg/hr occurring in the second hour after
ingestion. After 4-5 hours the mean excretion rate
of paracetamol was lower than each of the major
conjugates and remained so. Individual plots of
In (excretion rate) against time were usually linear
after 2 hours but sometimes fluctuated considerably.
The mean urinary elimination half-life was 2.86±0.91
hours (range 2.15 - 4.92 hours).
(ii) Paracetamol Sulphate: The mean excretion rate of
paracetamol sulphate was higher than that of any of the
other compounds during the first hour after ingestion
(41.5 ±11.9 mg/hr). The peak mean excretion rate
(60.8 ±14.2 mg/hr) occurred during the second, hour
after ingestion, as did the individual peak in 7 of the
























































































































































































































































Fig. 24-: Mean urinary excretion rates of paracetamol and
its conjugates following 20 mg/kg paracetamol
orally in 8 healthy subjects.
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TABLE 20
Apparent urinary elimination half-life of Paracetamol and
its conjugates in 8 healthy subjects following oral ingestion




mean ± S.D. (range)
Paracetamol 2.86 ± 0.91 (2.19 - b.92)
Paracetamol
Sulphate 3.66 ± 0.91 (2.6$ - 1+.95)
Paracetamol
Glucuronide 3.39 ± 0.52 (2.66 - 3.96)
Paracetamol
Mercapturate 3.88 ± 0.98 (2.1+8 - 1+.88)
Paracetamol
Cysteine
L+.72 ± 2.38 (1.97 - 9.7$)
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rate) against time declined linearly after 2-3 hours
and the mean individual urihary elimination half-life
was the same as the plasma elimination half-life (3.66 -
0.91 hours, range 2-65 - 4.95 hours).
(iii) Paracetamol G-lucuronide; Excretion rate-time
plcrt-s of paracetamol glucuronide were generally
smooth curves with maxima 2-3 hours after ingestion.
The maximum mean excretion rate (96.0 ^34.2 mg/hr) also
occurred at 2 - 3 hours. From the second hour the mean
excretion rate of paracetamol glucuronide exceeded that
of the other compounds. However, in one subject (PA)
excretion of the sulphate conjugate exceeded that of
the glucuronide for most of the 24 hour study period.
The mean individual urinary elimination half-life was
3.39—0.52 hours (range 2.66 - 3.96 hours) which was
similar to the value estimated from plasma concentrations.
(iv) Paracetamol Cysteine and Mercapturic Acid Conjugates
Both of these compounds were present in the first (1 hour)
urine sample of all subjects. The excretion rates were
initially very low but increased steadily to reach a
maximum usually between 2 and 4 hours after ingestion.
The maximum mean excretion rates of the., mercapturic
acid and cysteine conjugates were 7.5-2.7 and 5.3-1.7
mg/hr respectively.
The mean estimated urinary elimination half-lives
were 3.88 - 0.98 (range 2.48 - 4.88 hr) and 4.72- 2.38 hr
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(range 1.97 - 9.75 hr) for the mercapturic acid and
cysteine conjugates respectively.
(c) Recovery of Paracetamol and its Conjugates in Urine:
The percentages of the dose recovered in 24 hour
uiine collections as paracetamol and its conjugates in
individual subjects following ingestion of 20 mg/kg
paracetamol are shown in Table 21.
Only small amounts were recovered as unchanged drug
(mean 4.7 11.1$ of dose, range 3.2 - 6.3$)r over half
of which was excreted during the first 4 hours.
Excretion of the mercapturic acid and cysteine
conjugates was slow at first but after 12 hours the
recovery of each of these metabolites reached 87$ of the
24 hour totals. After 24 hours, 4.0-1.1$ (range 2.5 -
5.6) and 3.4- 1-0$ (range 2.0 — 5-1) of the dose was
recovered as paracetamol mercapturate and paracetamol
cysteine respectively. The individual combined recovery
of these conjugates accounted: for between 4.7 and 9.2$
of the dose (mean 7.4^1.7$).
Excretion of the sulphate and giucuronide conjugates
reached 48$ and 43$ of the respective 24 hour recoveries
after 4 hours and the amounts excreted after 12 hours
were 88$ of the 24 hour totals for both conjugates.
After 24 hours, paracetamol sulphate and giucuronide
accounted for 30.3-9.0 and 50.3-12.3 per cent of
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TABLE 21
Percentage of dose recovered in 2k hour urine collections
as Paracetamol (P) and its Sulphate (S), Glucuronide (G),
Mercapturic acid (M) and Cysteine (C) conjugates following
a 20 mg/kg oral dose of Paracetamol in 8 healthy subjects.
Percentage of dose recovered ass-
Subject
P S G M c M+C Total
PA b-3 b2.7 3l|.6 5.6 3.6 9.2 90.8
AB 6.3 23-9 1+9.1; i|.i| 3.1 7-5 87.1
JB 5.6 3b. 2 1+5.9 3-3 5.1 8.5 9U.1
IK 5.8 35.5 38.9 5.U 3.8 9.1 89.3
AP 3-2 19-3 65-9 3-7 3.7 7.1; 95.7
JP b.7 26.ii 55.3 i|.0 3.8 7.8 9b. 2
LP 3-6 20.1 69.0 3.2 2.0 5-2 97.9
HR k.l ilO.O b3.7 2.5 2.2 92.6
Mean b.7 30.3 50.3 l+.o 3.b 7.1; 92.7
±S.D. ±1.1 ±9.0 ±12.3 ±1.1 ± 1.0 ±1.7 ±3-5
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the dose respectively» Although mean recovery of the
glucuronide was considerably greater than that of the
sulphate conjugate, individual values varied widely,-
with ranges of 19.3 - 42.7 and 34.6 - 69»0# of the dose
recovered as sulphate and glucuronide conjugates
respectively. There was a statistically significant
inverse correlation between the 24 hour recoveries of
the two conjugates in each individual- In terms of
amounts recovered, rr-0.8l (p<.02) whereas in terms
of # of dose recovered, r I 0-92* (pc.OO!?). In one
subject (PA), 21 hour recovery of the sulphate was
considerably higher than that of the glucuronide
conjugate (42.7# and 34.6# of the dose respectively).
The a.pparent plasma paracetamol half-life appeared
to be related to the excretion of the sulphate and
glucuronide conjugates. A positive correlation was
obtained between the percentage of dose excreted as
paracetamol sulphate in 24 hours and the plasma
paracetamol half-life (r= 0.77* p<.025~). However, the
correlation obtained between the percentage of dose
excreted as paracetamol glucuronide in 24 hours and the
plasma paracetamol half-life was negative (rr-0.75;
pC.O?). No relationship was found between the plasma
paracetamol half-life and excretion of either the
unchanged drug or combined excretion of the mercapturic
acid and cysteine conjugates.
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Overall, 87.1 - 97.9 per cent of the dose was
recovered in 24 hours as paracetamol and its sulphate,
glucuronide, mercapturic acid and cysteine conjugates
in the 8 subjects,(mean 92.7-3.5 per cent).
(d) Proportional Excretion of Paracetamol and its
Conjugates;
The change in the pattern of renal excretion of
paracetamol and its metabolites with time is demonstrated
by considering the amounts of each compound excreted
relative to the total amount of all five compounds
excreted in each sampling interval. Pig. 25 shows
this pattern in a typical subject (JP) and Table 22
shows the mean individual values of all 8 subjects.
Sulphate conjugation accounted for a large
proportion of the total drug excreted initially
(mean 47.6—10.3$ in the first hour) but by 3 hours
this fell to 31.2^9.4$. The proportion excreted as
paracetamol sulphate then remained fairly constant
until 12 hours, after which it increased slightly.
Glucuronide conjugation followed the opposite course,
accounting for an increasing proportion of the total
drug excreted during the first 3 hours (initially 38.6^1
12.7$,up to 55.5—12.0$ in the third hour), followed
by a decrease after 11 - 12 hours.
Excretion of unchanged drug accounted for a higher
proportion of total excretion during the first 2 or 3
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Fi£_25_: Urinary excretion of paracetamol and its
conjugates after 20 mg/kg paracetamol
orally in subject JP. Amounts are expressed




Urinary excretion of Paracetamol and its conjugates expressed as
percentages of the total drug recovered in each sample following
20 mg/kg Paracetamol orally in 8 healthy subjects
(values are mean ± S.L>.)
Time after Percentage of total in sample excreted as:-
ingestion
(hr) S G P M c
0-1 1+7-6 ±10.3 38.6 ±12.7 11.1 ± 1+.3 1.3±0.6 1.1+ ± 0.6
1-2 38.1 ±10.8 1+9.6 ±13.0 7.0 ±2.3 2.9 11.2 2.3 ±0.8
2-3 31.2 ± 9.1+ 55-5 ±12.0 5.7 ±2.0 1+.5 ±1.6 3.1 ±0.9
3-1+ 29-3 ± 9-3 57.1 ±11.0 5.1 ±1.9 1+.9 ±1.7 3.6 ±0.7
1+-5 29-5 ± 9-1+ 57.1+ ±10.7 3.8 ±1.1+ 5.2 ± 1.9 1+.1 ±0.9
3-6 29.9 ±10.2 57.7 ±11.5 3.6 ±1.3 1+.5 ±1-5 1+.3 ±1.2
6-7 30.2 ±11.2 57-3 ±11.1+ 3-1+ ±1-3 1+.5 ±1.1 1+-7 ±1.7
7-8 29.6 ±11.5 56.8 ±12.2 1+.1 ±1.2 1+.9 ± 1.1 1+.7 ±1.8
8-9 30.0 ±11.5 56.1+ ±12.5 3-3 ±1-3 5-5 ±1.1+ 1+.9 ± 2.1
9-10 30.0 ±11.3 56.1 ±11.6 3-3 ±1.6 5.7 ±1.7 1+.9 ± 2.0
10-11 30.3 ±11.3 55-5 ±12.0 l+.o ± 2.1 5.2 ±1.7 5.1 ±2.1+
11-12 31.1 ±11.5 51+. 7 ±11.8 1+.3 ± 2.1+ 1+.9 ±2.6 5.0 ± 2.7
12-21+ 33-7 ±12.2 53-0 ±12.1 1+.1 ± 2.0 5.2 ±2.8 l+.O ± 2.3
KEY:
P = Paracetamol
S = Paracetamol sulphate
G = Paracetamol glucuronide
M = Paracetamol mercapturate
C = Paracetamol cysteine
137
hoars than subsequently (mean 11.1-4.3# in the first
hour down to 5.1—1.9# in the fourth hour). This
presumably reflects the higher plasma concentrations
of paracetamol in the 3 hours following paracetamol
ingestion.
Only 1.3# and 1.4# (mean values) of the total
excreted in the first hour was in the form of the
mercapturic acid and cysteine conjugates respectively.
However, the mean combined excretion of these conjugates
accounted for 8.5 - 10-6# of the total excreted1 after
3 hours. On average,, slightly more was excreted: as
the mercapturic acid than as the cysteine conjugate.
(e) Renal Clearance of Paracetamol and its Sulphate and
Glucuronide Conjugates:
Table 23 shows the renal clearance of paracetamol
and its sulphate and glucuronide conjugates (mean - SD
of 8 subjects) during the first eight; hours after
paracetamol ingestion. Renal clearance of paracetamolWss
relatively low during the first hour (10.71 5.2 ml/min),.
mainly due to very low values in 2 subjects who produced
very low urine volumes in the first hour. Values then
increased to a mean which remained relatively constant
(14 - 17 ml/min) from 2-8 hours after ingestion. The
overall mean value was 14.1-6.1 ml/min and there was
wide individual variation (range of individual means




























































































































































































of the sulphate and glucuronide conjugates were- "both
high with little variation. The respective mean values
for the renal clearance of paracetamol sulphate and
glucuronide were 167^34 and 135 —22 ml/min (ranges of
individual means 141 - 214 and 112 - 151 ml/min
respectively).
The relationship between renal clearance and urine
flow rate was studied using linear regression analysis.
The correlation coefficient with paracetamol was
r-0.33 (pc.Ol; n - 64 values) suggesting that the
renal clearance is dependent on urine flow rate. The
respective values for the sulphate and glucuronide con¬
jugates were r- -0.09 and r- 0.08,, indicating no corre¬
lation between renal clearance and urine flow rate.
Similar analysis of the relationship between renal
clearance and urine pH showed no significant correlations
with any of the 3 compounds (the respective r values
were 0.09, 0-03 and -0.14 for paracetamol and its
sulphate and glucuronide conjugates)-
2) Paracetamol with N-Acetylc.ysteine
(a) Plasma Concentrations of Paracetamol and its
Conjugates
N-acetylcysteine (NAC) had little effect on the
elimination of paracetamol and- its metabolites
from plasma in three subjects (Pig. 26; Table 24)-
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HOURS AFTER INGESTION
Fig 26:. Mean plasma concentrations of paracetamol and
its sulphate and glucuronide conjugates in
3 healthy subjects after oral ingestion of




Plasma concentrations of Paracetamol and its Sulphate and Glucuronide
conjugates following Oral Ingestion of Paracetamol in 3 healthy subjects













P - P +
(yg + S.L./mL)
0.25 20.k±3'3 17-21+.3 2.6 ±0.14- 2.2H.2 2.0±1.1; 1.7±1.8
0.5 20.611.9 17.1 ±2.9 1;. 8±0. 6 I;. 311 . 6 5-1;±2.9 5.3±1;.8
0.75 18.8 ±2.1 16.6±0.3 5.5±0.7 5.I4H.2 8.915.3 8.U+6.0
1.0 17.6±0.8 15.5±1 -3 6.1+0.8 5.611.2 11.716.5 10.5±8.1
1.5 1U-3 ±0-8 1U.9±2.9 6.010.5 6.110.7 15.9*16.8 15.1 ±7-8
2.0 11.8 ±1.8 12.5±2.U 5.7±0.5 6. oio.ii 16.5ii;.5 16.818.0
3.0 8.1±1.5 8.311.8 J+.610.2 1;.610.1; 15.1+U.3 15.3±5.1+
k.O 5.8H.5 5-9±l >h 3-8±0.5 3.6±0.5 12.7±2.0 12.913.8
6.0 2.6±i.o 3.U±1.2 2.0±0.5 2.no.3 7.112.1 8.3±1.6
8.0 1.6±0.6 2.211.5 1. 3± 0.1+ 1.1;±0.7 1;. 7—1.0 2+.9±0.9
* Plasma concentrations after ingesting Paracetamol alone
t Plasma concentrations after ingesting Paracetamol with N-acetylcysteine
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The only obvious difference was that individual peak
free drug concentrations were slightly lower (18.9-2.7
p.g/ml compared to 21.0-2.4 jug/ml) and occurred later
with NAC (0.83 -0.63 hr compared to 0.42^0.14 hr,
Table 25). The apparent plasma elimination half-lives
of paracetamol and its sulphate and glucuronide con¬
jugates were not significantly altered by NAC (Table 26)»
(b) Areas Under the Plasma Concentration - Time Curves
of Paracetamol and its Sulphate and Glucuronide
Conjugates:
The areas under the plasma concentration-time curves (AUC)
of paracetamol and its sulphate and glucuronide conjugates
were measured in three subjects following paracetamol
ingestion with and without NAC (Table 27). Intersubject
variation was considerable, especially for paracetamol
glucuronide. However, the values obtained for each
compound with and without NAC were very similar for
each individual. Overall,there were no significant
changes in the AUC of any of the three compounds
following ingestion of paracetamol with NAC.
(c) Urinary Excretion of Paracetamol and its Conjugates:
NAC had little effect on the urinary excretion of
paracetamol and its major conjugates in the same 3
subjects (Fig. 27, Tables 28 a and b). There was a sig¬







































































































































Apparent plasma elimination half-lives of Paracetamol and
its Sulphate and Glucuronide conjugates in 3 healthy
subjects following oral ingestion of 20 mg/kg Paracetamol














AB 2.03 1-99 2.31 2.63 2.71* 2.99
JP 2.32 2.26 3-1*1 3-09 3-31+ 3.30













Areas under the plasma concentration - time curves of
Paracetamol and its sulphate and glucuronide conjugates
in 3 healthy subjects following oral ingestion of
20 mg/kg Paracetamol with and, without N-acetylcysteine
Area under the plasma concentration







- * + - + - +
AB 63.0 56.8 27.0 21*. 8 61*. 5 71.9
JP 68.0 73.6 30-9 30.0 73.7 61.1*















7.8 10.9 2.2 3-0 22.1* 29.8



























F1? 27: Me&ri urinary excretion rates of paracetamol
and its conjugates following 20 mg/kg
paracetamol orally with and without
N-acetylcysteine in 3 healthy subjects.
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TABLE 28(a)
Mean hourly excretion of Paracetamol and its Sulphate and. Glucuronide
conjugates in the urine of 3 healthy subjects following oral ingestion of













P - P +
(mg ± S.D./hr)
0-1 11.9±1.3 O 6.1+73.8 1+1. 8± 1.6 35.8±7.3 50.7120.9 1+2.1120.6
1-2 l2.1+±0.9 9.8±2.9 53»8±l+.5 ^ 61+.6±5.5 115±52 11911+7
2-3 9.3±l+.6 9-5±l+.2 1+1+. 7±11.7 1+9 • 2 ±9.1+ 125137 130123
3-4 7.2±2.5 8.7±2.9 33.5±l+.2 38.5*3-9 102130 115±25
4-5 5.3±1.1 5-3*1.4 27.1+±1.8 30.0±1+.1 82.3±21.0 -90.1116.9
5-6 3-7±2.2 4-5*1.6 2l+.i+±l+.8 26.9±6.3 71.8+6.3 71+.9±6.9
6-7 2.3±1.1 3-3*1.1 16.1+±1.5 20.1 il+. 1 1+9.6111+.1 57.817.6
7-8 2.0±0.1+ 2.9±0.7 13.4+5.1 11+.312.0 1+1.6H0.8 1+1.6110.1
8-9 1.6±0.9 1.8±0.8 9.812.0 13.H5.2 29.3±2.7 35.3±4.3
9-10 1.6±0.6 1.3±0.1+ 9.012.1+ 8.012.1+ 26.1+4.9 21+.111+.6
10-11 1.l+±0.9 1. 2±0.5 7.U±2.5 7.912.9 20.113.8 21.2+1.2
11-12 1.3±0.7 1.3±0.1+ 6.712.9 8.211+.1 17.8+5.5 20.6i6.3
12-21+ 0.7±0.3* 0.5*0.1* 3.5+1.1* 2.710.8* 7.611.0* 5-8+1.0*
t Excretion rates after ingesting Paracetamol alone
tt Excretion rates after ingesting Paracetamol with N-acetylcysteine





Mean hourly excretion of Paracetamol Mercapturic acid and Cysteine
conjugates jn the urine of 3 healthy subjects following oral ingestion










P - P +
(mg ± S.L./hr)
0-1 1.5 ± o.k 0.9 ± 0.2 1.1 ± 0.5 1.0+ 0.3
1-2 5.2 ± 1.2 5.2 ± 1.7 3.7 ± 1-1). 3.7 ± 0.7
2-3 8.1; ± 1.9 7.2 ± 1.1 5.5 ± 2.3 5.3 ± 0.1;
3-k 6.6 ±0.6 6.1; ±1.5 5.1; ± 0.1; 1;.7 _± 1 -0
k-S 5.8 ± 0.6 5.6 ± 0.9 k-1 ± 0.7 h*k ± 0.2
5-6 U-9 ± 1.0 1+.3 ± 1.1 U.1 ±1.2 U.o ± 0.3
6-7 3-5 ±0.3 3.6 ± 0.6 3-1) ± 1.0 3-6 ± 0.1;
7-8 3.1 ± 0.9 2.8 ± 0.6 2.7 ± 1 .1) 208 ± 0.5
8-9 2.3 ± 0.7 2.9 ± 0.8 1.7 ± 0.5 2.8 ± 0.6
9-10 2.0 ± 0.7 1.8 ± 0.5 1.6 ± 0.7 1.5 ± 0.1;
10-11 1.1; ± 0.5 1.3 ± 0.6 1.2 ± 1.0 1.5 ± 0.2
11-12 1.3 ± 0.6 1.3 ± 0.6 1.0 ± 0.7 1.1) ± 0.5




Excretion rates after ingesting Paracetamol alone
Excretion rates after ingesting Paracetamol with N-acetylcysteine
Mean of total excreted "between 12 and 21; hours after ingestion
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in the first hoar (6.4 — 0.8 mg/hr compared with 11.9 -
1.3 mg/hr without NAC; p<.02) followed by an increase
in excretion of the sulphate conjugate during the
second hour (64.6 — 5.5 mg/hr compared with 53-8-4.5
mg/hr without NAC; p<.05). However, in terms of the
proportions of each compound excreted relative to the
total drug recovery in each sample, the differences were
not statistically significant although they were still
considerable. The percentage excreted unchanged relative
to the total drug recovered in the first hour decreased
from 11.5—3.0$ without NAC to 8.1 — 3.8$ with NAC and
the respective increase in paracetamol sulphate excretion
in the second hour was from 29.4-6.0$ without NAC to
33-2 -7.2$ with NAC.
The discrepancies noted above were due to a lower
urinary recovery of paracetamol and its conjugates in
the first hour followed by a slightly higher recovery in
the second hour with NAC. The recoveries obtained were
■j- _L
7.5—1.0 and 6.1—1.5 per cent of the dose in the first
hour after paracetamol without and with NAC respectively.
The values for the second hour were 13.3-^3.0 and 14.2 i
2.8 per cent of the dose respectively.
The initially lower excretion rate of unchanged drug
reflected the lower concentrations of plasma paracetamol
seen during the first hour after ingestion with NAC.
However, the differences in plasma paracetamol sulphate
concentration's were not as marked as the differences in
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urinary excretion of the sulphate conjugate.
Excretion of paracetamol and its conjugates in all
8 subjects up to 2, 4, 8 and 24 hours after ingestion
and also between these times is shown in Figs. 28 and
29 and Tables 29 and 30. The only appreciable effect
of NAC was to decrease the excretion of paracetamol
during the first two hours (mean 15.3 — 4.3 mg with NAC
and 21.li7.3 mg without NAC;: p<.05). No other
statistically significant differences were found.
(d) Total Becovery of Paracetamol and its Conjugates
in Urine:
The 24 hour recoveries of paracetamol and its
conjugates in all 8 subjects following ingestion of
paracetamol with NAC are shown in Table 31. The mean
value was 91.0 — 4-3 per cent of the dose (range 84.1 -
96.4$) which was very similar to the recovery following
paracetamol alone (mean 92.7 — 3.5$ Dose, range 87.1 -
97-9$). The mean recoveries of the individual compounds
were also very close to those obtained following
paracetamol alone (compare Tables 21 and 31) and no
statistical differences were observed either separately
or overall.
The inter-subject variation in the recovery of each
compound was as wide as after paracetamol alone. Also,
it was particularly notable that recoveries of the
sulphate and glucuronide conjugates after paracetamol
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Fig 28: Mean Cumulative excretion of paracetamol and
its conjugates in urine following 20 mg/kg
paracetamol orally with and without N—acetylcysteine
in 8 healthy subjects.
Paracetamol
P-=051
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Fig.29:Urinaryexcretionofpara etam landitsconju a sfoll wing20mg/kgparacetamoll ywithandith ut N-acetylcysteine.Valuesrm an±s. .m.of8subj cts.
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TABLE 29
Cumulative excretion of Paracetamol and its ma.ior conjugates in
the urine of 8 healthy subjects following oral ingestion of





excretion (mg ± S.D.)





21.1 ± 7-3 * 15-3 ± 1+-3
38.0 ± 11.5 32.9 ±9-6
52.1+ ± 11+.5 1+8.7 ± 11+.1+





102 ± 23 99 ± 28
196 ±1+6 196 ± 1+9
310 ± 82 313 ± 81+





119 ± 58 116 ± 55
299 ± 111+ 305 ± 117
520 ± 159 537 ± 16I+





5.9 ±2.1+ 5.3 ± 2.1
20.2 ±6.6 18.8 ± 5-6
38.6 ±10.6 36.3 ± 9-9





1+.8 ±1.5 1+.1 ± 1.2
15.2 ±3-7 13.7 ± 3-5
32.1+ +8.0 31-2 ± 9.3





10.7 ±3-6 9-1+ ± 3-2
35-1+ ±9.1+ 32.5 ± 8.6
71.0 ±15.8 67.5 ± 17.6
101.1+ ±22.5 99-7 ± 23.6
* p < 0.05
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TABLE 30
Excretion of Paracetamol and its major conjugates in urine during
different -intervals after: oral ingestion of 20 mg/kg Paracetamol





excreted (mg ± S.D.)





21.1 ± 7-3 *15-3 ± 1+-3
16.9 ± 2.1 17.6 ± 6.1
1L+.1+ 1 1+.2 15.8 ± 5-1+





102 ± 23 99-1+ ± 28.3
93-3 ± 2J+.1 96.7 + 21+.2
115 ± 39 117 ± 39





119 ± 58 116 + 55
180 ± 57 189 ± 61+
221 ± 52 233 + 51





5.9 ± 2.1+ 5-3 + 2.1
1I+.3 ± 1+.3 13.5 ± l+.o
18.1+ ± 5.1 17.5 ± 5-0





1+.8 ±1.5 1+.1 + 1.2
10.1+ ± 2.1+ 9.6 + 2.6
17.2 ± 5.8 17.5 + 6.6





10.7 ± 3.6 9.1+ ± 3-2
21+.7 ± 6.0 23.1 ± 6.2
35.6 ± 9.1+ 35.0 ± 10.6
30.5 ± 11.0 32.2 ± 9.1+
* p < 0.05
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TABLE 31
Percentage of dose recovered in 24 hour urine collections as
Paracetamol (P) and its Sulphate (s). Glucuronide (G). Mercapturic
acid (M) and. Cysteine (C) conjugates following a 20 mg/kg oral dose
of Paracetamol with N-acetylcysteine in 8 healthy subjects
Percentage of dose recovered as:-
Subject
P S G M c M+C Total
PA 4-9 42.0 34.9 4.6 3.6 8.2 90.0
AB 4-4 26.8 57.6 3.0 3-0 6.0 94.8
JP 5.2 32.7 46.4 2.9 4.9 7.8 92.2
IK 5.3 34.7 37.2 4.9 3.6 8.4 85.6
AP 1.9 14.9 57.3 5.1 4.8 9.9 84.1
JP 5.9 28.6 52.6 3-6 3.2 6.8 93.8
LP 2.8 19-4 67.4 3.8 3.0 6.8 96.4
HR 5.4 37.9 43.7 2.4 2.1 4-4 91.4
Mean 4.5 29.6 49-7 3-8 3-5 7.3 91.0
±S.D. ±1.4 *9.2 ± ll.l ±1.0 ±0.9 ±1-7 ±4-3
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with NAC were very similar to those obtained in each
subject following paracetamol alone.
The apparent relationship; between sulphate and
glucuronide conjugate excretion noted after ingestion
of paracetamol alone was maintained after paracetamol
with NAC, although the inverse correlation was slightly
weaker. In terms of amounts excreted as each conjugate^
rm-0.72 (p<.05) and in terms of per cent of the
dose excreted, r = -0..88 (p<.005").
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3) Summary of Results
1) Absorption of an oral dose of paracetamol was rapid
but may have been delayed by NAG. After paracetamol
alone the mean peak paracetamol concentration was 19.7
jug/ml and occurred 0.66hr after ingestion (mean of 8
subjects). In 3 subjects the mean peak paracetamol
concentration was reduced from 21.0 to 18.9 P-g/ml and
was delayed from 0.42 to 0.83 br after co-administration
of NAC. Absorption was essentially complete as judged
by the mean 24 hour urinary recovery of 92.7$ of the
ingested dose (91.0$ with NAC)as paracetamol and its
major conjugates.
2) Paracetamol was eliminated almost entirely by
metabolism since only 1.9 - 6.3$ of the dose was
recovered unchanged in the urine in 24 hours. The
mean plasma half-life was 2.30 + 0.41 hours. The urinary
half-life was more variable but not significantly
different from the plasma value (2.86 + 0.91 hr).
3) The sulphate and glucuronide conjugates were formed
rapidly and both were present in the plasma 15
minutes after paracetamol ingestion. Plasma concentrations
of paracetamol sulphate reached peak values of 4.2 - 8.1
pg/ml usually within 1 hour after those of the parent
drug. Plasma paracetamol glucuronide concentrations
increased slowly to maxima of 7.1 — 23.7 ;ug/ml 1.5 - 4
hours after paracetamol ingestion, usually exceeding the
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parent drag concentrations.
4) The mercapturic acid and cysteine conjugates were
not measurable in plasma following a 20 mg/kg oral
dose of paracetamol. The limit of detection for "both
conjugates was below 1 p.g/ml.
5) NAC (total dose 150 mg/kg) given with paracetamol
did not significantly affect plasma concentrations
of parent drug or its metabolites, although paracetamol
concentrations were lowered during the first hour.
6) The sulphate and glucuronide conjugates were rapidly
excreted in the urine. Sulphate conjugation accoun¬
ted for a mean of 47.6$ of the total excreted during
the first hour but means of only 29 - 34$ after the
second hour. In contrast, excretion of the glucuronide
conjugate increased from a mean of 38.6$ of the total
in the first hour to means of 53 - 58$ after the second
hour.. In 24 hours, individual totals of 15 - 43 and
35 - 69 per cent of the dose were recovered in urine as
the sulphate and glucuronide conjugates respectively.
7) Urinary excretion of the mercapturic acid and
cysteine conjugates was initially very low and
always accounted for a minor portion of the total drug
excreted (maximum 10.6$ combined). The 24 hour urinary
recoveries of these conjugates were 2.4 - 5.6 and 2.0 -
5.1 per cent of the dose respectively.
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8) NAC given with paracetamol had little effect on
the metabolism and urinary elimination of paracetamol.
9) Individual variability in the metabolism of paracet¬
amol was wide but reproducible.
10) The renal clearance of paracetamol (mean value 14.1
ml/min) was dependent on urine flow rate, suggesting
tubular reabsorption in the kidney. In contrast, the
renal clearance of the sulphate and glucuronide con¬
jugates (mean values 167 and 135 ml/min respectively)
were consistent with active tubular secretion. Urine
pH did not affect the renal excretion of any of these
compounds. There was no limitation of renal clearance
at the higher plasma concentrations of each compound
following the 20 mg/kg paracetamol dose-
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Chapter 4 : Discussion and Summary
(a) Paracetamol
The present study indicates that the absorption
and elimination of paracetamol in man are rapid and
essentially complete following a single oral dose of
20 mg/kg. The mean peak plasma concentration of parent
drug, which occurred at 0.66 hours, was high relative
to those of the metabolites and urinary excretion of
the unchanged drug and its sulphate, glucuronide,
mercapturic acid and cysteine conjugates accounted for
a mean of 92.7$ of the dose in 24 hours. The minor
metabolites,conjugated dihydroxy derivatives reported by
Mrochek et al (1974) and Andrews et al (1976) and the
thiomethyl derivative reported by Klutch et al (1978)
probably contribute to the fraction of the dose not
accounted for in the present study. Paracetamol and its
metabolites are unlikely to be excreted to any extent
by other routes.
Absorption of paracetamol after oral dosage occurs
mostly after gastric emptying into the duodenum (Heading
et al, 1973) and this is followed by passage through the
liver and then to the systemic circulation. Significant
metabolism is unlikely to occur in the gastro-intestinal
tract. Josting et al (1976) observed only about 4$
conjugation of paracetamol in rat intestine and gut
mucosal cell preparations after 30 minutes incubation,
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by which time most of a dose would be absorbed. However,
significant "first pass" metabolism of paracetamol
occurs, presumably mostly in the liver (Rawlins et al,
1977; Perucea and Richens, 1979).
The rate of paracetamol metabolism is affected by
its rate of delivery to the liver. In the present study^
the mean proportion of unchanged drug relative to total
drug excreted in urine fell from 11.1 - 4.3# in the
first hour, when drug delivery rates were relatively
high, to 5.7 - 2*0# in the third hour after ingestion,
by which time absorption was complete. The data of
Heading et al (1973) show that more than double the
proportion of unchanged to conjugated drug was excreted
in 4 hour urine collections from subjects with normal
gastric emptying rates (and hence drug delivery rates)
compared to those with slow emptying.
This effect is also reflected in studies on the
proportion of the dose reaching the systemic circulation
(ie the bioavailability) after initial passage through
the liver. Rawlins et al (1977) found that the bioavaila¬
bility of a 0.5g oral dose of paracetamol was consid¬
erably lower than that of lg and 2g doses * indicating
that drug reaching the liver in low concentrations
from small doses is more efficiently removed than in
higher concentrations. Their observation that this
difference was not maintained beyond a lg dose suggests
that this limitation of the ability of the liver to
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eliminate paracetamol is probably transient and related
to the short period of peak drag delivery.
In the present study, a mean of 89$> of the total
drug recovered in the first hour was in the form of
metabolites, almost all as the sulphate and glucuronide
conjugates. Sulphate conjugation appears to. "be
particularly important early after paracetamol ingestion*
Mean plasma concentrations of paracetamol sulphate
were higher than those of the glucuronide during the
first 30 minutes or so and the sulphate conjugate
accounted for a relatively high proportion of total
drug excreted during the first two hours. It seems"
likely, therefore,that this route is primarily res¬
ponsible for the first pass metabolism of paracetamol.
If glucuronidation, the other major route for paracetamol
elimination, contributes significantly, low first pass
metabolism would be expected in subjects with low
glucuronide-conjugating ability (Gilbert's Syndrome).
This was not found by Douglas et al (1978) who noted
that the first pass metabolism of paracetamol was
unimpaired in such subjects.
Elimination by glucuronidation rapidly becomes
more prominent once paracetamol absorption is complete.
Mean plasma concentrations of paracetamol glucuronide
continued to rise for about an hour after those of
the sulphate conjugate had begun to fall. Also, the
mean peak concentration of the glucuronide (12.8 -5.5
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jug/ml) was twice as high as that of the sulphate conjugate
(6.3 - 1.2 /ig/ml). These differences were not due to
renal clearance (which was similar for both compounds)
and were reflected in the urinary excretion pattern.
Other workers have suggested that sulphate conjugation
of paracetamol in man is easily saturated, even at
therapeutic doses (Levy and Yamada, 1971; Davis et al,
1976)» Weitering et al (1979) observed decreasing
sulphation and increasing glucuronidation with increas¬
ing doses of phenol in rats and concluded that different
relative affinities of the two enzyme systems for the
substrate rather than limited availability of sulphate
accounted for this.
A minor but significant proportion of the dose
(mean 7.4 - 1.7$) was excreted as the mercapturic acid
and cysteine conjugates. Neither conjugate was measur¬
able in plasma (with a limit of detection of less than
1 /ig/ml) following the 20 mg/kg dose and their urinary
excretion rates increased slowly relative to those of
the other metabolites. This may be explained by the
findings with rat cell preparations that these compounds
are formed in liver and kidney cells from the glutathione
conjugate. The glutathione conjugate is hydrolysed to
the cysteine conjugate, some of which is excreted as
such and some is acetylated to paracetamol mercapturate
(Moldeus et al, 1978). It seems, therefore, that the
rate of elimination of the mercapturic acid and cysteine
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conjugates depends on the rate of formation of glutathione
conjugate. From 3 to 24 hours, after absorption and
first pass effects were complete, these conjugates
combined accounted for a fairly constant 8.5 - 10.6^
(mean values, Table 22) of the total drug excreted in
urine.
The change in the pattern of urinary excretion of
paracetamol with time was similar in all the subjects
but the differences in metabolism and excretion by
each conjugation pathway were considerable. The vari¬
ation in the urinary recovery of the sulphate and
glucuronide conjugates was each about two fold and^ the
individual recoveries of these compounds were inversely
related. In addition, the plasma paracetamol half-life
was negatively and positively correlated with the
urinary recoveries of the glucuronide and sulphate
conjugates respectively. These relationships imply that
paracetamol elimination is primarily dependent on gluc¬
uronide conjugation and that in subjects with relatively
low glucuronidating activity more dependence is placed
on sulphate conjugation. The variation in the com¬
bined urinary recovery of the mercapturic acid and
cysteine conjugates wa3 again about two fold but this
did not appear to be related to the elimination of the
other compounds or "the paracetamol half-life at the
20 mg/kg dose level-
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In the present study, a mean of less than 5$ of the
dose was recovered unchanged in the urine in 24 hours,
indicating that the elimination of paracetamol depends
almost entirely on metabolism. However, elimination was
rapid as judged by its mean plasma elimination half-life,
regardless of individual metabolic variation. The mean
plasma half-life of paracetamol (determined during the
first 8 hours after ingestion) was 2.30 - 0.41 hours.
This was considerably less than the values of 3-67 - 0.90
and 3-19 - 0.51 hours for the sulphate and glucuronide
conjugates respectively. A mean of 69.6$ of the dose
was excreted in urine in the first 8 hours and 92.7$
* in 24 hours. This indicates that long-term distribution
of paracetamol into poorly-perfused tissues is negligible
after a single oral dose and that paracetamol may be
distributed into short-term, well-perfused tissue sites
(eg liver and kidney) during the first 8 hours. This is
followed by fairly rapid release and elimination from
these sites subsequently. Gwilt et al (1963) showed1 in
dogs that paracetamol distributes fairly evenly into
most tissues except fat- Duggin and Mudge (1976)
produced evidence for renal concentration of paracetamol
using dog kidneys and Douglas et al (1978) discussed
the possibility that the liver may act as a storage
compartment via the glucuronyl transferase system.
(b) Paracetamol with NAC;
NAC produced little effect on the overall elimination
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of paracetamol at the doses given (20 mg/kg paracetamol
and 150 mg/kg NAC)- The areas under the plasma
concentration-time curves of paracetamol and its sulphate
and glucuronide conjugates in 3 subjects were not altered
after NAC. Also,the hour urinary excretion of the
unchanged drug and its conjugates was almost unaltered
in all 8 subjects. Peak plasma paracetamol concentrations
were lower and later in 3 subjects,possibly indicating
a delaying effect on paracetamol absorption due to
nausea and delayed gastric emptying produced by the
large dose of NAC. This is supported by the fact that
the mean urinary recovery of paracetamol and its
metabolites was lower in these 3 subjects during the
first hour than after paracetamol alone. However,
neither of these findings was statistically significant.
It is also possible that NAC might affect the
metabolism of paracetamol. There was a decrease in
excretion of uncharged drug during the first hour
followed by a transient increase in the urinary output
of paracetamol sulphate in the second hour. This may
indicate increased first pass sulphate conjugation.
Sulphate conjugation depends on the availability of
sulphate and drugs such as salicylamide competitively
inhibit paracetamol sulphate formation (Levy and Yamada,
1971). This inhibition can be reversed by cysteine
which presumably acts as a precursor for sulphate
conjugation. It might therefore be expected that NAC
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would act similarly and enhance para.cetamol sulphate
production, thus increasing first pass paracetamol
metabolism. However, the differences described above
may also be explained by the probability that sulphate
conjugation is the most easily limited metabolic route
early after ingestion. The lower rate of delivery
of paracetamol with NAC may allow a greater proportion
to be metabolised by sulphation, regardless of extra
availability of sulphate. Small increases in the mean
proportion of the drug excreted as paracetamol sulphate
were observed in the first and second hours in the three
subjects studied in detail,- but the differences were
not significant. Taking all 8 subjects, the increase
was minimal»
It is also possible that NAC might have increased the
formation of the mercapturic acid and cysteine conjugates,
either directly (Chasseaud, 1974) or via glutathione
(Strubelt et al, 1974). There was no evidence of this
in the urinary excretion studies. However, sulphate
conjugation is saturated with doses of paracetamol
higher than 20 mg/kg (Levy and Yamada, 1971; Davis et alt
1976). NAC may have a significant effect on paracetamol
metabolism in such circumstances.
(c) Renal Clearance of Paracetamol and its Conjugates:
The very low mean value for the renal clearance of
paracetamol indicates extensive renal tubular reabsorption.
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The likelihood of this is confirmed by the dependence
of its renal clearance on arine flow rate. The low
renal clearance of paracetamol contrasts with the
values obtained for the sulphate and glucuronide con¬
jugates. The mean values were higher than the normal
glomerular filtration rate in each case, suggesting
active tubular secretion. Also, there was no correlation
between renal clearance and urine flow rate with the
conjugates. These compounds are highly hydrophilic
and, together with their active secretion, are presumably
not significantly reabsorbed at low urine flow rates.
The lack of effect of the urine pH on the renal
clearance of all 3 compounds is not surprising. Para¬
cetamol is only weakly acidic (pKa - 9*5) and the two
conjugates are both hydrophilic and therefore the
water/lipid partition characteristics of all 3 compounds
are hardly altered over the range of physiological pH»
The renal clearances of all 3 compounds did not change
significantly with time, implying no effect of plasma
concentration on their renal clearance after a 20 mg/kg
dose of paracetamol.
The absence of measurable concentrations of the
mercapturic acid and cysteine conjugates in plasma
has already been discussed (pl63). This fact and the
fact that the mean urinary excretion rates of these
compounds were similar to that of paracetamol after
about 3 hours suggest that their renal clearance is high
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and that they are actively secreted in a similar manner
to the sulphate and glucuronide conjugates.
Overall, changes in renal clearance have no dis-
cernable influence on paracetamol elimination after
therapeutic doses. Only the renal clearance of unchanged
drug could he influenced (by urine flow rate) and this
only accounts for a few per cent of the dose removed
via the kidneys.
The renal clearance of paracetamol and its sulphate
and glucuronide conjugates has been studied in dogs
(Duggin and Mudge, 1975» 1976) and in patients with
paracetamol overdosage (Prescott and Wright, 1973).
Their findings were similar to those of the present
study with regard to the relationships between urine
flow rate and pH and the renal clearance of the 3
compounds. Duggin and Mudge (1975) found that the
renal clearance of the conjugates was reduced at high
plasma concentrations in dogs, suggesting saturation of
the renal tubular transport system. The plasma con¬
centrations of the sulphate and glucuronide conjugates
ranged from 3 to 26 and 15 to 90 jug/ml respectively in
their study, about 3 times higher than those encountered
in the present study. However, the renal clearance values
for these conjugates combined reported by Prescott and
Wright (1973) in patients with paracetamol poisoning were
very similar to those obtained in the present study for
the separate conjugates. This suggests that saturation
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of the renal tabular transport of the sulphate and
glucuronide conjugates is unlikely to occur in man.
The renal clearance of these conjugates and paracetamol
at high plasma concentrations is discussed further in
the following section on paracetamol overdosage.
(d) Other Factors Influencing Paracetamol Metabolism:
The present study throws little light on the
influence of many factors which affect paracetamol
metabolism.. A notable finding in comparing paracetamol
metabolism with and without NAC was the consistent
metabolic pattern in each subject contrasting with great
inter-subject variation. The extent of individual
variation in the 24 hour urinary recovery of each compound
was very similar, as was the relationship between the
percentage of the dose recovered as the glucuronide and
sulphate conjugates in each individual. This consistency
in the wide variation between individuals has also been
noted by other workers (levy and Yamada, 1971). The
explanation for such wide but consistent differences in
paracetamol metabolism in normal subjects of similar age
and weight is not clear but is presumably related to
environmental and genetic factors.
Age appears to influence paracetamol metabolism
considerably. In young children and neonates sulphate
conjugation plays the major role in eliminating paracetamol
whereas glucuronide formation appears to be limited
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compared with young adults (Levy et al, 1975; Miller et
al, 1976). The same workers found that the mean
urinary recovery of paracetamol and its sulphate and
glucuronide conjugates was relatively low in neonates
(63 and of the dose respectively) and tended to
increase with older children. The urinary elimination
half-life tended to "be high (mean values of 3.5 hr
reported by Levy et al, 1975» and 4.9 hr by Miller et
al, 1976) indicating that overall metabolism of
paracetamol may be slow in the very young, although
slow gastric emptying in such subjects may partially
explain this finding.
%
Studies in elderly subjects (mean age above 65 years)
have revealed marginally slower paracetamol elimination
relative to young adults (age range 20 - 40 years;
Briant et al, 1976). There was very wide individual
variation in both subject groups and the plasma half-
life values overlapped considerably (0.95 - 2.79 hours
in young adults and 1.43 - 3.45 hours in the elderly).
No studies on paracetamol metabolite excretion in the
elderly have been reported.
Sex has little effect on paracetamol elimination.
No differences between the sexes were noted in the
urinary elimination of paracetamol in children and
young adults after a 10 mg/kg oral dose (Miller et al,
1976). Also, in young adults and elderly subjects, the
plasma half-life of paracetamol was no different follow-
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ing a lg dose orally (Briant et al, 1976). These work¬
ers noted that the apparent volume of distribution of
paracetamol was slightly lower in females but not
significantly so. In a more closely observed comparison
following lg paracetamol orally (Wojcicki et al, 1979),
the apparent volume of distribution was significantly
lower in 19- 21 year old women, particularly * in the
luteal phase of the menstrual cycle, compared to men of
similar age and weight. Paracetamol metabolism appeared
to be slower in women* particularly in the luteal phase.
However, the differences in the plasma paracetamol
half-life were not significant either with respect to
sex or the stage of the menstrual cycle»
Alteration of paracetamol elimination by agents
which induce metabolic enzyme activity has been reported*
Mitchell et al (1974) studied paracetamol elimination
in healthy subjects before and after phenobarbital
pretreatment and noted that this pretreatment produced
an increase in the amount of paracetamol mercapturate
excreted after a 1.2g dose. Perucca and Bichens (1979)
found that metabolically-induced patients eliminated
a significantly higher proportion of a lg oral dose
by first pass metabolism than normal subjects- The
overall urinary elimination of unchanged paracetamol
and its sulphate and glucuronide conjugates was no
$
different and the plasma half life was shorter but not
significantly so in these induced patients. Mitchell et
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al (1974) found no increase in the overall paracetamol
elimination rate following enzyme induction in normal
subj ects.
Metabolism of paracetamol is dose-dependent.
Mitchell et al (1974) noted an increase in the proportion
of the dose excreted as paracetamol mercapturate foll¬
owing 0.9, 1-2 and 1.8g doses of paracetamol in healthy
subjects. Davis et al (1976) found similar results
with doses of 1 - 4g and also noted limited paracetamol
sulphate excretion at the higher doses. Differences
in the affinities and capacities of the different
conjugation pathways and their relationship with the
cytochrome P-450-dependent oxidation of paracetamol
probably account for this dose-dependent metabolism.
Once sulphate conjugation is limited,, a larger
proportion of the remaining drug appears to be conjug¬
ated via glucuronidation and oxidised via cytochrome
P-450-dependent metabolism. This results in larger
proportions being excreted as the glucuronide and the
mercapturic acid and cysteine conjugates respectively.
These two pathways do not appear to become saturated
at paracetamol doses up to 4g since the 24 hour
urinary recovery of the drug is not decreased at the
higher doses (Davis et al, 1976). The effect of
very large doses of paracetamol on its metabolism is
discussed in the following section on overdosage.
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Comparisons with Previous Studies in Normal Subjects
i) Paracetamol Absorption and Elimination: Previous
reports on the elimination of paracetamol in normal
adults after therapeutic doses are summarised with the
present data in Table 32. The mean peak plasma
paracetamol concentration and time to reach peak values
obtained in the present study were comparable with other
studies, taking into account the dosage variation.
Similarly, the range and mean values for the plasma
and urinary paracetamol half-life in the present study
agree well with other reports. After oral doses of
0.5 - 2g in fasting subjects, the mean paracetamol
half-life ranged from 2.0 - 2.9 hours in plasma (Prescott
et al, 1968; McGilveray and Mattok, 1972; Richter and
Smith, 1974; Rawlins et al, 1977; Perucca and Richensj
1979)- This compares with the value of 2.3 hours
obtained in the present study. The values obtained
in urine were 2.0 - 3.6 hours (Nelson and Morioka, 1963;
Cummings et al, 1967; levy and Regardh, 1971; McGilveray
and Mattok, 1972; Miller et al, 1976) compared with
2.9 hours in the present study. Similar results were
obtained after intravenous paracetamol (Rawlins et al,
1977; Perucca and Richens, 1979).
ii) Elimination of Paracetamol Metabolites
There have been no previous detailed investigations
of plasma concentrations of paracetamol sulphate and
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TABLE 32'
Comparison of estimations .of Paracetamol elimination half-life (ti)


























































































glucuronic?e in normal subjects, although their combined
measurement has been reported (Brodie and Axelrod, 1948a,
1949; Lowenthal et al 1976). As noted in the present
study, Lowenthal et al(1976) found that the combined
plasma concentrations of these conjugates became
greater than that of the parent drug soon after ingestion
and that their combined elimination rate was similar to
that of paracetamol. The present study also showed that
the glucuronide usually accounted for most of the
conjugates present in plasma. Mrochek et al (1974)
reported plasma concentrations of paracetamol glucuronide
similar to and paracetamol sulphate somewhat lower than
those observed in the present study. These workers
also noted the absence of the cysteine conjugate in
plasma and paracetamol mercapturate was not reported in
plasma or urine.
The urinary excretion rates of paracetamol and its
sulphate and glucuronide conjugates measured by
Cummings et al (1967) and Levy and Yamada (1971) were
comparable to those measured in the present study. The
data of Cummings et al (1967) suggested that the urinary
elimination half-lives of the sulphate and glucuronide
conjugates were similar to that of the unchanged drug.
In the present study, metabolite urinary half-lives were
usually longer than that of paracetamol, as was also
observed by Miller et al (1976) and suggested by the
data of Levy and Yamada (1971). Levy and Yamada (1971)
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also noted a plateau effect in paracetamol sulphate
excretion which was not seen in any of the subjects in
the present study, although similar doses were administ¬
ered .
iii) Recovery of Paracetamol and its Conjugates in Urine
Studies concerning the recovery of paracetamol and
its conjugates in urine have been reported by many
authors. A representative selection is summarised in
Table 33» together with data from the present study.
Paracetamol dosage varied from 0.65g to 4g but the
percentage of dose recovered as the unchanged drug and
its sulphate and glucuronide conjugates was fairly
consistent between studies. Fewer workers have measured
the cysteine and mercapturic acid conjugates and there
is much greater variability in recovery. In most reports
less than 6# of the dose was recovered as each of; these
2 compounds and their combined total was 10$ or less.
There have been occasional notable exceptions to
the general range of values obtained. Davis et al (1976)
reported very low recovery of parent drug and very high
combined recovery of the mercapturic acid and cysteine
conjugates in 3 subjects taking 1 - 4g of paracetamol
orally. Their analytical method included TLC and
quantitation by densitometry,, an approach which was found
to be unworkable in this laboratory (Howie, 1977). Most














































































































































































of the glucuronide to be considerably higher than those
of the sulphate conjugate. However, Mitchell et al (1974)
used ^H-labelled paracetamol in 2 subjects and recovered
a mean of 47$ and 38$ of a 1.2g dose in 24 hours as the
sulphate and glucuronide conjugates respectively.
Quantitation relied on lyophilisation, elution and TIC
prior to scintillation counting of the separated compounds.
Recovery of the sulphate exceeded that of the glucuronide
conjugate in only 1 out of 3 subjects studied by
Jagenburg et al (1968) and 1 out of 8 in the present
study»
Overall,the 24 hour urinary recoveries were 70 - 100$^
although in one study in which only the combined
sulphate and glucuronide conjugates and parent drug
were measured (Nelson and Morioka, 1963), 92 - 113$
was recovered. An average of 77$ was recovered from 4
subjects as paracetamol and its sulphate and glucuronide
conjugates by Cummings et al (X967) following a mean
dose of 0.82g whereas Thomas et al (1975) recovered




The absorption, metabolism and elimination of
paracetamol was studied in 8 healthy male subjects
following a 20 mg/kg oral dose of paracetamol with and
without N-acetylcysteine (NAC; dose 150 mg/kg). Paracet¬
amol absorption was rapid and essentially complete but
may have been delayed with NAC. Metabolism was also
rapid and almost complete, showing wide but reproducible
individual variation- Metabolism via sulphate conjugation
was important in the first 1-2 hours after ingestion
but the overall order of importance was glucuronidation>
sulphation > glutathione conjugation (as mercapturic
acid and cysteine conjugates). Only a few per cent of
the dose was excreted unchanged. The mercapturic acid and
cysteine conjugates were not measurable in plasma (with
a limit of less than 1.0 pig/ml). The overall effect of
NAC on paracetamol metabolism at the above doses was
minimal.
The plasma paracetamol half-life (mean value 2.3 hrs)
appeared to be negatively and positively correlated with
the urinary excretion of the glucuronide a.nd sulphate
conjugates respectively. The renal clearance of all the
conjugates was rapid whereas the unchanged drug appeared
to be extensively reabsorbed in the kidney.
The results obtained in the present study agree well




PARACETAMOL METABOLISM IN OVERDOSAGE
182
PARACETAMOL METABOLISM IN OVERDOSAGE
Chapter 1 : Introduction
The effect of paracetamol taken in overdosage is a
clinical problem which has been studied extensively in
recent years. Early reports describing paracetamol
overdosage (Davidson and Eastham, 1966; Thomson and
Prescott, 1966; Maclean et al, 1968) recognised the
danger of hepatotoxicity. However, effective ways of
preventing liver damage have since been developed using
various sulphydryl compounds (Prescott et al, 1974, 1976,
1977, 1979; Crome et al, 1976; Peterson and Rumack,- 1977).
Paracetamol is probably absorbed rapidly and
completely (Heading et al, 1973), even in overdosage
(Prescott et al, 1971), although factors such as the
drug formulation, and the presence of food and other
drugs may affect the rate of absorption (Richter and
Smith, 1974; McGilveray and Mattok, 1972; Nimmo et al
1973&, 1975). There is probably little likelihood of
significant metabolism in the gut (Josting et al, 1976)
and kidney (Jones et al, 1979) therefore the rate of
delivery of paracetamol to its major site of metabolism
and toxicity, the liver, is likely to be dose related.
In the previous section (pp 134 - 137)paracetamol
metabolism was observed to be related to the time after
ingestion, with sulphate conjugation showing signs of
limitation following the high initial rate of drug
183
delivery. Saturation of sulphate conjugation was observed
even with therapeutic doses of paracetamol (Levy and
Yamada, 1971; Davis et al, 1976) and was more notable
with larger doses (Davis et al, 1976; Howie et al 1977).
This saturation is probably related to the depletion of
inorganic sulphate (Houston and Levy, 1976; Galinsky et al,
1979) and since this appears to occur readily, the
relationship between paracetamol sulphate formation and
the time after ingestion is likely to be important in
overdosage. There is also indirect evidence that the
major pathway for paracetamol elimination, via glucuron-
idation, may also be saturable (Levy and Yamada, 1971).
This has been demonstrated in isolated rat hepatocytes
(Moldeus, 1978) and has been reported to occur with
overdoses in man (Davis et al, 1976; Slattery and Levy,
1979), although this may be a result of toxicity
(Prescott and Wright, 1973).
The mechanism whereby paracetamol causes liver and
renal toxicity and the nature of the intermediate
metabolite involved have already been discussed
(pp 17 - 24 ). The potentially toxic pathway is act¬
ive at all dose levels but with therapeutic doses the
toxic metabolite is inactivated by conjugation with
reduced glutathione (Mitchell et al, 1974). The
glutathione conjugate is eventually excreted in the
urine as the cysteine and mercapturic acid conjugates
(Moldeus et al, 1978). Paracetamol overdosage results in
a shift in metabolsm via this pathway, with an increase
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in the proportions of drug excreted as the cysteine and
mercapturic acid conjugates (Davis et al, 1976; Howie et
al, 1977)- This shift in metabolism is related to the
extent of liver damage sustained and probably reflects
the increased conversion of paracetamol to the toxic
intermediate. Renal toxicity occurs in a similar manner
to hepatotoxicity (Mitchell et al, 1977; Healey et al,
1978).
Other metabolites of paracetamol (Mrochek et al,
1974; Andrews et al, 1976; Knox and Jurand, 1977, 1978;
Klutch et al, 1978), which account for a minor proportion
of therapeutic doses, are an unknown quantity in
overdosage. However, their contribution to the overall
elimination of paracetamol is likely to remain small.
(Andrews et al, 1976).
Other factors have been shown to affect paracetamol
elimination at therapeutic doses. Age has little effect
beyond childhood and there are only minor sex differences
(Miller et al, 1976; Levy et al, 1975; Briant et al, 1976;
Wojcicki et al, 1979). However, it is possible that
more marked differences in metabolism related to these
factors may occur with overdoses of paracetamol, although
there are no detailed reports on paracetamol metabolism
after overdosage with respect to age or sex. The ingestion
of more than one drug in overdosage is a common occurrence
(Matthew, 1971). This may affect paracetamol elimination
by competitive metabolism (Levy and Yamadar 1971; Dybing,
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1976), by altering its rate of absorption (Nimmo et al,
1973a, 1975) and by enzyme induction (Mitchell et al,
1974; Perucca and Richens, 1979). Such effects may be
particularly relevant in overdosage. Wright and Prescott
(1973) found that potentially induced patients developed
significantly more severe liver damage than non-induced
patients following paracetamol overdosage. Impaired
renal function does not alter the plasma half-life of
paracetamol (lowenthal et al, 1976) but the reduced
renal excretion of paracetamol conjugates results in their
accumulation in the plasma (Prescott, 1969; lowenthal et
al, 1976). Thus renal function is important in assessing
the metabolic effects of paracetamol overdosage*
The 3 compounds investigated in the present study
were L-methionine, N-acetyl-L-cysteine (NAC) and
cysteamine (Pig. 30). The hepatoprotective effect of
all 3 compounds following paracetamol overdosage has
been demonstrated in animals (see pp 33-35).Methionine
probably acts by repleting hepatic glutathione (Mclean
and Day,1975; Mclean and Nuttall, 1978), cysteamine
appears to inhibit the microsomal oxidation of paracetamol
to its toxic intermediate (Prescott et al, 1974; Harvey
and levitt, 1976) and NAC may be first converted to
cysteine (Chasseaud, 1974) which then probably repletes
hepatic glutathione (Strubelt et al, 1974). Recently,
Buckpitt et al (1979), using mouse liver microsomal
preparations,. have shown that NAC can be conjugated







S—CH~CH < 32 COOH
N-acetylcysteine
Fig 30: Molecular structures of cysteamine,. methionine
and N-acetylcysteine.
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paracetamol, as can cysteamine to a much lesser extent.
Also, high concentrations of cysteamine reduced the
rate of paracetamol metabolism. Methionine formed no
conjugate directly and did not alter the rate of paracetamol
metabolism.
In the present study, the metabolism of .paracetamol
was investigated in relation to overdosage in patients
with and without hepatotoxicity and with and without
specific treatment. Serial measurements of paracetamol
and its conjugates were made in the plasma and urine of
patients admitted to the Edinburgh Regional Poisoning
Treatment Centre following paracetamol overdosage. In
addition, the renal clearance of paracetamol and its
sulphate and glucuronide conjugates was calculated.
Varying degrees of liver damage were observed, from
absent to mild and severe, and some of the latter died.
Comparisons were made using data from untreated patients,
patients treated with methionine, cysteamine or NAC and
healthy volunteers given a therapeutic dose of paracetamol-
It was hoped that such studies might throw light
on the relationship between paracetamol metabolism and
toxicity and the mechanism of hepatoprotection of the
3 sulphydryl compounds..
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Chapter 2 Patients and Methods
Patients admitted on more than one occassion were consid¬
ered as separate cases.
Assessment of the Severity of Overdosage
Ingestion of the drag was confirmed "by rapid estim¬
ation of plasma paracetamol on admission using a
spectro-photometric method (Gibson, 1972). Information
concerning the time of ingestion and amount claimed to
have been ingested was obtained from the patients' records.
b) Treatment
Patients admitted within 4 hours of paracetamol
ingestion were normally given gastric aspiration and
lavage in order to remove any unabsorbed drug. The need
for specific treatment was assessed from the admission
plasma paracetamol concentration in relation to the time
of ingestion (Prescott et alf 1974, 1978,. 1979 ; Pig 5 ,
p 31 ). Patients whose admission plasma paracetamol
concentrations were above a line joining 200 pig/ml at
4 hrs and 50 pig/ml at 12 hrs on a semilogarithmic graph
of plasma paracetamol concentration against time after
ingestion were considered to be at risk of developing
liver damage (Prescott et al, 1974, 1978, 1979).
All treatments were administered intravenously according
to the following regimes.
(i) Cysteamine (as the hydrochloride) was infused in
an initial loading dose of 2.0g (free base equivalent)
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over 10 minutes, followed "by 0*8g over 4 hours and 0.4g
in each of two subsequent 8 hour periods. The total dose
was 3.6g cysteamine base over 20 hours (Prescott et al,
1974).
(ii) L-Methionine was given in a loading dose of 5g
infused over 10 minutes, followed by 5g in the next 4 hrs
and 5g in each of two subsequent 8 hour periods (total
20g in 20 hours).
(iii) N-acetyl-L-Cysteine (NAC) was infused in a
loading dose of 150 mg/kg over 15 minutes. This was
followed by 50 mg/kg during the next 4 hours and 100 mg/kg
over the subsequent 16 hours (total 300 mg/kg in 20 hours).
Patients not treated with specific agents (subse¬
quently referred to as "untreated" patients) were given
supportive therapy which included intravenous fluids and
vitamin K, where necessary (Prescott et al, 1971). In
subsequent comparisons, patients were divided into those
treated within 10 hours of paracetamol ingestion (early-
treated) and those treated after 10 hours (late-treated).
The efficacy of specific treatment has been shown to
diminish markedly when given more than 10 hours after
overdosage (Prescott, 1978; Prescott et al, 1979).
c) Clinical Assessment of Liver Damage
Plasma concentrations of aspartate and alanine
aminotransferases (AST, ALT) are thought to be reliable
indicators of hepatic damage after paracetamol overdosage
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(Prescott et al, 1971; Stewart and Simpson, 1973). Thes
enzymes were estimated daily for up to 5 days after
admission using standard methods of enzyme reaction rate
analysis (Kessler et al, 1975). Normal values were
below 40 iu/L. Patients with liver damage were graded
as trivial,, mild and severe cases according to the
maximum AST or AIT values recorded (40 - 99r 100 - 1000
and > 1000 iu/L respectively).
d) Collection of Samples
Blood was usually taken 4 to 8 hourly for at least
24 hours after admission and the plasma stored at -20°c
prior to analysis. Urine was collected for 2-5 days.
The volumes and pH were measured and 15 ml aliquots
stored at -2oPc prior to analysis.
e) Analytical Methods
The concentration of paracetamol and its sulphate
and glucuronide conjugates in plasma and urine and the
concentrations of the cysteine and mercapturic acid
conjugates in urine were measured as described in Sect¬
ion III. Plasma paracetamol concentrations had been
measured by gas liquid chromatography (Prescott, 1971b)
in some patients who were admitted before this study was
undertaken. Quantities of the paracetamol metabolites a
expressed as the parent drug equivalent throughout.
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f) Paracetamol Disposition
Various aspects of paracetamol disposition used to
compare the metabolism and elimination of paracetamol are
described in each appropriate chapter.
g) Statistical Methods
Mean values are given with standard deviations
unless stated otherwise. Comparisons were made by using
2




Clinical Details of Overdosage Patients
The clinical details relating to patients in this
section are shown in Table 34. Unless otherwise stated,
renal function was normal as judged "by urine output and
plasma creatinine and urea concentrations.
The metabolism and elimination of paracetamol was
studied in 22 untreated patients and 61 patients given
methionine* cysteamine or NAC. Their mean ages were
28^9 and 30^10 respectively. Severe liver damage
occurred in 25 of the 83 patients and one (Ul) died as a*
result of fulminant hepatic failure. The ratio of females
to males was high in the untreated group and the groups
given cysteamine and methionine (15 to 7, 7 to 3 and
12 to 5 respectively) but the disproportion was small in
patients given NAC (19 females, 15 males). More than
half the patients (46) had taken other drugs either with
or regularly before paracetamol overdosage* the most
common being heavy consumption of alcohol (28). This was
particularly common in the patients given NAC and
cysteamine (12 of 34 and 7 of 17 respectively). The ing-
estion-to-admission and ingestion-to-treatment intervals
varied considerably (from 1.8 to 32 and 3.8 to 20.3 hours
respectively). The lack of control introduced by these
factors together with other factors related to sample















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Plasma Paracetamol Concentration at 4 Hoars after
Ingestion
a) Relationship with Liver Damage
The relationship "between the 4 hoar plasma paracet¬
amol concentration and the maximum plasma transaminase
values (which reflect the severity of poisoning and liver
damage respectively; Prescott et alr 1971) was investig¬
ated. The 4 hour plasma paracetamol concentration was
calculated "by semiiogarithmic extrapolation or inter¬
polation of measured values.
p
Data were assessed (/( test) from 78 untreated
patients (25 males,. 53 females, mean age 29-14) and
also 103 treated patients (38 malesr 65 females, mean
age 30±12), 33 of whom were treated more than 10 hours
after paracetamol ingestion.
Results
In the untreated patients,, there was a trend
towards increasing liver damage with increasing 4 hour
plasma paracetamol concentrations (*)£ = 40.5*
p<.0001, Table 35; Pig 31). Every untreated patient
with a 4 hour plasma paracetamol concentration above
300 jig/ml sustained severe liver damage, as did 6 out of
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In the early-treated patients, the trend towards
severe liver damage at high 4 hour plasma paracetamol
concentrations was broken CX.^ - 3.8, N.S.; Table 35)
suggesting the efficacy of early treatment. Across the
whole range of 4 hour plasma paracetamol concentrations,.
16 and 4 of these 70 patients developed mild and severe
liver damage respectively. However, 7 and 18 of the 33
late-treated patients sustained mild and severe liver damage
respectively, illustrating the relative lack of effect
of treatment if geven more than 10 hours after paracet¬
amol ingestion. The outcome of late treatment was
significantly worse than that of early treatment
0 ~
(X = 34.0, p <.0001; Table 35), even though the mean
4 hour plasma paracetamol concentrations in the two
groups were not significantly different ( 343 *90 and
384 —119 Mg/ml in the early and late treated groups
respectively).
b) Relationship with Total Urinary Recovery of Paracetamol
and its Metabolites
The relationship between the 4 hour plasma paracetamol
concentration and the total urinary recovery of
paracetamol and its conjugates was studied in 16
untreated, 11 cysteamine-treated, 9 methionine-treated
and 15 NAC-treated patients (U1 - 16, CI - 11, Ml - 9
and N1 - 15 respectively, Table 34). The data were
assessed by linear regression analysis.
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Results
The 16 untreated patients were admitted "between
2.2 and 32 hours after ingestion and the correlation
between the total urinary recovery of paracetamol and its
conjugates and the 4 hour plasma paracetamol concentration
was not significant (r = 0.35; N.S.). However, if only
patients admitted up to 10 hours after ingestion are
considered (n = 13), the correlation was highly signif¬
icant (r = 0.84; p<.001). The total urinary recovery of
paracetamol and its conjugates in the 3 patients admitted
more than 10 hours after ingestion was very low relative
to their respective 4 hour plasma paracetamol concentrations.
This is expected because of loss of urine samples prior
to admission. The treated patients were all admitted and
treated within 10 hours of ingestion and in each group
there was a very significant correlation between total
urinary recovery of paracetamol and its conjugates and
the 4 hour plasma paracetamol concentration (correlation
coefficients r = 0.82, p<.005; r = 0.68, p <.025 and
r = 0.74, p <.005 for the cysteamine, methionine and
NAC treated groups respectively).
Four hour plasma paracetamol concentrations in the
treated patients were all greater than 200 /Ug/ml. In the
8 untreated patients with similar values the correlation
between total urinary recovery of paracetamol and its
conjugates and the 4 hour plasma paracetamol concentration
was still significant (r = 0.76; p<.05).
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Discussion
The comparisons described above indicate that the
severity of paracetamol poisoning, as judged by the
4 hour plasma, paracetamol concentration, is reflected in
the total urinary recovery of paracetamol and its
conjugates in patients from whom little or no urine is
lost following overdosage. Also, the 4 hour plasma
paracetamol concentration gives some indication of the




Plasma Concentrations of Paracetamol and its Conjugates
Plasma concentrations of paracetamol and its sulphate
and glucuronide conjugates were measured in 6 untreated,
10 NAC-treated and 4 cysteamine-treated patients without
severe liver damage (patients U8,. 10, 17 - 20; N12, 13,
26-33; C9, 10, 12, 17 respectively, Table 34). Pour
untreated, 5 NAC-treated and 4 cysteamine-treated
patients with severe liver damage were studied similarly
(patients U7, 12, 21, 22; N21 - 25; C13 - 16 respectively,
Table 34).. All the treated patients without severe
liver damage were given treatment within 10 hours of
paracetamol ingestion (mean 7.2 ±1.1 and 5.7±1.5 hours
in the NAC and cysteamine-treated groups respectively).
All the treated patients with severe liver damage were
treated more than 10 hours after paracetamol ingestion
(mean 16.4 —3.9 and 14.3 i 3.-5 hours in the NAC and
cysteamine-treated groups respectively).
If necessary, paracetamol concentrations were
interpolated (on a semilogarithmic scale) to specific
times after overdosage (see results, Tables 36 - 38,
pp 207,210,212)so that mean values at these times could
be calculated for each group. Plasma concentrations of
the sulphate and glucuronide conjugates were interpolated
on a linear scale. The plasma paracetamol half-life in
each individual patient was determined by a least
squares fit of the measured plasma paracetamol concentrat-
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ions. Concentrations of the cysteine and mercapturic
acid conjugates were too low to measure.
Results
a) The first "blood sample was often obtained more than
4 hours after ingestion and therefore the absorption and
distribution phases were missed. Paracetamol absorption
after overdosage was usually complete within 4 hours
since plasma concentrations nearly always declined
rapidly thereafter.
i) Untreated Patients
Fig- 32 and Table 36 show the mean interpolated
concentrations of paracetamol and its sulphate and
glucuronide conjugates in the plasma of untreated
patients with and without severe liver damage. Patients
with severe liver damage were generally admitted later
than other patients and therefore no values before
12 hours are included for this group. Mean plasma
paracetamol concentrations showed a linear exponential
decline in both groups. However, the mean individual
plasma paracetamol half-life in the group with severe
liver damage (5.2^1.6 hours) was significantly longer
than in the group without severe liver damage (3-5 ^ 0.7
hours; p <..05)- Both these values were significantly
longer than the value of 2.3±0.4 hours obtained in
healthy volunteers taking a therapeutic dose (p <_ -001
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TABLE 36
Mean plasma concentrations of paracetamol and its Sulphate and
Glucuronide conjugates following -paracetamol overdosage in












WITHOUT SEVERE LITER DAMAGE
4 4 186 + 9 8.2 ± 2.5 71 ± 19
6 5 132 + 14 7.6 ± 1.4 73 ± 17
8 6 90 + 15 6.2 ±1.1 72 ± 22
10 6 62 ± 13 5.0 ±1.6 64 ± 19
12 6 43 ± 12 4.5 ±1.5 55 ± 14
16 6 19 ± 9 3-3 ± 1.1 30 ± 12
20 4 8.2 ± 4.1 2.1 ± 0.4 16 ±5
WITH SEVERE LIVER DAMAGE
12 3 79 + 80 9-7 ± 6.4 72 ± 30
14 4 59 + 55 7-3 ± 5.2 58 ± 26
16 4 46 + 45 6.2 ±4*6 45 ± 27
18 4 36 ± 37 5-3 ± 3-9 33 ±24
20 4 29 + 30 4-7 ± 3-3 27 ± 21
24 4 19 + 19 3.5 ±2.2 18 ±14
* Interpolated where necessary - see page 204
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severe liver damage respectively)-
In the group without severe liver damage, the relation¬
ship "between mean plasma concentrations of paracetamol
glucuronide and those of the parent drug was similar to
that found with therapeutic doses (Pig.23, p 122 )
although mean concentrations of the glucuronide conjugate
did not exceed those of paracetamol until about 10 hours
after ingestion, compared with about 2.5 hours after
therapeutic dosage. In the group with severe liver
damage, mean plasma concentrations of the glucuronide
conjugate were similarto but slightly lower than those of
the parent drug- Mean plasma concentrations of
paracetamol sulphate were very low relative to those of
paracetamol and paracetamol glucuronide in both overdosage
groups and were not far above those observed following
therapeutic dosage. However, a complete comparison was
not possible since no early plasma samples were obtained
after overdosage.-
ii) Treated Patients
Pig. 33 and Table 37 show the mean interpolated
plasma concentrations of paracetamol and its sulphate and
glucuronide conjugates in the groups treated early with
NAC and cysteamine who did not sustain severe liver damage.
Similar data in the late treated groups with severe liver
carnage are shown in Pig 34 and Table 38.
Mean plasma paracetamol concentrations showed an
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TABLE 37
Mean plasma concentrations of paracetamol and its sulphate and
glucuronide conjugates in MAC and Ovs-teamine-treated patients
who did not develop severe liver damage following paracetamol
overdosage. (All patients were treated within 10 hours of
ingestion).
Time after Number of Mean Plasma Concentration *
ingestion patients ( Vg/mjl ± S.D.)
(hr) Paracetamol Paracetamol Paracetamol
Sulphate Glucuronide
NAC-treated Patients
4 4 305 ± 102 16.5 ±6.3 134 ± 58
6 7 235 ± 71 16.5 ±7.5 138 ± 50
8 9 177 ± 55 18.8 ±9-4 139 ± 57
10 10 124 ± 42 20.7 ±11.2 111 ± 48
12 10 82 ± 29 19-9 ± 8.9 90 ± 35
16 10 34 ± 15 14-3 ±5.2 50 ± 19
20 10 14 ± 7 8.6 ±3-5 26 ± 10
24 10 5.4 ± 2.6 4-3 ±2.1 12 ± 6
32 8 1.6 ±0.6 1.2 ±0.7 3.1 ± 1.2
Cysteamine-treated Patients
6.5 4 261 ± 90 13.6 ± 4.4 150 ± 44
8 4 210 ± 75 13-1 ± 2.0 141 ± 36
10 4 155 ±58 13-5 ± 1.1 122 ± 27
12 4 110 ±45 13.0 ± 1.4 100 ± 23
16 4 56 ± 29 10.3 ± 2.2 60 ± 22
20 4 28 ± 18 7.0 ±1.8 31 ± 16
24 4 13 ± 11 4.0 ± 1.1 16 ± 9
32 4 3.7 ± 3-3 1.4 ± 0.7 4.8 ± 2.5
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TABLE 38
Mean -plasma concentrations of -paracetamol and its sulphate and
glucuronide conjugates in NAC and Oysteamine-treated patients
who developed severe liver damage following paracetamol overdosage.
(All patients were treated more than 10 hours after ingestion.)
Time after Number
Mean Plasma Concentration *
ingestion of VM8/m4 xo.u. j
(hr) patients Paracetamol Paracetamol Paracetamol
Sulphate Glucuronide
NAC-treated Patients
16 3 106 + 53 7-9 + 7-7 63 ± 22
18 4 97 + 46 7-4 + 5.6 64 CO+l
20 5 Qb + 36 7.3 + 3-1 59 ± 34
22 3 68 + 31 8.0 + 1.2 44 ± 27
2b 3 56 ± 27 8.5 + 1.7 31 ± 19
32 5 28 ± 16 4-9 + 1.8 11 ± 6
Cysteamine-treated Patients
14 3 115 ± 61 6.0 + 2.1 86 ± 37
16 3 93 ± 54 6.9 + 1.5 64 ± 26
18 4 78 ± 39 6.9 + 1.7 47 ± 15
20 4 6U ± 35 6.7 + 0.9 35 ± 12
22 4 53 ± 31 6.4 + 1.0 25 ± 8
24 4 U6 ± 30 6.0 + 1.4 20 ± 6
32 4 25 ± 21 3-5 + 1.2 8.0± 1.0
* Interpolated where necessary - see page 204 .
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increase in the rate of decline in the NAC treated group
without severe liver damage shortly after the mean
ingestion-to-treatment interval. The mean individual
plasma paracetamol half-life was initially 4.511.0
hours and this subsequently decreased to 2.8 ±0.6 hours
(p <. .001) after a mean initial period of 10.5 - 2.6 hours.
There was little evidence for enhanced paracetamol
elimination in the cysteamine-treated group without
severe liver damage and the mean individual plasma
paracetamol half-life in this group was 4.0±0.7 hours,
longer than the value of 3.5 hours in untreated patients
without severe liver damage- The mean plasma paracetamol
half-life in the NAC-treated group without severe liver
damage was between the value in the corresponding
untreated group and the value obtained after therapeutic
dosage (2.3 - 0.4 hours).
The elimination of paracetamol from the plasma of
both treated groups with severe liver damage was slower
than in the respective untreated group and much slower
than in the early-treated groups. The mean individual
plasma paracetamol half-lives were 6.5— 2.2 hours and
7.5±2.6 hours in the groups treated late with NAG and
cysteamine respectively. Late treatment with NAC showed
little evidence for the enhanced elimination of paracetamol
observed after early treatment.
As with the untreated patients without severe liver
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damage, mean concentrations of paracetamol glucuronide
eventually exceeded those of the parent drug in both
early-treated groups, although this occurred later and
to a lesser extent in the cysteamine-treated group. In
both late-treated groups,mean concentrations of paracetamol
glucuronide were considerably lower than those of the
parent drug at all times, indicating that glucuronide
conjugation was apparently more impaired than in the
untreated group with severe liver damage.
A marked rise in mean plasma paracetamol sulphate
concentrations was observed in the group treated early
with NAC. The maximum occurred at 10 hours, shortly after
the mean ingestion-to-treatment interval and at about the
same time as the mean paracetamol half-life began to
decrease. There was a less marked rise in plasma paracet¬
amol sulphate concentrations in the group treated early
with cysteamine and the rise occurred later in relation
to the mean ingestion-to-treatment interval. The
pattern of plasma paracetamol sulphate elimination in
the two early-treated groups (Fig.33) contrasts with the
steady decline and considerably lower mean plasma
concentratiore observed in the untreated groups (Fig. 32)
and therapeutic dose group (Fig.23, p 122 ). In the
two late-treated groups, small increases in mean plasma
paracetamol sulphate concentrations were observed.
The data described above are summarised with the
mean 4 hour plasma paracetamol concentrations in each group,
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including extrapolated values where necessary (Table 39).
The severity of poisoning, as judged from the mean 4 hour
plasma paracetamol concentration, was similar in the
untreated groups although the outcome of overdosage was
very different. All the treated groups appear to have
been more severely poisoned than the untreated patients
particularly the group treated late with NAC. In the
cysteamine-treated patients,, the plasma paracetamol
half-life was considerably longer in those with severe
liver damage than in those withoutr even though poisoning
was apparently less severe in the former group.
Pig. 35 shows the changes in the ratios of the
concentrations of paracetamol to its sulphate and gluc-
uronide conjugates in plasma in each of the 3 groups
without and with severe liver damage. The enhancement
of sulphate conjugation produced by NAG and cysteamine
is apparent in the lowered ratios of paracetamol to
paracetamol sulphate following treatment, even in the
groups with severe liver damage. Glucuronide conjugation
in the cysteamine-treated groups appeared to be more
limited than in the other groups whether severe liver
damage was present or not.
Discussion
The decline in plasma paracetamol concentrations in
overdosage was usually exponential, implying that
saturation kinetics do not apply to the elimination of
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suggested otherwise,, although supporting evidence was
not provided. Judging from the 4 hour plasma paracetamol
concentrations, the plasma paracetamol half-life was
dose-dependent and was particularly prolonged with
severe liver damage. Paracetamol glucuronide was
always the major metabolite in plasma, eventually exceed¬
ing the parent drug in concentration if no liver damage
was present. Also, plasma concentrations of paracetamol
sulphate, although always low, were particularly low in
relation to the parent drug in patients with severe
liver damage (Pig. 35). Thus liver damage appears to
strongly influence paracetamol metabolism and elimination.
Similar observations were reported by Prescott et al
(1971) and Prescott and Wright (1973).
The low plasma concentrations of paracetamol sulphate
suggest limitation of the sulphate conjugation pathway.
This could result from either enzyme saturation or
depletion of the cofactors required for sulphate conjug¬
ation or both. The former explanation was favoured by
Weitering et al (1979 ). They found that "high" doses
of phenol in rats did not deplete plasma concentrations
of inorganic sulphate, although the proportion excreted
as phenyl sulphate decreased with increasing doses.
However, the highest dose given was only equivalent to
40 mg/kg paracetamol. Overdoses in man are often more
than 150 mg/kg (more than 10gr see total urinary
paracetamol, Table 34) and serum concentrations of
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inorganic sulphate in rats are much higher than in man
(Weitering et al, 1979). Thus depletion of inorganic
sulphate may well occur in man following paracetamol
overd osage.
In favour of inorganic sulphate depletion,. Houston
and Levy (1976) found that sodium sulphate could reverse
the competitive effect of ascorbic acid on sulphate
conjugation with paracetamol. Also,. Gaiinsky et al (1979)
observed enhanced paracetamol elimination and increased
plasma paracetamol sulphate concentrations following
the administration of sodium sulphate to rats given a
150 mg/kg dose of paracetamol.
Treatment of paracetamol overdosage with NAG and
cysteamine had significant but different effects on
paracetamol metabolism and elimination (Table 39). After
early treatment with NAC, plasma paracetamol half-lives
were significantly reduced to values which were not much
longer than those observed after therapeutic dosage,,
even though the apparent dose ingested by the NAC-treated
patients was high even for overdosage. The enhanced
elimination of paracetamol was associated with increased
production of paracetamol sulphate. Thus NAC appears to
be acting in a similar manner to sodium sulphate
(Gaiinsky et al, 1979) in aiding the supply of the
necessary cofactors required for sulphate conjugation.
This was also observed with the related compound, cysteiner
in reducing the competitive inhibition of paracetamol
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sulphate conjugation with salicylamide (levy and Yamada,
1971).
Early treatment with cysteamine had less effect on
sulphate conjugation than NAG and did not enhance
paracetamol elimination significantly. In addition,
cysteamine may have inhibited glucuronide conjugation.
Late treatment with either compound did not protect
against liver damage although a small enhancement of
sulphate conjugation was apparent. Thus the hepatoprotect-
ive action of these two compounds appears to be related
to early treatment and the mechanisms whereby protection
is afforded appear to differ.
In addition to the effects on sulphate conjugation
described above, NAC has also been shown to conjugate
directly with the toxic metabolite of paracetamol and
reduce its covalent binding to macromolecules in mouse
liver microsomal preparations (Buckpitt et al, 1979).
The hepatoprotective action of cysteamine may be similar
to that of piperonyl butoxide,. which inhibits both the
glucuronidation and microsomal oxidation and also the
covalent binding of paracetamol in hamsters (Jollow et al,
1974; Potter et al, 1974). Apparent inhibition of the
hepatic microsomal oxidation of paracetamol and a
reduced rate of metabolism of paracetamol have been
reported with cysteamine in isolated perfused rat liver
(Harvey and Levitt,. 1976) and mouse liver microsomal
preparations (Buckpitt et al, 1979) -
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Chapter 6
Total Urinary Recovery of Paracetamol and its Conjugates
The total urinary recovery of paracetamol and its
conjugates was studied in 13 untreated and 9r an(3 15
patients treated with methionine, cysteamine and NAC
respectively (patients Ul - 13, Ml - 9, CI - 11 and
N1 - 15 respectively in Table 34). The patients were
all admitted and/or treated within 10 hours of paracetamol
ingestion and there was a significant correlation between
the 4 hour plasma paracetamol concentration and the
total drug recovered in urine within each group (see_pp
201-203 ). The 4 hour plasma paracetamol concentrations
in the treated patients were all above 200 yug/ml. 'fhe
clinical details for each group are shown in Table 40.
Pooled urine samples were analysed and the total
recovery of each compound and the percentage of the
total drug recovered as each compound (expressed as the
paracetamol equivalent) were compared in relation to
the overall recovery of drug,, liver damage and treatment.
One NAC-treated patient (N8) apparently excreted an
abnormally high proportion of drug unchanged (41.8$,,
4.73g) together with an abnormally low proportion of
paracetamol glucuronide (28.8$,, 3»3g> Tables 44d and 45d,
pp 234,238). This was probably the result of bacterial
hydrolysis of the glucuronide conjugate prior to freezing
























































































































of urine samples from patients and processing of the
samples in the laboratory (for instance with evening
collections). In such cases some of the giucuronide
conjugate could be hydrolysed to paracetamol by bacterial
J3-glucuronidase.. Patient N8 was excluded from
comparisons involving paracetamol and its giucuronide
conjugate.
a) Results
i) Untreated Patients; Table 41a and b shows the
amounts of each compound recovered and their proportions
relative to the overall urinary recovery of paracetamol
and the maximum AST/ALT concentrations in the untreated
group. The recovery of each compound generally reflected
the total recovery of the drug and its metabolites
except in the case of paracetamol sulphate, where there
was no relationship with the total recovery of drug and
metabolites(Table 42). Also,, a wide range of recoveries
was observed for all compounds except the sulphate
conjugate (Table 42).
The proportions excreted as each compound relative
to the total urinary recovery of drug showed wide
individual variationr especially with the cysteine
conjugate (Table 42). The proportion excreted as paracet¬
amol sulphate was inversely related to the total recovery
of drug and metabolites, whereas no similar relationships
were observed with the other compounds (Table 42).
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TABLE 1+1 ( a)
Amounts of paracetamol and its conn-ggates recovered in urine












U1 381+0 1.88 1.37 11+.8 1.25 2.1+1 3.66 21.7
TJ2 23 1.1+5 0.80 8.9 0.30 0.11+ o.i+5 11.6
U3 6000 1.96 1.21 12.1 1.10 0.68 1.78 17.0
Ul+ h9 1.32 0.81+ 13.0 0.33 0.25 0.58 15.8
U5 681+ 1.01+ 0.91+ 10.0 0.1+9 0.56 1.05 13.1
U6 62 0.38 1.1+3 7.3 0.60 0.51+ 1.11+ 10.3
U7 99UO 0.60 1.1+0 9.1+ 0.96 0.92 1.88 13.3
TJ8 19 0.66 0.95 7.2 0.56 0.1+2 0.97 _ 9-8
U9 576 1.1+1+ 0.80 6.1 0.29 0.22 0.51 8.8
U10 18 0.71+ 1.00 6.6 0.31+ 0.27 0.60 8.9
111 23 0.76 1.10 6.6 0.26 0.37 O.63 9.1
TJ12 581+0 0.51+ 0.62 5.9 0.38 0.61 0.99 8.1


















































* Significantly different from patients with max. AST/ALT £ 1000, p<.005
t » " " " " " " "
, p <.02 .
KEY:-
P - Paracetamol; S, G, M, C - sulphate, glucuronide, mercapturic acid
and cysteine conjugates respectively.
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TA3LB 41(b)
Urinary recovery of Paracetamol and its conjugates expressed as
percentages of the total drug recovered in urine following










TJ1 8.7 6.3 68.2 5-7 11.1 16.8 381+0
U2 12.5 6.9 76.8 2.6 1.2 3.8 23
U3 11.6 7-1 70.8 6.5 i+.o 10.5 6000
ui+ 8.1+ 5.3 82.6 2.1 1.6 3-7 1+9
u5 8.0 7.2 76.8 3.8 k.3 8.1 681+
U6 3.7 13-9 71.lt 5-8 5.2 11.0 62
U7 k.5 10.5 70.8 7.2 6.9 1i+.1_ 99UO
U8 6.7 9-7 73-6 5.7 1+.2 9-9 19
U9 16.3 9.0 68.9 3.2 2.5 5.7 576
U10 8.3 11.2 73.7 3.8 3.0 6.8 18
TJ11 8.3 12.1+ 72.3 2.9 U.1 7.0 23
TJ12 6.7 7.7 73. h 1+.7 7.5 12.2 581+0
U13 1+.6 12.7 75-6 U.1 3.1 7.2 33
(See Table43 for comparisons with respect to liver damage)
KEY:-
P - Paracetamol; S, G, M, C - sulphate, glucuronide, mercapturic acid





































































































































The mean recovery of each compound was higher in the
patients with severe liver damage than in those withoutP
due mainly to the considerably higher mean total recovery
of drug in the former group than in the latter (Table 41a).
However,, the mean amount of drug excreted as the mercapt-
uric acid and cysteine conjugates was very much higher
with severe liver damage (2.08 1 1.13g) than without
(0.70 ± 0.27g; p < .005, Table 41a). The same was true
of the mean proportion of drug recovered as these conjugates
(13.4 ± 2.7$ and 7.4 ± 2.9$ in the patients with and
without severe liver damage respectively; p <.005,-
Table 43). The mean proportions excreted as unchanged
paracetamol and its sulphate and glucuronide conjugates
were not significantly different between the 2 groups.
The pattern of urinary excretion after overdosage
(with or without severe liver damage) differed markedly
from that observed after therapeutic dosage (Table 43).
The mean proportions of the total urinary recovery
excreted as unchanged paracetamol and its glucuronide
conjugate were each significantly higher after overdosage,
irrespective of liver damage, than after a 20 mg/kg dose
whereas the mean proportion recovered as paracetamol
sulphate was very much lower (p < .001; Table 43). The
mean proportion excreted as the mereapturic acid and
cysteine conjugates was little different in overdosage
without severe liver damage (7.0 ± 2.5$) compared with
therapeutic dosage (8.1 ± 2.9$). However, in the group
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TABLE 1+3
Recovery of •paracetamol and its conjugates in relation to
total urinary recovery of drag following overdosage and
therapeutic dosage with paracetamol.
Compound
Mean % of total recovered in urine
±S.D.
overdose overdose therapeutic
without severe with severe dose
liver damage liver damage "(20 mg/kg;
(n=9) (n=i-0 n^8)
Paracetamol 8.5 ± 3-9 7-9 ± 3-0 5.1 ± 1.1+ (d)
Paracetamol
Sulphate
9-8 ± 3-0 7.9 ± 1.8 •o+1COOJro (e)
Paracetamol
Glucuronide 71+.6 ± 3-9 70.8 ± 2.1 51+.o ± 11.7 (f)
Paracetamol
Mercapturate 3.8 ± 1.3 (a) 6.0 ± 1.1 1+.1+ ± 1.2 (g)
Paracetamol





7.0 ± 2.5 (c) 13-1+ ± 2.7 8.1 ± 1.9 (i)
(a); (b); (c) - p<.02; p<.005; p<.005 respectively, comparing overdosage
with and without severe liver damage.
(d); (e) - p<.05; p<.001 respectively, comparing therapeutic dosage
with each overdosage group.
(f) ~ p<.001 and p<.02 comparing therapeutic dosage with
overdosage, without and with severe liver damage respectively.
(g); (h); (i) - p<.05; p<.01; P<.0C>5 respectively, comparing therapeutic
dosage with overdosage resulting in severe liver damage.
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with severe liver damager proportional excretion of
these conjugates was significantly higher than after
therapeutic dosage (13.4 ± 2.7^ compared with 8.1 1 2.9$>;
p < .005). Excretion of the mercapturic acid and
cysteine conjugates considered separately generally
reflected their combined excretion (Tables 41a, 43).
ii) Treated Patients: Tables 44 and 45 (a - d) show the
total recovery of paracetamol and its conjugates in
comparable treated and untreated patients (see p 221 )..
The mean total drug recoveries according to liver
damage and treatment (Table 46) show that similar mean
"amounts were recovered from all 4 treatment groups.
Untreated patients without severe liver damage excreted
a somewhat smaller mean quantity of paracetamol overall
than all the other groups (although the difference was
significant only with respect to the methionine-treated
group). Patients with severe liver damage tended to
excrete larger quantities than those without severe liver
damage.
A larger mean amount of paracetamol was excreted
unchanged by untreated patients with severe liver damage
than by those without but this was not so with
treated patients (Table 47). The proportions of total
paracetamol recovery excreted unchanged were similar in
patients with and without severe liver damage. Unchanged
paracetamol accounted for a higher mean percentage of
overall drug recovery in the NAG-treated group than in
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TABLE 44(a)
Amounts of Paracetamol and its conjugates recovered in urine following
Paracetamol overdosage in 8 untreated patients (It hour -plasma ~~~~
Paracetamol concentrations were above 200 lg/m& in each patient).
Patient
No. P










U1 1.88 1.37 11+.8 1.25 2.1+1 3.66 21.7 381+0
U2 1.1+5 0.80 8.9 0.30 0.11+ 0.1+5 11.6 23
N3 1.96 1.21 12.1 1.10 0.68 1.78 17.0 6000
Ul+ 1.32 0.81+ 13.0 0.33 0.25 0.58 15.8 1+9
u5 1.01+ 0.91+ 10.0 0.1+9 0.56 1.05 13.1 681+
U6 0.38 1.1+3 7-3 0.60 0.51+ 1.11+ 10.3 62
U7 0.60 1.1+0 9-1+ 0.96 0.92 1.88 13.3 991+0
U8 0.66 0.95 7.2 0.56 0.1+2 0.97 9-8 19
KEY;-
P - Paracetamol; S, G, M, C - Paracetamol sulphate, glucuronide,
mercapturic acid and cysteine conjugates respectively.
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TABLE 44(b)
Amounts of Paracetamol and its conjugates recovered in urine folio-wing
Paracetamol overdosage in 11 patients treated with Cysteamine within











( -i n /t. 3
C1 1.23 1.96 16.9 0.38 0.1+7 0.86 21.0 16
C2 1.02 1.27 6.7 0.25 0.30 0.55 9-6 23
C3 0.93 1.57 11.3 0.68 0.58 1.26 15.0 602
ci+ 1 'lb 1.1+0 9.9 0.26 0.21 0.1+7 13.5 153
c5 3.21+ 1.59 15.5 0.1+7 0.81+ 1.31 21.6 960
C6 0.71+ 0.99 9.1+ O.36 0.1+1 0.77 11.9 22
C7 1.11 1.98 9-3 0.20 0.37 0.57 13.0 19
08 1.32 2.21 15.5 0.81+ 0.77 1.61 20.6 66
09 0.77 1.31 10.6 0.1+1 0.1+1 0.82 13.5 29
C10 1.78 2.85 13.2 1.16 0.93 2.09 19.9 91
C11 0.69 1.35 5-3 0.22 0.21 0.1+3 7-8 1+0
No patient treated with cysteamine within 10 hours of paracetamol ingestion
developed severe liver damage.
KEY:-
P - Paracetamol; S, G, M, C - Paracetamol sulphate, glucuronide,
mercapturic acid and cysteine conjugates respectively.
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TABLE 44(c)
Amounts of Paracetamol and its conjugates recovered in urine following
Paracetamol overdosage in 9 patients treated with Methionine within
10 hours of Paracetamol ingestion.
Patient
No. P








m1 0.96 1.31 11.8 0.67 0.33 1.00 15.1 21
m2 0.67 0.82 12.0 0.32 0.36 0.68 11+.2 78
m3 1.31 2.11 11.3 0.70 0.57 1.27 16.0 70
Mlj. 1.85 1.08 9.3 0.1+1+ 0.33 0.77 13.0 13
m5 1.18 1.72 9.0 0.95 0.75 1.70 13.6 1+3
m6 1.73 1.79 11.1+ 1.08 1.70 2.77 17.7 9200
m7 0.67 1. 2i+ 8.3 0.58 0.60 1.17 11.1+ 3200
m8 1.37 1.31+ 11.0 0.61 0.32 0.93 11+.7 61
m9 1.08 2.20 12.2 1.21 0.85 2.06 17.6 161
KEY:-
P - Paracetamol; S, G, M, C - Paracetamol sulphate, glucuronide,
mercapturic acid and cysteine conjugates respectively.
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TABLE 44 (d )
Amounts of Paracetamol and its conjugates recovered in urine following













N1 1.17 2.26 8.6 1 .22 0.98 2.20 11+. 2 3b
N2 1.85 1.82 11.6 0.59 0.57 1.16 - I6.ii 35
N3 0.81 1.2i| 8.0 0.1+1 0.59 1.00 11.0 ■ 19
Ni; 1.63 1.78 12.2 1.32 1.06 2.38 18.0 3990
N5 3-^8 1.75 15.8 0.62 0.55 1.16 22.2 25
N6 2.10 1.62 8.8 0.37 0.37 0.7U 13.2 56
N7 1.U9 1.25 5-2 0.50 0.1+6 0.96 8.8 27
N8 U- 73* 2.05 3.3* 0.59 O.69 1.28 11.3 - 23
N9 2.77 2.53 11.1+ 0.78 1.08 1.86 18.6 38
N10 1.29 2.73 6.8 0.i|D 0.31 0.72 11.6 81
N11 0.97 3-52 10.6 1.27 0.70 1.97 17.0 35
N12 1.36 1.77 8.1 0.i|2 0.33 0.75 12.0 37
N13 0.73 2.09 12.2 0.50 0.66 1.15 16.2 36
N1i| h'b3 2.31 13.3 2.09 1.93 1+.03 2l+. 1 570
N15 1.28 3.09 11.3 1.21+ 1.33 2.56 18.2 270
* Patient N8 not included in mean values of P and G - see page 221
for explanation.
KEY;-
P - Paracetamol; S, G, M, C - Paracetamol sulphate, glucuronide,
mercapturic acid and cysteine conjugates respectively.
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TABLE 1+5 (a)
Urinary recovery of paracetamol and its conjugates expressed as
•percentages of the total drug recovered in urine following
paracetamol overdosage in 8 untreated patients. (1+ hcmr plasma














U1 8.7 6.3 68.2 5.7 11.1 16.8 381+0
U2 12.5 6.9 76.8 2.6 1.2 3.8 23
U3 11.6 7-1 70.8 6.5 1+.0 10.5 6000
Ul+ 8.1+ 5.3 82.6 2.1 1.6 3.7 1+9
u5 8.0 7.2 76.8 3.8 k-3 8.1 681+
U6 3.7 13.9 71. 1+ 5.8 5.2 11.0 62
U7 1+-5 10.5 70.8 7.2 6.9 11+.1 991+0
U8 6.7 9-7 73-6 5.7 1+.2 9-9 19
KEY:-
P - Paracetamol; S, G, M, C - Paracetamol sulphate, glucuronide,
mercapturic. acid and cysteine conjugates respectively.
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TABLE U5(b)
Urinary recovery of paracetamol and its conjugates expressed
as percentages of the total drug recovered in urine following
■paracetamol overdosage in 11 patients treated with Cysteamine.









C1 5.9 9-3 80.7 1.8 2.3 2+.1 16
C2 10.7 13.3 70.2 2.6 3.2 5.8 23
C3 6.2 10.2+ 75.0 h.5 3.9 8.2+ 602
Ci+ 12.8 10.2+ 73.3 1.9 1.5 3.5 153
c5 1U-9 7-3 71-7 2.2 3-9 6.0 960
06 6.2 8.3 78.9 3.1 3-2+ 6.5 22
C7 8.6 15.3 71.8 1.5 2.9 h.h 19
C8 6.I4. 10.7 75.1 ii-1 3-7 7.8 66
C9 5.7 9-7 78.5 3.1 3.1 6.1 29
010 8.9 12+-3 66.2 5.8 k-7 10.5 91
C11 8.9 17.3 68.1+ 2.8 2.6 5.5 Uo
No patient treated with cysteamine within 10 hours of paracetamol ingestion
developed severe liver damage.
KEY:-
P - Paracetamol; S, G, M, C - Paracetamol sulphate, glucuronide,
Mercapturic acid and cysteine conjugates respectively.
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TABLE L5(c)
Urinary recovery of -paracetamol and its conjugates expressed
as percentages of the total drug recovered in urine following
paracetamol overdosage in 9 patients treated with Methionine.
(Treatment commenced, within 10 hours of paracetamol ingestion)
Patient
No. P
Percentage of the total recovered as:-




M1 6.2+ 8.6 78.u 1+.1+ 2.2 6.6 21
M2 i+.7 5.8 82+. 7 2.3 2.5 2+.8 78
M3 8.1 13.2 70.8 b.k 3.6 7.9 70
ml 11+. 2 8.3 71.6 3-1+ 2.5 5-9 13
m5 8.7 12.7 66.1 7.0 5.5 12.5 1+3
M6 9.8 10.1 62+. 2+ 6.1 9.6 15.7 9200
M7 5-9 10.9 72.9 5.1 5.2 10.3 3200
M8 9-3 9-1 75.2 1+.1 2.2 6.3 61
m9 6.2 12.5 69.6 6.9 2+.8 11.7 ■ 161
KEY:-
P - Paracetamol; S, G, M, C - Paracetamol sulphate, glucuronide,
mercapturic acid and cysteine conjugates respectively.
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TABLE l+5(d)
Urinary recovery of -paracetamol and its conjugates expressed
as percentages of the total drug recovered in urine following
•paracetamol overdosage in 15 patients treated with MAC.
(Treatment commenced within 10 hours of paracetamol ingestion.)
Patient
No. P







N1 8.2 15-9 60.1+ 8.6 6.9 - 15.5 3h
N2 11.3 11.1 70.6 3-6 3-5 7.1 35
N3 7.3 11.2 72.3 3-7 5.1+ 9.1 19
Nl+ 9-1 9-9 67.8 7.1+ 5.9 13.2 3990
N5 15-7 7-9 71.2 2.8 2.5 5.2 25
N6 15.9 12.3 66.3 2.8 2.8 5-6 56
N7 16.8 11+.1 58.3 5.6 s5.2 10.8 ~ 27
N8 1+1.8* 18.1 28.8* 5-2 6.1 11.3 23
N9 11+.9 13-6 61.5 1+.2 5.8 10.0 38
N10 11.1 23.6 59.0 3.5 2.7 6.2 81
N11 5.7 20.7 62.1 7-1+ 1+.1 11.5 35
N12 11.3 11+.8 67.6 3.5 2.8 6.2 37
N13 k'B 12.9 75.1+ 3-1 1+.1 7.1 36
N1l+ 18.1+ 9.6 55.3 8.7 8.0 16.7 570
N15 7.0 17-0 61.9 6.8 7-3 11+.1 270
* Patient N8 not included in mean values of P and G - see page 221
for explanation.
KEY:-
P - Paracetamol; S, G, M, C - Paracetamol sulphate, glucuronide,
mercapturic acid and cysteine conjugates respectively.
238
TABLE 1+6
Mean total urinary recovery of -paracetamol and its conjugates
in relation to liver damage following -paracetamol overdosage
in treated and "untreated patients. (Treatment commenced
within 10 hours of paracetamol ingestion in all specifically-
treatedpatients.)
Treatment
mean total drug recovered in urine
(g) ± S.L. and number of patients (n)
without severe with severe
liver damage liver damage
TOTAL






Cysteamine 15.2 ± 1+.8
(11)
- 15.2 + 1+.8
(11)




















































































































































































































































each of the other groups "but the difference was not
significant in any case.
Specific treatment was associated with a significant
increase in the mean amounts and proportions of drug
excreted as paracetamol sulphate (mean values 1.83±0-61g,
12-3 - 3-9$ in all treated patients and 1.12 ± 0.26g
8.4 ^ 2.8$ in untreated patients; p < .005 and p < .02
respectively, Table 48). Considering each treatment
separately, the increase was highly significant with
NAC (2.12 ± 0.64g, 14.2 ± 4.3$; P < .001 and p < .005
respectively), significant with cysteamine (1.68 ± 0.53g>
11.5 — 3»-l$» P ^.02 and p .05 respectively) but not
significant with methionine. Patients with severe
liver damage usually excreted a smaller proportion of the
total recovery as paracetamol sulphate than those without
severe liver damager although the differences were
generally minor (overall mean values 9.1 — 1.9$ and 12.0
± 4.1$ respectivelyr Table 48).
The mean amounts of paracetamol glucuronide excreted
by each treatment group were similar (Table 49). However,
the mean proportions of total drug recovered as paracetamol
glucuronide in patients given NAC was significantly lower
than in each of the other treatment groups, both in
patients without severe liver damage and overall (Table 49).
There were no consistent differences in terms of the amounts
excreted in relation to liver damage, although generally-
lower proportions of drug were excreted as paracetamol


































































































































































































































































































































































































































































The combined recovery of paracetamol mercapturic
acid and cysteine conjugates was markedly higher in the
groups with severe liver damage than in those without
(Table 50). Considering the 4 treatment groups combined,
patients without severe liver damage excreted a mean of
1.21±0-72g (8„0 ± 3*4$) compared with 2.27 ±0.87g
(13.4 ± 2.lio) in patients with severe liver damage;
p < .005 and p .001 with respect to the amounts and
proportions respectively. In the patients without severe
liver damage, those given NAC excreted a larger mean
amount and proportion of total drug recovery as the
mercapturic ; acid and cysteine conjugates than each of
the other groups. In relation to the cysteamine-treated
group,, the difference in these proportions was significant
(p< .02; Table 50). Considering all the patients in
each group,, the cysteamine-treated group excreted a
significantly smaller mean percentage as the mercapturic
acid and cysteine conjugates than each of the other
treatment groups (Table 50). A mean of 6.2 ±2.0$ was
excreted as these compounds by the patients given
cysteamine,. compared with 9.7 ± 4.6$ in the untreated
group (p < .05), 9.1±3.7$ in the patients given
methionine (p < .05) and 10.0 ± 3.7$ in the NAC-treated
group (p -=£ .01).
The observations noted above for the excretion of
the mercapturic acid and cysteine conjugates combined

























































































































































































































































compounds (Tables 44 and 45 a-d). The excretion of both
compounds was equally limited following cysteamine
treatment. In addition, proportionately more cysteine
conjugate than mercapturic acid conjugate was excreted by
patients with severe liver damage than by those without
in the untreated and methionine-treated groups. The
mean ratios of cysteine to mercapturic acid conjugate
excreted by these groups combined were 1.22 ± 0.52 and
0.77 - 0.21 in patients with and without severe liver
damage respectively (p < .02).
b) Summary
1) The pattern of urinary excretion of paracetamol after
overdosage was considerably different from the pattern
after therapeutic dosage.
In relation to the total drug recovered in urine
(a) The proportion recovered as paracetamol sulphate
was significantly reduced and was inversely proportional
to the total recovery of paracetamol.
(b) The proportions recovered unchanged and as paracetamol
glucuronide were significantly increased.
(c) The proportions recovered as the cysteine and
mercapturic acid conjugates were not significantly
different,- except in patients who developed severe liver
damage.
2) Significantly larger amounts and proportions of drug
(about double) were excreted as the mercapturic acid and
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cysteine conjugates by patients with severe liver
damage than by those without.
3) Excretion of unchanged paracetamol and its sulphate
and glucuronide conjugates was not significantly different
in untreated patients with and without severe liver damage.
4) Treatment with cysteamine and particularly NAC was
associated with significantly increased, excretion of
paracetamol sulphate. The increase observed with meth¬
ionine was not statistically significant.
5) A significantly reduced percentage of paracetamol was
recovered as the glucuronide conjugate in patients
given NAG.
6) Treatment with cysteamine significantly reduced the
proportion of paracetamol excreted as its mercapturic
acid and cysteine conjugates. In patients without
severe liver damager a larger mean amount and proportion
of drug was recovered as these conjugates in those
given NAC than in each of the other grouos.
c ) Discussion
The change in the urinary excretion pattern of
paracetamol and its metabolites observed with increased
dosage is consistent with saturation of sulphate
conjugation and compensation by increased glucuronide
conjugation (as also noted by Davis et alr 1976) and
increased renal excretion of unchanged drug, as observed
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by Prescott and Wright (1973). The larger amounts of
the mercapturic acid and cysteine conjugates produced
following paracetamol overdosage indicate that the
production of the toxic intermediate increased with the
dose. As expected,the amounts and proportions of drug
excreted as these conjugates were larger in patients who
developed severe liver damage, as also noted by Davis et alr
1976 and Howie et al„ 1977. In addition, patients
without severe liver damage excreted similar proportions
of drug as the mercapturic acid and cysteine conjugates
as did healthy volunteers after a therapeutic dose,,
whereas in patients with severe liver damage, the
proportions were significantly higher-
In treated patients, protection against liver
damage was apparent despite ingestion of large doses of
paracetamol, although this was less obvious after treat¬
ment with methionine. The most consistent metabolic
effect of specific treatment was an increase in the
amount and proportion of paracetamol excreted as the
sulphate conjugate. This finding was in keeping with
the observation of increased plasma paracetamol sulphate
concentrations following NAC and cysteamine treatment
(pp 214-215 ). Similar increases were observed with
the related compound,, cysteine, after sulphate conjugation
of paracetamol had been competitively inhibited with
salicylamide (Levy and Yamada,. 1971).
The excretion of the mercapturic acid and cysteine
24-8
conjugates was affected in different ways by the
different treatments. The results of treatment with
methionine were similar to those in the untreated
patients with regard to liver damage and excretion of
these conjugates. This suggests that methionine has
little or no effect on the production or detoxification of
the toxic intermediate metabolite, as also observed in
vitro by Buckpitt et al (1979). Cysteamine appeared to
reduce the excretion of the mercapturic acid and cysteine
conjugates. Therefore, a possible explanation for the
hepato-protective action of cysteamine is that it
inhibits the formation of the toxic intermediate which
causes liver damage (Harvey and Levitt,. 1976; Buckpitt
et al, 1979). However, large quantities of the reactive
intermediate must already have been formed before
treatment was given. In contrast,. NAC appeared to
increase the excretion of these conjugates but it still
protected against liver damage. Thus NAC might act as a
direct precursor of glutathione or it might undergo
direct conjugation with the toxic metabolite (Strubelt
et al, 1974; Buckpitt et al, 1979).
By far the largest proportion of paracetamol was
recovered as the glucuronide conjugate, irrespective of
treatment or liver damage. However, treatment with NAC
significantly lowered the proportion excreted as this
conjugate. This was probably due to the enhanced
sulphate conjugation and possibly increased excretion of
249
the mercapturic and cysteine conjugates- With cysteamine,.
sulphate conjugation was increased and glutathione
conjugation was decreased resulting in little overall
effect on glucuronide conjugation.
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Chapter 7
Changes in the Urinary Excretion of Paracetamol and its
Conjugates with Time
Paracetamol and its conjugates were measured in
sequential urine samples from treated and untreated
patients. The data were assessed graphically by comparing
individual excretion patterns with time and also the
excretion patterns in different treatment groups during
various intervals after overdosage. Mean individual
excretion rates and the proportions of the total drug
excreted as each compound were plotted at the mean
mid-points of the urine collection intervals. In some
cases plots were constructed using data from 3 urine
collection intervals only (approximately 0-15, 15-24
and > 24 hours after paracetamol ingestion),.
Pour untreated patients who developed only trivial
liver damage and 2 untreated patients who developed
severe liver damage were studied in detail. Five treated
patients who developed trivial liver damage (3 given NAC
and 2 given cysteiner within 10 hours of paracetamol
ingestion) and 2 patients treated late with NAC who
developed severe liver damage were studied similarly
(Table 51). Two other groups were given cysteamine and




Changes in the urinary excretion of paracetamol and its















Untreated, U6, 8 9*5 ±0.6
no severe 10 and
liver damage 11
Untreated, U1 21.7
severe U12 - 8.1
liver damage
MAC/Cys teine,. N2, 3, 20t
no severe 7.8 ± 1.2+ 13.1 ± 3.9
liver damage N18, 19 tt
NAC, severe N16 10.2 11.0
liver damage N17 11.7 9-1
**




M6, 7, 10 9.1+ - 0.6 13.7 ± 3-5Methionine,
severe
liver damage
* Full details in Table 3b
** All treated within 10 hours of paracetamol ingestion
t given NAC
ft given cysteine
Values are mean ± S.D.
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a) Results
i) Untreated Patients: In the patients without severe
liver damage, the mean excretion rate of unchanged para¬
cetamol declined from the outset with a half-life of
3.6 hours (Pig 36a* Table 52).. Excretion of the sulphate
and glucuronide conjugates was maximal in the -first
period but declined slowly at first. Excretion of the
mercapturic acid and cysteine conjugates was relatively
slow at first, peaking in the second interval and
subsequently paralleling that of the unchanged drug.
The excretion rate-time patterns of the paracetamol
metabolites in patients U1 and U12 (Pig 37, Tables 53
and 54) followed that of the unchanged drug in a
similar manner to that observed in the patients without
severe liver damage. However, the urinary half-life of
paracetamol was prolonged in patient U1 but short in
patient U12. Renal function in patient U1 was not
impaired until 40 hours after paracetamol ingestion. The
maximum excretion rate of paracetamol sulphate was
similar (60 - 70 mg/hr) in all the untreated patients
but the decline was most rapid in patient U12. Paracetamol
glucuronide was excreted at a very high rate compared to
patients without severe liver damage, particularly by
patient Ul. In both patients large amounts of the
mercapturic acid and the cysteine conjugates
were excreted,, especially in patient Ul.
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Fig.37; Changes in the urinary excretion rates of
paracetamol and its conjugates with time in
2 untreated patients who developed severe
liver damage following paracetamol overdosage
(a) Patient TJ1: Total urinary recovery - 21.7g
paracetamol equivalent. (This patient
subsequently died in hepatic failure).












































































































































































































































































































































The proportion of drug excreted unchanged in the
patients without severe liver damage was initially high
(mean 20$; Pig.36b, Table 52) but only 5$ or less was
recovered unchanged after 10 hours or so. The proportion
excreted as paracetamol sulphate was about 12$ initially
and after falling slightly this increased steadily to
31$ after 40 hours. In contrast, the proportion excreted
as the glucuronide conjugate peaked at 77$ in the second
collection period and then declined steadily to 46$.
The mercapturic acid and cysteine conjugates each
accounted for less than 2$ of the total drug excreted
initially, increasing to 7 - 10$ each subsequently..
The proportional excretion patterns in patients U1
and U12 ( Tables 53 and 54, Pig 38) differed in detail
from that of the patients without severe liver damage-
Notable differences were the very low proportion of
drug excreted as paracetamol sulphate initially and the
dramatic rise in the proportions excreted as the merc¬
apturic acid and the cysteine conjugates.
ii) Treated Patients; In the group without severe liver
damage the mean excretion rate of all 5 compounds
increased initially (Pig 39a, Table 55). Subsequently,
unchanged paracetamol was excreted with a half-life of
2.8 hours and the mean excretion rate of paracetamol
glucuronide declined from a peak of 733 mg/hr in parallel
with unchanged drug:. In contrast, the mean excretion
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Fig.39:Urinaryexcretionofpara etamolanditsc njugatesfoll w ngp r cetamolove dos gin5p tien swith ut severelivdamagefollowingtreatmentwithNAC(3)ndcy teine2with10h ursfp race amol ingestion.(Themeatot lrecoverywas13.1±3.9gparacetamolequivalent).


























































































































































































































104 mg/hr for about 15 hours before declining rapidly
and was wore than double the rate observed in the untreated
group between 12 and 28 hours (Figs 36a. and 39a),
The pattern of urinary excretion of the mercapturic
acid and cysteine conjugates was similar to that of the
sulphate conjugate. The mean excretion rates(maximum.
41 and 33 mg/hr for the meroapturic acid and cysteine
conjugates respectively) were almost double the rates
observed in the untreated group (Figs, 36a and 39a).
The urinary excretion of paracetamol and its conjug¬
ates in the patients with severe liver damage following
late treatment with NAG was relatively rapid in one
(patient N16; Fig. 40a, Table 56) but prolonged in the
other (patient N17f Fig. 40b, Table 57). Renal function
was normal. The urinary half-life ox unchanged drug
was 3.5 hours in patient N16 and 7.5 hours in patient N17.
The initial excretion rate of paracetamol sulphate in
both patients was comparable with the early-treated
group. The predominance of paracetamol cysteine over
paracetamol mercapturate resembled that seen in the 2
untreated patients with severe liver damage.
The mean proportion of paracetamol excreted unchanged
by the early-treated group was initially high (12/«, Fig. 39b
Table 55)7 falling to less than 5i°» Howeverr the mean
proportion excreted as paracetamol sulphate was vary low
at first (Q°/l) but rose progressively to 32^. Paracetamol


















































































































































































































































































































































from 76$ to about 50$ at 30 hours. The mean proportions
excreted as the mercapturic acid and cysteine conjugate
increased steadily from 2$ to 11$ each over the same
period.
The proportional excretion pattern in patient N16
(Fig- 41a) was similar to that observed in the early-
treated group (Fig 39b). However, unchanged paracetamol
accounted for a higher proportion and the proportion
excreted as paracetamol glucuronide declined more sharply
(to about 30$). The proportions excreted as the mercapturic
acid and cysteine conjugates rose more rapidly to much
highe^r levels (more than 16$ each). The pattern in¬
patient N17 (Fig. 41b) was similar to patient N16 but
the changes were less dramatic.
iii) Urinary Excretion of Paracetamol and its Conjugates
at Intervals After Overdosage
Important differences between the groups were
observed in the urinary excretion of paracetamol and its
conjugates in the 3 intervals studied (Fig. 42*. Table 58a
and b). In the group given cysteamine* the proportional
excretion of the mercapturic acid and cysteine conjugates
was particularly low at all times, less than 5$ was
excreted as each compound compared with 10$ or more in
the other groups. The amounts excreted were comparable
in all 3 groups without severe liver dama.ge.
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F i g.4 2 : Change in the proportional excretion of para¬
cetamol and its conjugates in urine collected at
different intervals after paracetamol overdosage,
in treated and untreated patients.
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The methionine-treated group who developed severe
4
liver damage despite early treatment showed a similar
excretion pattern to the other groups with severe liver
damage (Table 58br, Figr 42). In all 3 groups the mean
proportion of unchanged drug was always more than 5#
and large proportions and amounts were excreted as the
mercapturic acid and particularly the cysteine conjugates.
Most of the drug and metabolites were recovered in
the first collection period in all groups except the
untreated patients with severe liver damage (Table 58a
and b) and 80 - 95# of the total was usually recovered
in the first 24 hours. Elimination was delayed relatively
in patients with severe liver damage.
Summary
1) There was a common pattern in the urinary elimination
of paracetamol and its metabolites following overdosage.
a) The initial relatively high proportion excreted as
unchanged drug (about 10#) fell to less than 5#.
b) The proportion excreted as paracetamol glucuronide fell
from 70 - 80# initially to about 50# after 24 hours,
whereas paracetamol sulphate (less than 12# initially)
accounted for increasing proportions subsequently (up to
30#) ►
c) The mercapturic acid and cysteine conjugates each
accounted for very small proportions ( usually 3# or less)
initially but eventually accounted for 10# or more.
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2) This basic pattern was modified by liver damage and
treatment as follows
a) Patients with severe liver damage continued to excrete
relatively large amounts of unchanged drug. The proportions
excreted as paracetamol glucuronide fell more markedly
and the proportions and amounts excreted as paracetamol
sulphate were initially lower . Paracetamol mercrapturate
and particularly paracetamol cysteine were excreted
in larger amounts and proportions at all times.
b) Treatment with NAC and cysteine and,, to a lesser
extent,, cysteamine was associated with an increase in the
amounts and proportions excreted as paracetamol sulphate.
c) The proportions excreted as the mercapturic acid and
cysteine conjugates were reduced" following treatment with
cysteamine. NAC and cysteine apparently increased the
excretion rate of these conjugates.
d) Little alteration ih paracetamol elimination was obser¬
ved in the patients who developed severe liver damage
following treatment with methionine.
3) Elimination of paracetamol was rapid regardless of
liver damage and treatment ( > 80$ excreted in 24 hours).
4) The pattern of urinary excretion of paracetamol with
time differed markedly from that following therapeutic
doses,, as follows
a)A higher proportion was excreted unchanged initially.
b) The proportions excreted as the sulphate and glucuron¬
ide conjugates were much smaller and larger respectively
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c) The proportions excreted as the mercapturic acid
and cysteine conjugates were eventually about double
those observed after therapeutic doses.
c) Discussion
The urinary excretion pattern of paracetamol and
its metabolites after overdosage and therapeutic doses
indicated early saturation or limitation of the sulphate
conjugation pathway. Similar observations were made by
Houston and Levy (1976) who compared the urinary elimin¬
ation of lg doses of paracetamol with and without ascorbic
acid, a competitive inhibitor of sulphate conjugation- The
maximum excretion rate of paracetamol sulphate appeared to
be about 70 mg/hr. Levy and Yamada (1971) reported
similar findings with a 2g dose of paracetamol. The
renal clearance of paracetamol sulphate is not dose-
dependent, and is not reduced after overdosage in the
absence of renal failure (see following chapter,, pp 277-281
The shortfall in sulphate conjugation was largely
compensated for by glucuronide conjugation until most
of the drug had been eliminated. The increased production
and excretion of pa.racetamol sulphate following treatment
with NAC suggests that availability of inorganic sulphate
may be a limiting factor.
The peak excretion rates- of the mercapturic acid
and cysteine conjugates occurred later than with the
other metabolites. This suggests that these conjugates
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and/or their precursor (paracetamol glutathione conjugate )
are not totally eliminated from the body immediately
after formation. Biliary excretion of the glutathione
conjugate (which has been demonstrated in isolated
perfused rat liver; Harvey and Levitt, 1976) followed
by recirculation may account for this. In patients
with severe liver damage, very small proportions of the
drug were eliminated by sulphate conjugation initially,
and more must have been diverted to the other routes of
elimination, including the potentially toxic oxidative
route. In such cases relatively high proportions of
drug continued to be excreted unchanged rather than as
conjugates. This* finding together with the observation
that the plasma paracetamol half-life is prolonged from
the outset indicates early impairment of hepatic metabolism
of paracetamol. This is confirmed by the reduced plasma
concentrations of paracetamol sulphate and glucuronide
conjugates in patients with severe liver damage
(Chap 5). Similar observations were reported by Prescott
and Wright (1973).
NAC ( and cysteine) appeared to modify the metabolism
of paracetamol. The maximum excretion rate of paracetamol
sulphate in patients given NAC or cysteine was much
higher than in untreated patients. Less effect was
seen in patients who developed severe liver damage
after late treatment with NAC. It seems unlikely that
the difference s in paracetamol sulphate excretion were
due to differences in the amount of paracetamol absorbed
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or incomplete urine collections since similar effects
were seen with plasma concentrations of paracetamol
sulphate following early and late treatment with NAC.
In the patients treated early with NAC or cysteine,
the mean excretion rates of the mercapturic acid and
cysteine conjugates were high but none develo.ped severe
liver damage. The excretion rates of these compounds
were also high with late treatment but severe liver
damage occurred. It appears that early treatment with
NAC or cysteine protected against liver damage in spite
of the increased production of the mercapturic acid
and cysteine conjugates. This contrasts with the
increased excretion of these conjugates associated with
severe liver damage in other patients who were either
not treated, treated late or treated with methionine.
These findings may be explained in terms of repletion of
hepatic glutathione following NAC and cysteine treatment
(Strubelt et al,. 1974) and/or direct conjugation with
the toxic metabolite of paracetamol (Buckpitt et al, 1979),
a reaction which apparently does not occur with methionine.
Cysteamine treatment was associated with the reduced
excretion of the mercapturic acid and cysteine conjugates.
In addition, the overall elimination rate of paracetamol
was slower relative to the other groups without severe
liver damage. Thus cysteamine apparently reduced the
rate of conversion of paracetamol to its reactive
metabolite, therefore giving protection to the liver,
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while also reducing the overall elimination rate of
paracetamol. Similar observations were made by Buckpitt
et al (1979) in mouse liver microsomal preparations.
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Chapter 8
Renal Clearance of Paracetamol and its Conjagates
The renal clearance of paracetamol and its sulphate
and glucuronide conjugates was measured at different
plasma concentrations. The plasma concentrations of
the 3 compounds at the beginning and end of the approp¬
riate urine collection periods were estimated by inter¬
polation as in Chap. 5, P 204 and the renal clearances
determined aa in Sec. IV, p 119 . The relationships
between renal clearance and plasma concentration,,
urine flow rate and urine pH were investigated using
linear regression analysis.
Twelve urine collections from 9 patients were
analysed. Renal function was normal in all patients,
as judged by urine flow rate and plasma creatinine
concentrations(Table 59)-
a) Results
Table 59 shows the renal clearances of paracetamol
and its sulphate and glucuronide conjugates in the 9
patients. In the three patients who developed severe
liver damage, the renal clearances of all 3 compounds
were comparable with those in the other patients. The
correlations between renal clearance and plasma concen¬
trations,. urine flow rate'and urine pH are summarised













































































































































































































































































































































































































(.10.4 — 5*0 ml/rain. ) indicated extensive tabular reabsorp-
tion and the high values for the sulphate and glucuronide
conjugates (148 ± 42 and 129 — 35 ml/min. respectively)
suggested active secretion. The mean renal clearance
values of all 3 compounds following overdosage were sim¬
ilar to the values obtained following a 20 rag/kg dose
(Table 60).
There were no significant correlations between
renal clearance and plasma concentrations of any of the
compounds (Table 60). The correlation between renal
clearance and urine flow rate was only significant with
paracetamol (r = 0.84; p .001) and there was no
correlation between the renal clearance of any compound
and urine pH (Table 60). Similar observations were made
at therapeutic dosage ( pp 137 - 139).
b )])iscuss Ion
Following overdosage,, the renal clearance of
paracetamol and its glucuronide and sulphate conjugates
and the correlations with urine flow rate and pH were
similar to +hose observed following therapeutic doses
( Sec lV,ppl67-170). Unchanged paracetamol apparently
underwent extensive renal tubular reabsorption and its
sulphate and glucuronide conjugates were apparently
actively secreted. Active tubular secretion of the
mercapturic acid and cysteine conjugates probably
occurs also since their plasma concentrations were too
low to measure despite high urinary excretion rates.
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Thus these findings show that the renal tabular
transport of the glucuronide and sulphate conjugates
is not saturated following paracetamol overdosage. The
studies in dogs reported by Duggin and Mudge (1975*- 1976),
although in broad agreement with the present study,
indicated saturation of the renal clearance of these
conjugates at high plasma concentrations. The concentration
ranges encountered in their studies were 8 - 150,- 3-26
and 15 - 19 /ig/ml for paracetamol and its sulphate and
glucuronide conjugates respectively, compared with
30 - 262r 8-25 and 22 - 167 /ug/ml respectively in the
present study. It would appear that the renal transport
mechanism is more easily saturated in dogs than in man.
The renal clearance measurements made by Prescott and
Wright (1973) involved plasma concentrations similar to





1) The plasma concentration of paracetamol 4 hours
after overdosage showed a highly significant relationship
(p < .0001) with the degree of liver damage sustained in
untreated patients. No such relationship was observed
after treatment within 10 hours of ingestion with
intravenous methionine,, cysteamine or N-acetylcysteine
(NAC), indicating that such treatment is highly effective
in reducing liver damage. Treatment more than 10 hours
after overdosage had little or no effect.
2) The 4 hour plasma paracetamol concentration correlated
significantly with the total urinary recovery of paracet¬
amol and its conjugates for patients admitted within
10 hours of overdosage.
3) The actual paracetamol dose absorbed could not be
accurately determined owing to loss of urine samples
and possible formation of unidentified metabolites.
4) The absorption of paracetamol in overdosage was
rapidr with peak plasma concentrations occurring within
4 hours of ingestion.
5) Paracetamol was eliminated rapidly, almost entirely
by metabolism irrespective of liver damage or treatment
with NAC, cysteamine or methionine. In 13 untreated
patients, from whom a mean of 11.8g was recovered as
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parent drug and its 4 major conjugates (sulphate,
glucuronide, mercapturic and cysteine conjugate), only
8.3$ was unchanged drug.
6) The plasma paracetamol half-life was significantly
prolonged in poisoned patients without severe liver
damage (3.5 -± 0.7 hours) relative to therapeutic
dosage ( 2.3 ± 0-4 hours). The half-life was longer in
patients with severe liver damage (5-2 ± 1.6 hours).
Early treatment with NAC reduced the half-life in 10
patients, from 4.5 — 1.0 hours to 2.8 — 0.6 hours hut
the effect of cysteamine was much less marked (mean
plasma paracetamol half-life of 4.0 ± 0.7 hours)-
Treatment more than 10 hours after overdosage did not
alter the plasma paracetamol half-life.
7) In patients with normal renal function, plasma
concentrations of the glucuronide, and particularly the
sulphate conjugate, were low in relation to those of the
parent drug after overdosage compared with therapeutic
doses. Treatment with NAC (and to a lesser extent
cysteamine) increased the plasma concentrations of
paracetamol sulphate, although this effect was less
marked in patients treated more than 10 hours after
overdosage.
8) Plasma concentrations of the mercapturic acid and
cysteine conjugates were too low to measure.
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9) In overdosage, an initially high proportion of
paracetamol was excreted unchanged, together with a low
proportion as the sulphate conjugate. Overall elimination
was prolonged compared with therapeutic dosage.
10) Urinary excretion of the mercapturic acid and cysteine
conjugates after overdosage was very low at first and
peak excretion rates occurred much later than after
therapeutic doses (about 10 hours and 2-3 hours after
ingestion respectively).
11) The proportions excreted as the mercapturic acid and
cysteine conjugates in overdosage were similar to the.
proportions excreted after therapeutic dosage except in
patients with severe liver damage. Patients with
severe liver damage excreted significantly larger proport¬
ions as these conjugates, with the cysteine conjugate
predominating.
12) Treatment of overdosage with intravenous NAC was
associated with a significant increase in the amount
and proportion of drug excreted as paracetamol sulphate.
Also, large amounts of the mercapturic acid and cysteine
conjugates were excreted without the liver damage usually
associated with production of such large quantities of
these compounds.
13) Treatment of overdosage with intravenous cysteamine
was associated with a significant increase in the proportion
of drug excreted as paracetamol sulphate but a decreased
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proportion excreted as the mercapturic acid and cysteine
conjugates^
14) Intravenous methionine resulted in an insignificant
increase in the proportion of drug excreted as paracetamol
sulphate following paracetamol overdosage and there was
no charge in the excretion of the cysteine and mercapturic
acid conjugates. Methionine was the least effective of
the 3 specific treatments in preventing liver damage
after overdosage.
15) The renal clearances of paracetamol and its sulphate
and glucuronide conjugates at high, toxic plasma
concentrations were not significantly different from those
at therapeutic concentrations. As observed with therapeutic
dosage, the renal clearance of paracetamol was very low
(mean 10.4 ml/min) and dependent on urine flow rate,,
indicating extensive renal tubular reabsorption. The
renal clearances of the sulphate and glucuronide conjugates
however,, were high (mean 148 and 129 ml/min respectively)
and independent of urine flow rate, suggesting active
tubular secretion. Urine pH had no effect on the




The present study indicates that elimination of
paracetamol taken in overdosage is rapid. Similar findings
were reported "by Prescott et al (1971).
The three specific treatments studied in detail
were effective in preventing liver damage after paracetamol
overdosage, particularly NAC and cysteamine. Efficacy of
treatment was paralleled by effects on the metabolism
and elimination of paracetamol. The treatment which had
the least effect on paracetamol metabolism (methionine)
%
was also the least effective in preventing liver damage.
i) Assessment of Overdosage and Liver Damage
The relative lack of control in drug overdosage
studies greatly hinders interpretation of the results
obtained. This problem cannot readily be overcome since
one cannot ethically conduct a controlled clinical trial.
For this reason it was necessary to assess the severity of
poisoning using the 4-hour plasma paracetamol concentration,,
overall urinary recovery and maximum plasma AST/AIT values
for comparison of paracetamol dispositon and the effects
of treatment.
Accurate 4 hour plasma paracetamol values depend on
accurate knowledge of the time of drug ingestion and
speed of absorption. The general unreliability of
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overdosage patients (Matthew, 1971) undoubtedly leads
to errors in the estimation of this value. The 4 hour
plasma paracetamol concentration (which was calculated by
extrapolating later plasma concentrations back to 4 hours)
is subject to additional error if the half-life changes.
This is very important in the case of patients admitted
many hours after paracetamol ingestion. Further, where
the half-life was shortened by treatment,values would
be overestimated. In practice,, most patients were
admitted within 10 hours of drug ingestion and sufficient
samples were collected to estimate the 4 hour plasma
paracetamol concentration before significant changes in
the half-life occurred. Patients with severe liver
damage tended to be admitted late, therefore it is
possible that their 4 hour plasma paracetamol concentrat¬
ions may have been underestimated.
The "total urinary recovery" of paracetamol only
referred to the unchanged drug and its sulphate,
glucuronide, cysteine and mercapturic acid conjugates*
Other minor metabolites of paracetamol are known
(Mrochek et al,, 1974f Andrews et al, 1976; Klutch et al,
1978) and Knox and Jurand (1977, 1978) reported at
least one other metabolite (methoxyparacetamol) in urine
after overdosage. Also, some paracetamol may remain
covalently bound to liver (Jollow et al,. 1973). The
contribution of these other compounds to the total
urinary recovery after overdosage is not known but is
unlikely to be large (Andrews et al,. 1976) and in any
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case 110 assumptions have heen made regarding the actual
dose ingested. Completeness of urine collections could
never be guaranteed and despite the exclusion of oatients
admitted more than 10 hours after paracetamol ingestion,
some losses were known to have occurred. Nevertheless,
the significant correlation' between 4 hour plasma
paracetamol concentrations and the total urinary recovery
of paracetamol in the 4 treatment groups suggested that
the groups were comparable.
The definition of liver damage is arbitary with
respect to the cut-off values of the peak serum
concentrations of the aminotransferases (AST and ALT).
Prescott et al (1971) found that the peak serum concent¬
rations of the transaminases (and also bilirubin and
prothrombin time ratio) correlated well with the 4 hour
plasma paracetamol concentrations and plasma paracetamol
half-life. This indicates the association between the
extent of liver damage sustained (as estimated by these
measurements) and the amount of paracetamol absorbed
and its elimination rate.
James et al (1979) compared AST,, bilirubin and
prothrombin time ratio measurements with estimations of
liver damage in liver biopsy samples from patients with
paracetamol overdosage. They' noted that serum AST conc-
trations were a good indicator of severe histological
damage whereas serum bilirubin concentrations and the
prothrombin time ratio often changed little in cases of
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moderate cell damage. They are alone in considering
that peak AST concentrations of greater than 400 iu/l
indicated severe liver damage. Maximum AST/ALT concen¬
trations ahove 1000 iu/L have been used as and index of
severe liver damage by most workers (Prescott et al,.
1976; Crome et al,. 1976; Smith et al, 1978) and this
level was adopted in the present study.
Of the 48 patients studied in detail, 22 were
clinically normal with respect to ALT/AST measurements
(less than 40 iu/L) compared with 29 "by serum bilirubin
concentrations and 28 by prothrombin time ratio (upper
normal limits 1.0 mg/100 ml and 1.3 respectively).
ii) Limitations
Many factors other than dose, liver damage and
treatment can affect paracetamol metabolism and some of
these factors could have influenced the results of
the present study.
Age; The patients investigated in the present study showed
a wide age range with a bias towards young adults
(20 - 30 years). Briant et al, (1976) noted a wide
variation in the elimination rate of a lg dose of
paracetamol in adults although there was a tendency
towards slower elimination in the elderly. Children
appear to eliminate paracetamol more slowly than adults
and rely on sulphate conjugation in particular (Levy
et al, 1975; Miller et al, 1976). However, Miller et al
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noted that the urinary excretion pattern of paracetamol
and its sulphate and giucuronide conjugates in 12 year
olds was similar to that in adults. The youngest
patient in the present study was 16 years old.
Sex: There were many more females than males in the
present study and the ratio varied considerably between
the patient groups. Some workers (Briant et al,. 1976;
Wojcicki et al, 1979) have found small sex differences
in the kinetics of elimination of the parent drug follow¬
ing a lg dose in young adults. However, Miller et al
(1976) noted no sex differences in either the urinary
half-life of paracetamol or the overall excretion of.,
the unchanged drug and its sulphate and giucuronide
conjugates after a 10 mg/kg dose in both young adults
and children.
Other Drugs: Many of the patients treated for paracetamol
overdosage had also ingested other drugs and many were
regular consumers of large quantities of alcohol. This
may well have affected both the clinical outcome and
the metabolism of paracetamol in some of the patients
due to the induction of liver microsomal enzymes (Kater
et al, 1969; Soloman et alr 1971; Wright and Prescott
1973). Studies in rats and mice havd shown that
microsomal enzyme induction with phenobarbital potentiates
paracetamol hepatotoxicity (Mitchell et al,. 1973 a,b).
Induction was also associated with a higher proportion
of the paracetamol dose being recovered as the mercapturic
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acid conjugate in animals (Jollow et al, 1974). In man,
Wright and Prescott (1973) observed that potentially
induced patients developed significantly more severe
liver damage than non-induced patients after paracetamol
overdosage► Also, Mitchell et al (1974) showed that
volunteers excreted a higher proportion of a 1.2g
dose of paracetamol as the mercapturic acid conjugate
following pre-treatment with phenobarbital.
Dextropropoxyphene, a narcotic analgesic, is now
commonly taken in overdosage with paracetamol (in a
combination preparation,"Distalgesic")- Narcotics
delay gastric emptying and hence absorption of paracetamol
(Nimmo et al,, 1975) and this may have occurred in
patients who took Distalgesic. Delayed absorption will
probably result in an unreliable estimate of the 4 hour
plasma paracetamol concentration but the pattern of
urinary excretion is unlikely to be altered (Slattery
and Levy, 1979). However, delayed absorption followed
by specific treatment may result in altered urinary
excretion since a larger proportion of the dose
absorbed will be exposed to the metabolic effects of
treatment.
ill) Paracetamol Metabolism and Liver Damage
The oxidation of paracetamol via cytochrome P-450
to the potentially toxic intermediate and its subsequent
inactivation with reduced glutathione are particularly
important. The present study showed that the metabolisim
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of paracetamol in overdosage and therapeutic dosage
differs. The prolonged elimination half-life, together
with substantially reduced sulphate conjugation ana more
extensive cytochrome P-450-dependent oxidation, is
consistent with saturation of sulphate conjugation with
increased production of the reactive intermediate. These
effects of paracetamol metabolism were most marked in
patients who developed severe liver damage. However,
even in these patients paracetamol elimination was rapid
and most of the drug recovered was excreted within 24 hours.
In the 13 untreated patients,the mean overall
urinary recovery of paracetamol and its metabolites in
the 4 patients who developed severe liver damage was
15.Og compared with 10-4g for those without severe
liver damage. These values were similar to the
pharmacokinetically-derived estimates of the dose ingested
in two similar groups of 4 patients (Prescott and Wright,
1973)► Their estimates of the mean dose in patients
with and without liver damag« were 18.8g and 12.7g
respectively. The amount of oxidised paracetamol covalently
bound to liver proteins probably accounts for only a
small proportion of drug absorbed (Jollow et al, 1973;
Davis et al, 1976a).
The overall urinary recoveries following overdosage
reported by Davis et al (1976) were also similar to
those observed in the present study. However, these
workers reported that the proportions of dose excreted
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as the glutathione-derived conjugates were far larger
(up to 50$) and the proportion excreted unchanged much
smaller (up to 2$) than in the present study. These
differences were probably attributable to the unsatisfact¬
ory analytical methods they used (Howie, 1977). The
lack of a clear association between dose and toxicity
of paracetamol was also noted by Prescott and Wright
(1973) and Davis et al (1976).
Jollow et al (1974) showed in animals that the
proportions excreted as the sulphate and glucuronide
conjugates decreased and increased respectively and the
unchanged,proportion increased with increasing paracetamol
dosage (as found in the present study). Also, as the
dose of paracetamol increasedt the proportions of
overall recovery represented by the oxidative metabolites
began to decrease, reflecting glutathione depletion,,
and this stage was associated with the occurrence of
liver damage. The doses encountered in the present study
(up to at least 300 mg/kg) were comparable with those used
in animal studies (mostly 100 - 1000 mg/kg). Considerable
species differences exist in the metabolism of paracetamol
and in the susceptibility to its toxic effects (Mitchell
et al, 1973 a; Jollow et al, 1974; Davis et al, 1974)-
The proportion recovered ss the mercapturate and cysteine
conjugates in the present study were always low during
the first 10 hours or so and particularly immediately after
ingestion, during which time most of the drug is metab¬
olised. It is therefore possible that the excretion
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pattern during this period may reflect the depletion
of glutathione to an extent likely to cause liver damage
in some individuals.
The delayed appearance of the mercapturic acid and
cysteine conjugates in urine may "be due in part to
biliary excretion and recirculation of these compounds
and/or their precursor, the glutathione conjugate
(Harvey and Levitt,. 1976). However, in overdosage the
maximum excretion rates of these compounds occurred 7
hours or more later than after therapeutic dosage,, which
may reflect the period during which glutathione depletion
occurs.
Dose-related changes in paracetamol metabolism were
also found by other workers. Prescott and Wright (1973)
noted the rapid excretion of unchanged drug shortly after
ingestion,, and the higher proportion excreted unchanged
overall. They also noted, in patients with liver damage,
the high ratio of parent drug to conjugates in plasma
and the high proportion of unchanged drug excreted at all
times after overdosage. Davis et al (1976) observed
that overall excretion of the glucuronide conjugate was
limited with paracetamol doses above lOg whereas that of
paracetamol sulphate was limited with doses of less than
4g. Production of the glutathione-derived conjugates was
not limited with increasing dosage and correlated with
the incidence of liver damage. Similar observations
were noted in the present study although glucuronide
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conjugation did not appear to be limited to the same
extent.
Slattsry and levy (1979) studied the data of other
workers from overdosage patients and subjects taking
therapeutic doses of paracetamol and obtained similar
results to the present study. They predicted saturable
metabolism via glucuronide and particularly sulphate
conjugation and non-saturated oxidative metabolism. This
was verified using computer-aided pharmacokinetic
analysis which also revealed the dose-related plasma
paracetamol half-life reported in the present study.
They also commented on an apparent lack of influence of
liver damage on the plasma half—life of paracetamol.
Their predictions for the proportions of dose excreted as
the various compounds in overdosage were based on the
data of Davis et al (1976) and therefore differed
somewhat from the present study.
iv) Effects of Specific Treatment on Paracetamol Metabolism
In the present study cysteamine, methionine and NAC
were shown to produce various effects on the metabolism
of paracetamol taken in overdosage and these effects could
be related to the efficacy of treatment in preventing
hepatotoxicity. The use of these treatments in man was
based on the results of their hepato-protective effect in
animals given large doses of paracetamol (Mitchell et al,
1973b, 1974; Strubelt et al, 1974; McLean and Day, 1975;
Piperno and Berssenbruegge, 1976). The clinical efficacy
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of these agents in man has since "been reported (Prescott
et alr 1974, 1976, 1977, 1979; Crome et al, 1976;
Peterson and Rumack, 1977)»
However, there are no published studies relating to
metabolic effects of these treatments on paracetamol
overdosage in man except for the limited investigation
by Howie et al(1977). In this study it was noted that
paracetamol metabolism showed greater differences in
relation to liver damage than in relation to treatment
with cysteamine or methionine, a finding which was
confirmed in the present study. Howie et al also
observed that excretion of the mercapturic acid and
cysteine conjugates was halved during- a 6 hour infusion
of cysteamine (lg) in one volunteer who took a 1.5g dose
of paracetamol. This suggested that cysteamine limits
the cytochrome P-450-dependent oxidation of paracetamol in
man. The findings in the present study support this
hypothesis even though the 11 patients studied were given
cysteamine on average 6.8 hours after paracetamol overdosage.
A major additional finding in the present study was
the enhancement of sulphate conjugation with these
treatments, levy and Yamada (1971) noted a similar
effect (after therapeutic doses of paracetamol)with cysteine,
which reversed the limitation of paracetamol sulphate
production caused by salicylamide. Slattery and levy (1979)
investigated the effect of "unsaturating" sulphate conjug¬
ation on the elimination rate of paracetamol following
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large and small doses using pharmacokinetic analysis.
They predicted that little effect would be found with
therapeutic doses but a pronounced enhancement of
paracetamol elimination should be seen with doses of
lOg or more. This was precisely as observed with NAC
in the present study. Prescott et al (1974) found
that plasma paracetamol half-lives were significantly
reduced following cysteamine treatment.
Piperno et al (1978)did not find this effect with
NAC in mice. "Early" administration of NAC did not
change the plasma half-life of paracetamol. Paracetamol
(1200 mg/kg orally) followed 1 hour later by 1200 mg/kg
NAC orally resulted in a reduction in the urinary
excretion of paracetamol sulphate and an increase in
the excretion of the mercapturic acid and cysteine
conjugates. They concluded that the protective effect
of NAC was not associated with either enhanced eliminat¬
ion or major changes in the urinary excretion pattern
of paracetamol. However, the metabolism and elimination
of paracetamol overdoses is considerably more rapid
in mice (half-life about 1 hour) than in man (half-life
3 hours or more).
McLean and Nuttall (1978) showed that the fall in
free sulphydryl concentrations following the incubation
of rat liver slices with paracetamol could be reversed
with methionine and cysteine, which is consistent the
replenishment of glutathione stores. Harvey and Levitt
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(1976) studied the effects of various agents on
paracetamol metabolism in the isolated perfused
rat liver. Cysteamine was found to markedly inhibit
the formation of the glutathione conjugate whereas
cysteine and methionine did not. They concluded that
methionine and cysteine protect the liver by supplying
precursors for glutathione synthesis whereas cysteamine
inhibited the cytochrome P-450-dependent oxidation of
paracetamol rather than becoming incorporated into
paracetamol conjugates.
Buckpitt et al (1979) investigated the effects of
various sulphydryl compounds on the oxidation and
sulphydryl conjugation of paracetamol in mouse liver
microsomal preparations. They found that cysteamine
in high concentrations decreased both the rate of paracet¬
amol metabolism and the rate of covaient binding but in
low concentrations it was capable of forming an adduct
with paracetamol. Both cysteine and NAC inhibited covaient
binding and both formed conjugates with paracetamol,
NAC particularly so. Cysteine appeared to decrease the
rate of paracetamol metabolism also. On the other hand,,
methionine did not form an adduct with paracetamol and
had no significant effect on the rates of paracetamol
metabolism and covaient binding.
These findings are in complete agreement with the
present study. Methionine did not inhibit or enhance
the formation of the oxidative metabolites and its
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hepatoprotective effect was inferior to the other
treatments. Cysteamine reduced the formation of the
oxidative metaboites and also appeared to decrease the
rate of metabolism of paracetamol while at the same
time preventing liver damage. NAC (and cysteine)
treatment resulted in larger amounts of the oxidative
metabolites being excreted without the otherwise
expected liver damage. In man, the enhanced elimination
of paracetamol probably contributed to the reduced
incidence of liver damage with NAC.
v) Summary
The metabolism and elimination of paracetamol was
studied in patients with paracetamol poisoning and
was related to disposition of the drug following
therapeutic dosage. The effects of liver damage and
specific treatment on paracetamol disposition were
also studied. The scope of the investigation was limited
by the uncontrolled nature of drug overdosage, ingestion
of other drugs, difficulty in obtaining complete urine
collections and the variation in times of admission
and treatment.
The metabolism and elimination of paracetamol
was related to dosage and hepatotoxicity. However,-
the drug was always extensively metabolised. Sulphate
conjugation was readily saturated and inorganic sulphate
was probably depleted. Oxidative metabolism did not
appear to be limited and this may account for toxicity
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at higher doses.
Paracetamol toxicity was related to the plasma
concentration in relation to the time after ingestion
although individual susceptibility varied widely. Specific
treatment with methionine, cysteamine and N-acetylcysteine
(NAC) within 10 hours of paracetamol ingestion reduced
toxicity whereas later treatment was ineffective. The two
most effective treatments, intravenous NAC and cysteamine,
apparently had different effects on paracetamol metabolism.
NAC enhanced the elimination of paracetamol via, sulphate
conjugation and increased the urinary excretion of the
mercapturic acid and cysteine conjugates. Cysteamine
increased sulphate conjugation to a lesser degree and
seemed also to inhibit the formation of the oxidative
metabolite,. as shown by a decrease in the proportions
of drug excreted as the mercapturic acid and cysteine
conjugates. Intravenous methionine had no obvious
effect on the metabolism of paracetamol.
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COMMUNICATIONS
Paracetamol metabolism following overdosage: application of high
performance liquid chromatography
D. Howie, P. I. Adriaenssens, L. F. Prescott*, University Department of Therapeutics, The Royal Infirmary,
Edinburgh, EH3 9YW, U.K.
There has been renewed interest in the metabolism of
paracetamol since Mitchell, Thorgeirsson & others
(1974) described the mechanisms of hepatic necrosis
induced by this drug. In particular, the significance of
the cysteine and mercapturic acid conjugates has been
established in relation to the formation of a hepato-
toxic intermediate metabolite (Mitchell & others, 1974;
Andrews, Bond & others, 1976; Davis, Simmons &
others, 1976). Sulphydryl donors such as cysteamine
and L-methionine protect against severe liver damage
following overdosage (Prescott, Park & others, 1976),
but the mechanisms involved are unknown.
The urinary excretion of paracetamol and its conju¬
gates (as measured by high performance liquid chroma¬
tography, h.p.l.c.) was studied in 5 males and 5 females
admitted to the Regional Poisoning Treatment Centre,
Edinburgh, following severe paracetamol poisoning.
Their ages ranged from 19-54 years (mean 30-4). The
mean plasma paracetamol concentration 4 h after
ingestion was 371 fig ml-1 and the mean total urinary
recovery of paracetamol ranged from 11-8-24-2 g
(mean 18-3 g). Serial blood samples were taken and
urine collected for 3-5 days for estimation of paraceta¬
mol and its metabolites. Blood was also taken daily for
5 days for estimation of aspartate and alanine amino¬
transferases, bilirubin and prothrombin time ratio to
obtain a composite 'liver damage score' as described
previously (normal value < 2-4) (Prescott & others,
1976). Four patients were treated with L-methionine, 3
with cysteamine, 1 with L-cysteine and 2 with supportive
therapy only. Treatment was begun in all within 10 h of
ingestion (Prescott & others, 1976). Severe liver damage
(aminotransferases > 1000 i.u. litre^1) occurred in 3
patients given L-methionine and the two receiving sup¬
portive therapy, one of whom died in hepatic failure.
None of the patients developed renal failure.
The pattern of urinary excretion of paracetamol
metabolites did not appear to be influenced by the
treatment given, but was related to the severity of liver
damage (Table 1). The proportion of the total excreted
as the sulphate conjugate was significantly less in the
patients with severe liver damage than in those without,
* Correspondence.
and was inversely related to the liver damage score
(r = 0-76, P = < 0 01). In contrast, the proportion
excreted as the cysteine conjugate was significantly
higher in the patients with severe liver damage than in
those without, and was directly related to the liver
damage score (r = 0-96, P — <0 0001). A similar but
less marked trend was observed with the mercapturic
acid conjugate. In all patients there was a marked change
in the proportional excretion of paracetamol conjugates
with time. During the first 10-20 h after overdosage
very little paracetamol was excreted as the sulphate
(5-15%) and the glucuronide was the major metabolite
(> 80%). After 50-60 h however, the proportions ex¬
creted as sulphate and glucuronide were similar and
each accounted for about 40% of the total. The propor¬
tion excreted as cysteine and mercapturic acid conju¬
gates tended to increase with time, and reached a peak
at about 30 h in some patients with liver damage.
The urinary, excretion of paracetamol metabolites
was also studied in a healthy volunteer given single oral
doses of 1-5 g of paracetamol with and without cystea¬
mine (1-0 g infused intravenously over the first 6 h). In
the control study 18-6% was excreted in 24 h as the
sulphate, 76% as glucuronide, 3-1% as mercapturic
acid, 1-0% as cysteine conjugates, and 3-3% as un¬
changed paracetamol. Cysteamine reduced the urinary
excretion of mercapturic acid and cysteine conjugates.
In the control study 2 0% of the dose was excreted as
Table 1. Urinary excretion ofparacetamol (P) and its
sulphate (S), glucuronide (G), mercapturic acid (M)
and cysteine (C) conjugates in relation to severity of
liver damage following overdosage.
4 h plasma Liver
P damage Urinary excretion (%)
Patients (pg ml-1) score P S G M C
Liver damage 402 22-3 7-2 10 1 70 1 5 0 7-6












71-6 4 0 3 4**
(3-4) (18) (10)
Values given arc means with s.d. * P— <0 05, ** P= <0 005.




these metabolites in the first 6 h while the corresponding
value during the infusion of cysteamine was only 1-0%.
Taken together, these observations are consistent
with the hypothesis that the protective agents act by
inhibiting the formation of the hepatotoxic metabolites
of paracetamol. Had they acted by replacing hepatic
glutathione (Strubelt, Siegers & Schiitt, 1974), an in¬
creased excretion of mercapturic acid and cysteine
conjugates would be expected in the patients without
liver damage. No new metabolites of paracetamol were
detected in the treated patients, and the excretion of the
cysteine conjugate was directly related to the severity of
liver damage irrespective of treatment. The initial very
low proportional excretion of paracetamol sulphate is
consistent with early saturation of sulphate conjugation
(Levy & Yamada, 1971), although it is possible that
available sulphur is diverted to vital glutathione syn¬
thesis in the face of impending hepatic necrosis. Gener¬
ally similar findings were reported by Davis & others
(1976) in untreated patients with different degrees of
liver damage following paracetamol overdosage. How¬
ever, they reported a much greater excretion of mer¬
capturic acid and cysteine conjugates, ranging from 21 %
in healthy volunteers given high therapeutic doses to
39% in patients with severe liver damage. These
differences may be related to methodology since our
results are similar to those reported by Mitchell &
others (1974).
The estimation of urinary cysteine and mercapturic
acid conjugates of paracetamol has been a problem.
Davis & others (1976) used two dimensional thin-layer
chromatography and scanning densitometry which in
our hands lacked reproducibility and had poor
sensitivity. Other methods required the use of radio-
labelled paracetamol (Mitchell & others, 1974) or
analysis times of 21-45 h (Mrochek, Katz & others,
1974) and did not measure both the cysteine and
mercapturic acid conjugates. Reported h.p.l.c. methods
for the estimation of plasma paracetamol are complex,
do not use an internal standard, and give no details of
reproducibility (Riggin, Schmidt & Kissinger, 1975;
Mrochek & others, 1974; Wong, Solomonraj &
Thomas, 1976).
High performance liquid chromatographic methods
have now been developed for (A) the simultaneous
estimation of paracetamol and its sulphate, glucuron-
ide, cysteine and mercapturic acid conjugates in urine
and, (B) unchanged paracetamol in plasma.
H.p.l.c. system A assembly and running conditions
Orlita Model AE 10-4 pump, Cecil Model 212 ultra¬
violet detector (set at 250 nm, 10 p\ flow cell), Honey¬
well Model 194 recorder, Hewlett-Packard Model
3370A integrator. Column: internally polished stainless
steel tube, 170 x 4-9 mm. i.d., packed with octadecyl-
silane-bonded spherical silica, particle size 10 pm
(Spherisorb 10-ODS, Phase Separations, Clwyd), with a
septum injector. Mobile phase: 1 % aqueous acetic acid
-methanol-ethyl acetate (90:15:01) at 4-5 MNm~2
(650 lb in2); flow rate 1-6 ml min-1. Dilute urine
sample up to 50-fold with distilled water if necessary. To
0-8 ml add internal standard solution (4-fluorophenol:
0-2 ml of a 20 mg ml-1 solution in water). Mix and
inject 2-4 p\. For less concentrated urine samples (e.g.
those collected several hours after a therapeutic dose of
drug) reduce internal standard concentration to 4 mg
ml"1. Run appropriate aqueous paracetamol standards
with each set of unknowns.
H.p.l.c. method B
Apparatus: as in A with a short column (90 x 4-5 mm
i.d.) and the same reverse-phase packing. Mobile
phase: water-acetic acid-ethyl acetate (98:1:1) at
2-75 MNm"2 (400 lb in2); flow rate 3 ml min-1. To 1 ml
of plasma containing 25-500 pg ml"1 of paracetamol
in a 10 ml glass tube add slowly 10 ml of 25% (w/w)
aqueous trichloroacetic acid containing 5 mg ml"1 of
4-fluorophenol with agitation on a vortex mixer.
Centrifuge off the precipitated protein and inject
clear supernatant. For samples containing less than
25 pg ml"1 of paracetamol, add 100 p\ of a solution
containing 7 mg ml"1 of 4-fluorophenol in 75% (w/w)
aqueous trichloroacetic acid to TO ml of plasma and
inject up to 25 pi of supernatant.
Symmetrical peaks are obtained for all compounds
(Fig. 1) and calibration graphs of the peak area ratios
of paracetamol to 4-fluorophenol plotted against para¬
cetamol concentrations are linear and pass through
the origins for both assays. The responses to para¬







Fig. 1. High performance liquid chromatogram from a
urine sample obtained 3-4 h after ingestion of 1-5 g of
paracetamol in a healthy volunteer (2 p\ injection).
S = paracetamol sulphate, G = paracetamol glucu¬
ronide, P = paracetamol, M = paracetamol mer¬
capturic acid, C = paracetamol cysteine, IS = in¬
ternal standard (4-fluorophenol).
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mercapturic acid conjugates in urine are linear over the
ranges of 3-1600, 5-2600, 50-10 000, 2-800 and 2-1100
fig ml-1 respectively. The concentrations of con¬
jugates are expressed as 'paracetamol equivalents'
since their molar extinction coefficients are essentially
the same as for paracetamol. Replicate analyses of
urine samples containing different amounts of para¬
cetamol and its conjugates yielded standard deviations
of about 1, 2, 4 and 9% at concentrations of 1000, 200,
50 and 10 /ig ml-1 respectively. Interference by other
drugs has not been encountered in either assay, but
interference by other glucuronide and sulphate con¬
jugates in urine has not been excluded. Paracetamol
and its conjugates in urine are stable at —20° for at
least 9 months, but 4-fluorophenol solutions should
be freshly made weekly.
The plasma paracetamol assay can be completed
within 15 min. The retention times of the drug and
internal standard were 2-1 and 3-7 min respectively,
there were no interfering peaks with drug-free plasma
and the limit of detection was about 0-1 fig ml-1. The
standard deviations of replicate analyses of samples
containing 500-50 and 30-1 fig ml-1 were 3-7 and 5-8%
respectively using peak height ratios. There was a
highly significant correlation between the concentra¬
tions of paracetamol in 125 plasma samples assayed
once by the above method and once by gas-liquid
chromatography (Prescott, 1971) (Fig. 2).
We gratefully acknowledge advice and guidance
given by Dr J. Jurand and Professor J. H. Knox,
1000
g.l.c.
Fig. 2. Comparison of results of 125 plasma paraceta¬
mol estimations (^g ml-1) by high performance liquid
chromatographyjh.p.I.e. and gas-liquid chromatography
g.l.c.
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sensitised red blood-cells, and by some antibodies which
react with lymphocyte surface antigens.2
In transplant patients, there are at least three possible
sources of immune complexes. Firstly, they could result
from the reaction of host antibodies with graft antigens.
The development of alloantibodies may result from pre¬
vious pregnancy or blood-transfusion or from the anti¬
genic stimulation of the renal transplant. Release of
alloantigens into the blood may be a feature of normal
cells and tissues, since HLA antigenic material has been
detected in normal human serum.3 However, the varia¬
bility of the results of Fc-rosette inhibition tests per¬
formed before rejection, and the consistently positive
results during rejection episodes, suggest that release of
antigen in amounts sufficient for the formation of detect¬
able immune complexes in the blood occurs at the time
of rejection. The injury caused by the rejection process
may itself be responsible for antigen release, just as
ischaemic injury is presumably responsible for release of
antigen from recently placed renal transplants in dogs.4
Secondly, most types of glomerulonephritis are regarded
as being the result of immune-complex disease, which
can presumably remain active after renal failure and
transplantation. This could not, however, explain the
positive tests observed in those of our patients whose
renal failure was attributable to pyelonephritis. Thirdly,
immune complexes might result from the various infec¬
tions which are so common in immunosuppressed trans¬
plant patients. All three of these sources of complexes
may have contributed to the result observed for group-I
patient 2, in whom the test was positive during rejection
and remained positive after removal of the transplant:
this patient's renal failure was due to glomerulonephritis
and during rejection cytomegalovirus infection devel¬
oped which persisted after removal of the transplant.
Antibodies capable of Fc-rosette inhibition do not
seem to have conventional HLA specificity.2 As lympho¬
cytes bearing Fc receptors are mostly B cells and K cells
(which are probably of B-cell origin3), Fc-rosette inhibi¬
tion may well be a property of those antibodies which
react preferentially with B-cell antigens, perhaps deter¬
mined by the HLA-D locus.6 By using a cytoxicity test
on suspensions enriched with B cells, Ettenger et al.7
detected such antibodies in the serum of some transplant
patients and noted their association with rejection. We
are aware of only one report on the use of an Fc-rosette
inhibition test in transplant patients:® inhibition was
observed with the serum of 6 transplant patients show¬
ing signs of rejection, while sera from 4 non-rejecting
patients were negative. The serum was ultracentrifuged
before testing and the inhibitory effect was attributed to
donor-specific alloantibodies, but the work is reported as
an abstract and details are not available.
Evidence for the occurrence of immune complexes in
the blood of transplant patients is largely indirect, but
such complexes may be important in immunological en¬
hancement .9,1° Palosuo et al.11 have reported the use of
a platelet-aggregation test for immune complexes: the
test was positive in 3 of 16 transplant patients, but no
correlation with rejection was demonstrated.
In conclusion, we found that inhibition of Fc-rosette
formation by the serum of renal allograft patients pro¬
vides useful confirmation of rejection, although its value
as a predictive test remains doubtful.
The roles of immune complexes and alloantibodies in
the lancet, august 27, 1977
Fc-rosette inhibition also require elucidation. In prelim¬
inary experiments, the effects of alkylation and reduc¬
tion suggest that both factors have contributed to our
findings. The inhibitory activity of some normal sera
accords with similar results with other tests purporting
to demonstrate immune complexes.12,13
It is unlikely that positive results were due to anti-
rejection therapy (1 g prednisolone intravenously), since
only 1 of the acute-rejection cases (group Ic) had
received such therapy within the preceding five days,
whereas the same therapy was used routinely at the time
of transplantation and 6 non-rejecting cases in group-I
with negative tests had received therapy within the
twelve days preceding (3 of them within five days) test¬
ing.
We thank Dr Heather Dick for permission to quote the results of
tests for alloantibodies in thepatients' serum.
Requests for reprints should be addressed to J. R. A. , Pathology
Department, University ofGlasgow, Western Infirmary, Glasgow Gil
6NT.
references
1. Sandilands, G., Gray, K., Cooney, A., Froebel, K., Anderson, J. R. Inc.
ArchsAllergy appl. Immun. 1976,50,416.
2. Morito, T., Tanimoio, K., Hashimoto, Y., Horiuchi, Y., Juji, T. Ann. rheum.
Dis. 1976,35,415.
3. Van Rood, J. J., van Leeuwen, A., van Santen, M. C. T. Nature, 1970, 226,
366.
4. Najarian, J. S., May, J., Cochrum, K. C., Baronberg, N., Way, L. W. Ann.
N. Y. Acad. Sci. 1966,129,76.
5. Rachelefsky, G. S., McConnachie, P. R., Amman, A. J., Tercsaki, P. I.,
Stiehm, E. R. Clin. exp. Immun. 1975,19,1.
6. Lancet, 1976, U, 240.
7. Ettenger, R. B., Teresaki, P. I., Ting, A., Malekzadch, M. H., Pennisi, A. J.,
Uittenbogaart, C., Garrison, R., Fine, R. N. Nexo Engl. J. Med. 1976, 295,
305.
8. Suthanthiran, M., Garovoy, M. R., St. Louis, G., Kaldany, A., Fagan, G.,
Strom, T. B., Carpenter, C. B. Proc. Am. Soc. Nephrol. 1976, abstr. 124.
9. French, M. E., Batchelor, J. R. Transplant Rev. 1972, 13,115.
10. Carpenter, C. B., d'Apice, a. J. F., Abbas, A. K. Adv. Immun. 1976, 22, 1.
11. Palosuo, T., Kano, K., Anthonc, S., Gerbasi, J. R., Milgrom, F. Transplan¬
tation, 1976,21, 312.
12. Smith, M. D., Barratt, T. M., Hayward, A. R., Soothhill, J. F. Clin. exp.
- Immun. 1975,21,236.





L. F. Prescott J. Park
A. Ballantyne P. Adriaenssens
A. T. Proudfoot
Regional Poisoning Treatment Centre, and University
Department ofTherapeutics, Royal Infirmary, Edinburgh
EH3 9YW
Summary Fifteen patients with paracetamol
(acetaminophen) poisoning were treated
with intravenous N-acetylcysteine (300 mg/kg given
over 20 h). Mean admission and 4 h plasma-paracetamol
concentrations were 262 and 369 frg/ml, respectively.
Liver-function tests remained normal or were only
slightly disturbed in 11 of 12 patients treated within 10 h
of paracetamol ingestion. Severe liver damage devel¬
oped in the other patient and in the three in whom treat¬
ment was started more than 10 h after paracetamol in¬
gestion. In contrast to cysteamine, N-acetylcysteine was
\
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very well tolerated and has the advantage of being avail¬
able as a pharmaceutical preparation in a 20% sterile
solution.
introduction
Current treatment of paracetamol (acetaminophen)
poisoning is unsatisfactory. Although cysteamine can
prevent severe liver damage if given intravenously in
adequate dosage within 10 h of ingestion, it causes un¬
pleasant and occasionally alarming side-effects.1,2 Fur¬
thermore, it is not available commercially as a pharma¬
ceutical product. Other available agents such as
dimercaprol, penicillamine, and methionine are less
effective and do not always prevent severe liver
damage.1"3 Some time ago we suggested that N-acetyl-
cysteine might be a useful alternative to cysteamine.4
N-acetylcysteine has the advantage of being available as
a sterile 20% aqueous solution ('Airbron', Duncan
Flockhart) and, although intended for intrabronchial
administration, as much as 36 g daily has been given
orally and rectally without incident.3 Investigations in
mice have shown that N-acetylcysteine is less toxic than
cysteamine and more effective in protecting against
paracetamol hepatotoxicity.6 N-acetylcysteine is rapidly
hydrolysed to cysteine in vivo and presumably protects
by the same mechanisms.7
method
We used N-acetylcysteine to treat fifteen patients with
admission plasma-paracetamol concentrations above a line
joining 200 pg/ml at 4 h and 60 fig/ml at 12 h on a semilogar-
ithmic plot.1 Paracetamol was taken as 'Distalgesic' (dextro-
proxyphene hydrochloride and paracetamol) by patients 1, 4,
9, and 13, and as 'Para-Hypon' (paracetamol, caffeine, codeine
phosphate, and phenolphthalein) by patient 7 (table i). Other¬
wise, no other drugs were taken at the time of overdosage.
Three patients who took distalgesic were in deep coma (grade
iv) on admission including patient 1 who was apnceic, hypoten¬
sive, and had several convulsions. Adequate doses of naloxone
reversed the effects of the dextropropoxyphene in every case.
Five patients were regarded as being at particular risk of
severe hepatic necrosis because of alcoholism or previous con¬
sumption of microsomal-enzyme inducing drugs.8 An initial
dose of 150 mg/kg of N-acetylcysteine (airbron) was given di¬
rectly intravenously over 15 min. followed by infusion of 50
mg/kg in 500 ml of 5% dextrose in 4 h, and 100 mg/kg in a
litre of 5% dextrose over the next 16 h (total 300 mg/kg in 20
h).
Hepatic, cardiac, and renal function was monitored daily
for at least 5 days and severe liver damage was defined as an
increase in serum-aspartate-aminotransferase (a.s.t.) or serum-
alanine-aminotransferase (a.l.t.) above 1000 i.u./1. Serial
blood and urine samples were collected for estimation of plas¬
ma-paracetamol and total urinary recovery of drug by gas
liquid or high-performance liquid chromatography.'-10 The
severity of overdosage was assessed by the actual or extrapo¬
lated plasma-paracetamol concentration 4 h after ingestion.1
results and discussion
Mean admission and 4 h plasma-paracetamol concen¬
trations were 262 and 369 ug/ml, respectively, and de¬
spite incomplete urine collections the mean urinary re¬
covery of paracetamol was 14-9 g (range 8-8-24-9 g).
Twelve patients were treated with N-acetylcysteine
within 10 h of ingestion (mean 7-2 h) (table i). Liver-
function tests remained normal, or were only slightly
disturbed in all except patient 12. This patient had
taken other unknown drugs and a rodenticide contain-



























1 64M 4-5 461 34 17 0-8 1-3
2 16F 9-0 264 19 16 0-5 1-3
3 20F* 7-7 366 33 35 0-6 1-4
4 61F 9-5 299 34 51 0-8 1-3
5 40F* 6-3 633 64 81 0-7 1-3
6 28M 8-5 427 36 43 0-7 1-2
7 29M* 7-8 327 ■ 56 34 1-1 1-2
8 21F 5-3 245 27 16 0-9 1-4
9 44F 4-7 320 23 20 0-8 1-3
10 31F* 90 393 45 28 0-6 1-4
U 40F 5-8 463 90 38 0-9 1-3
12 22M 7-9-5 342 2520 3260 1-4 2-7
13 52F* 10-2 307 10 400 5020 3-2 20
14 53M 23-5 474 3960 13 600 5-3 2-4
15 25M 11-7 210 1608 10 300 3-5 1-6
alanine-aminotransferase.
table ii frequency of severe liver damage* in patients with paracetamol poisoning treated with supportive therapy







































'Severe liver damage=a.s.t. ora.l,t. > 1000 i.u./l.
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ing warfarin during the previous week and the prothrom-
bin-time ratio was 2-7 on admission. Patient 1 died from
a cerebrovascular accident 9 days after admission.
Three patients (13-15) were treated after 10 h. All
sustained severe liver damage without hepatic encepha¬
lopathy and in patient 14 acute renal failure also devel¬
oped.
The frequency of severe liver damage after paraceta¬
mol overdosage in patients receiving supportive therapy
only, cysteamine, methionine,1 or N-acetylcysteine
within 10 h of ingestion is shown in table ii. Although
the numbers are too small for statistical comparison,
N-acetylcysteine given within 10 h seems to protect most
patients from severe liver damage. It failed in one pa¬
tient treated within this time and in all the patients
treated more than 10 h after ingestion. Larger doses of
N-acetylcysteine might have given better protection, but
the results of treatment after 10 h remain to be estab¬
lished. The efficacy of N-acetylcysteine could perhaps be
increased by oral administration since most of the dose
should pass through the liver. However, in our experi¬
ence nausea and vomiting usually develop within 10 h
ofoverdosage in the most severely poisoned patients.
In contrast to cysteamine, N-acetylcysteine was very
well tolerated. Eight patients had nausea with
Hypothesis
POSSIBLE EFFECTS OF GROWTH HORMONE
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Summary Growth hormone (g.h.) or a g.h.-depen-
dent somatomedin may be involved in
the process of acute lymphoblastic leukaemia (a.l.l.).
Growth hormone has a trophic effect on lymphoid tissue
and also specific receptors on lymphocytes, most prob¬
ably T cells. Hypophysectomy in rats with induced
T-cell leukaemia can suppress the leukaemic process.
Resting concentrations of g.h. and somatomedin activity
are raised in some children with a.l.l. and may be
reduced after remission is achieved. It is suggested that
control of g.h. and/or somatomedin concentrations may
be necessary for adequate treatment of some cases of
a.l.l. in children.
Are humoral regulators which are out of control in¬
volved in the pathogenesis of leukaemia? Erythropoietin,
colony-stimulating factor, and thymic humoral factor
were not clearly shown to influence the leukaemia pro¬
cess.1 Hormonal substances are involved in the prolifer¬
ation of neoplasms such as breast cancer and prostatic
cancer. Evidence is accumulating that growth hormone
occasional retching and vomiting mostly during the first
hour or so of treatment, but these symptoms had usually
been present before treatment. There was a minor tran¬
sient rise in blood-pressure in three patients, but no
arrhythmias were observed during treatment. N-acetyl¬
cysteine had no obvious effects on the central nervous
system. The availability of sterile N-acetylcysteine as a
pharmaceutical preparation is a further advantage
which may make it the treatment of choice for paraceta¬
mol poisoning.
We thank the nursing staff of the Regional Poisoning Treatment
Centre for their help and Mrs L. Brown for technical assistance. This
work was supported in part by McNeil Laboratories Inc., Fort Wash¬
ington, Pennsylvania, U.S.A.
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(g.h.) or a g.h.-dependent factor influences the develop¬
ment or maintenance of acute lymphoblastic leukaemia
(a.l.l.). g.h.-dependent factors, known as somatome¬
dins,2 are peptides under partial control of g.h.
Although they are not insulin, they are insulin-like in
their action and stimulate cell growth in numerous tis¬
sues.
~ What evidence is available to implicate g.h. or its end
organ operator in the pathogeneses of leukaemia? Firstly,
g.h. has a trophic effect on lymphoid tissues—-either di¬
rectly, or indirectly via somatomedin. Simultaneous ad¬
ministration of g.h. prevented thymic cortex involution
and spleen follicular atrophy after hypophysectomy in
animals.3-* Thymic size in mice was reduced by g.h.
antibodies.5 Reduced'H-thymidine incorporation into
d.n.a. of thymocytes and splenocytes of hypophysec-
tomised rats was corrected by the administration of g.h.6
g.h. receptors are present on circulating human lym¬
phocytes,7 bovine thymocytes,8 and cultured human
lymphocytes.9,10 This was demonstrated by incubating
the cells with radiolabelled g.h. and measuring specific
binding by displacement of the labelled growth hormone
by unlabelled human g.h. Circulating lymphocytes with
the receptor are probably T cells, as demonstrated by
the alteration in electrophoretic mobility which was pro¬
duced by the binding of g.h. to a specific subpopulation
ofT cells.6
Human g.h. also had an effect on lymphocyte trans¬
formation in cell-culture.11,12 Incubation of cultured
lymphocytes with human g.h. increased the percentage
of cells undergoing blastogenic transformation. Morpho¬
logically the stimulated blast forms were typical lym-
phoblasts and not immunoblasts, suggesting increased
stimulation of T cells rather than B cells. Human lym¬
phocyte transformation as measured by 3H-thymidine
uptake is enhanced by the addition ofg.h., and transfor¬
mation by phytohaemagglutinin stimulation plus g.h.
exceeds that ofphytohaemagglutinin alone.
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HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ESTIMATION OF
PARACETAMOL METABOLITES IN PLASMA
There has been considerable interest in the metabolism
of paracetamol following the elucidation of the
mechanisms, of hepatotoxicity after overdosage
(Mitchell, Thorgeirsson, Potter, Jollow & Keiser,
1974). Only one method for the estimation of para¬
cetamol metabolites in plasma has been published
(Mrochek, Katz, Christie & Dinsmore, 1974) but this
procedure takes at least 24 h and the mercapturic acid
conjugate, a metabolite of major toxicological
significance, was not identified. We describe here a
simple, rapid method for the simultaneous assay of
paracetamol and its sulphate, glucuronide, cysteine
and mercapturic acid conjugates in plasma using high
performance liquid chromatography.
An Orlita pump (Model AE 10-4) was used with a
Waters model 440 U.V. absorbance detector (254 nm
filter) and peak areas were measured with a Hewlett-
Packard HP 3370A integrator. The columns were
internally-polished stainless steel tubes 100 mm x 4.9
mm i.d. slurry packed with Hypersil-ODS (Shandon
Southern Products) and fitted with a septum injector.
The mobile phase was 0.1 M potassium dihydrogen
20
Time(min)
Figure 1 Chromatograms obtained from drug-free
plasma (above) and plasma obtained 60 h after
severe paracetamol overdosage (below). The peaks
are: paracetamol glucuronide (G), sulphate (S),
cysteine conjugate (C), free drug (P), internal standard
(N) and mercapturic acid conjugate (M).
phosphate, 98% formic acid and isopropanol
(100:0.1:1.7 v/v/v). Stock solutions of internal
standard/protein precipitant were prepared containing
360 jig/ml of N-propionyl-4-aminophenol in 6%
aqueous perchloric acid and were stored deep frozen
prior to use. Aliquots (1 ml) of plasma from patients
with paracetamol overdosage were pipetted into glass
tubes which were placed on a vortex mixer while 1.0
ml of internal standard/perchloric acid solution was
added slowly. The tubes were centrifuged and up to
5 pi of the clear supernatant injected directly onto the
column. Samples containing lower concentrations of
paracetamol and metabolites (e.g. after therapeutic
doses) were assayed by the same procedure except
that the internal standard/protein precipitant solution
contained 300 pg/ml N-propionyl-4-aminophenol in
30% aqueous perchloric acid and 100 pi was added to
1.0 ml plasma.
With a solvent flow of 0.9 ml/min (650 p.s.i.) the
glucuronide, sulphate and cysteine conjugates, para¬
cetamol, internal standard and mercapturic acid
conjugate eluted in 2.5, 4.8, 5.3, 6.5, 14.3 and 16.5
min respectively. The peaks were sharp and well
resolved with no interference from endogenous
compounds (Figure 1) and samples could be injected
every 18 min. The limit of measurement with a 5 pi
injection was less than 1 pg/ml for all compounds.
Plots of the peak, area ratios of paracetamol and the
sulphate and glucuronide conjugates to internal
standard against concentration were linear and passed
through the origin. These three compounds normally
account for practically all the paracetamol-related
material in plasma. However, in patients developing
severe liver damage after overdosage, easily
measurable concentrations of the cysteine and
mercapturic acid conjugates may be present
(Figure 1). The extinction 'coefficients of the
glucuronide and sulphate conjugates relative to para¬
cetamol and the recoveries from plasma relative to
water differ somewhat, but using the appropriate
correction factors (0.84 for glucuronide, and 1.03 for
sulphate at 254 nm) it is possible to calibrate the assay
with plasma standards containing paracetamol only.
Insufficient authentic mercapturic acid and cysteine
conjugate was available for the preparation of plasma
standards and the linear relationship previously
demonstrated for the corresponding assay in urine
(Howie, Adriaenssens & Prescott, 1977) was assumed
to hold for plasma. The standard deviation of replicate
assays of paracetamol and its glucuronide and
sulphate conjugates was less than 3% (mean 1.0%) for
each compound with concentrations ranging from
1-250 pg/ml (paracetamol equivalent). Day-to-day
reproducibility was 3—4%. Despite the direct injection
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of deproteinized plasma, the columns have lasted for
many months with daily use.
Figure 1 shows chromatograms of drug-free plasma
and a sample obtained 60 h after paracetamol over¬
dosage in a patient who developed severe liver
damage.
The method has been used together with a
previously described high performance liquid
chromatographic assay for paracetamol metabolites in
urine (Howie et al., 1977) in studies of paracetamol
metabolism following therapeutic doses as well as
overdosage of paracetamol.
P.I. ADRIAENSSENS & L.F. PRESCOTT
University Department of Therapeutics and Clinical
Pharmacology, The Royal Infirmary, Edinburgh EH3 9YW,
Scotland
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DOUBLE-BLIND TRIAL OF
INDORAMIN IN DIGITAL ARTERY DISEASE
Trophic changes in the fingers resulting from digital
artery disease secondary to scleroderma or other
connective tissue disorders are difficult to treat
(Rowell, 1972), and no wholly satisfactory form of
therapy has been suggested. Vasoconstrictor tone in
the periphery is controlled by a-adrenoceptor
sympathetic innervation, and blockade of this control
leads to peripheral vasodilation. Indoramin (3-[2-(4-
benzamidopiperid-l-yl)ethyl]indole hydrochloride) has
been shown to possess potent a-adrenoceptor
blocking activity in all species so far studied (Alps,
Hill, Johnson & Wilson, 1970; Alps, Hill, Johnson
& Wilson, 1972; Collis & Alps, 1973) including man
(Royds & Lockhart, 1972; Royds & Lockhart, 1974),
and intravenous indoramin has been shown to be
effective in increasing cutaneous blood flow to affected
digits of patients with Raynaud's disease (Fares &
Milliken, 1974). There is also a suggestion from other
studies that indoramin may provide subjective
improvement in both primary and secondary
Raynaud's phenomenon (Alps et al., 1972; Fares &
Milliken, 1974). This preliminary study was
undertaken to assess the effect of oral indoramin on
digital blood flow, and on the symptoms ofRaynaud's
phenomenon associated with digital vascular
insufficiency resulting from scleroderma and other
connective tissue diseases.
Sixteen patients suffering from digital artery disease
in association with trophic changes in the digits were
selected for study, eleven of whom were suffering from
scleroderma with sclerodactyly as its most prominent
manifestation and were receiving no other therapy
during the trial. The primary disorder in the other
patients, all but two of whom were female, was either
rheumatoid arthritis, systemic lupus erythemetosus or
polymyositis, and these patients continued to receive
their maintenance dose of prednisolone and/or
azathioprine throughout the study. Apart from four
subjects who continued to receive therapy for hyper¬
tension and two subjects who. were receiving anti
inflammatory propionic acid derivatives for arthritic
pain, all other agents were discontinued before the trial
commenced and the dose of existing therapy which
was not changed had been stabilized for at least 6
months before the period of assessment
Patients were randomly allocated to two groups and
the study was conducted in double-blind manner.
Group A received indoramin 90 mg daily in three
divided doses for 3 weeks followed by placebo for 3
weeks. Group R received placebo for the first 3 week
period followed by 3 weeks receiving 90 mg indoramin
in divided doses. Each patient entered a daily record of
the number of attacks of Raynaud's phenomenon, and
an overall estimate of the discomfort suffered in the
day on a five point scale. Additional comments related
to unusual physical activity, marked climatic changes
.V
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Inappropriate methods for the emergency
determination of plasma paracetamol
M. J. STEWART, P. I. ADRIAENSSENS, D. R. JARV1E, AND L. F. PRESCOTT
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summary Methods for the estimation of plasma paracetamol which depend on acid hydrolysis to
y;-aminophenol without a prior extraction step also measure inactive metabolites which are present
in high concentrations.
The extent cf the overestimate obtained with such methods was determined using 24 samples from
patients after paracetamol overdosage. There was a positive error of between 40 and 700% compared
with a high-performance liquid chromatographic reference method which measured only unchanged
paracetamol.
These non-specific methods should not be used to determine the need for specific therapy in
patients with paracetamol poisoning.
Since the observation by Davidson and Eastham
(1966) that paracetamol poisoning may lead to fatal
hepatic damage, there have been numerous subse¬
quent reports (Proudfoot and Wright, 1970;
Prescott etal., 1971; Clark et al., 1973). Paracetamol
poisoning is an increasingly common problem; the
number of admissions to the Edinburgh Regional
Poisoning Treatment Centre in which paracetamol
was implicated rose from 15 in 1967 to 247 in 1977
(10-4% of all admissions in 1977).
There is much individual variation in the suscepti¬
bility to the hepatotoxicity of paracetamol. In
particular, patients whose liver microsomal enzymes
have been previously induced by alcohol or drugs
such as barbiturates are liable to be more severely
affected than others (Wright and Prescott, 1973).
The severity of paracetamol poisoning cannot be
determined on clinical grounds alone since paraceta¬
mol does not cause coma, nor are there any specific
early signs or symptoms. Clinical evidence of liver
damage does not become apparent for many hours,
and abnormal liver function tests (in particular
aminotransferase) may net be noted until 24 hours or
more after ingestion while maximum abnormalities
may be delayed for several days (Stewart and
Simpson, 1973).
The use of sulphydryl compounds to protect
against liver damage was suggested by the work of
Mitchell ana his colleagues (Jollow et al., 1973;
Mitchell et al., 1973a, b; Potter et al., 1973), who
showed that hepatic necrosis was associated with
depletion of glutathione and covalent binding of a
reactive intermediate metabolite of paracetamol to
hepatic macromolecules. Glulathione itself is rela¬
tively ineffective but a variety of sulphydryl donors
has been investigated. Intravenous (iv) cysteamine is
effective (Prescott et a'l., 1974; Douglas et al., 1976;
Prescott et al., 1976; Hughes et al., 1977) but it
causes unpleasant and prolonged side effects. The
use of oral and iv methionine has been advocated by
Crom'e et al. (1976) and Solomon et al. (1977) and
may reduce the severity of liver damage in some
cases. Currently, iv N-acetyl cysteine (NAC) is
considered to be the treatment of choice. It is
effective and is available as a pharmaceutical
preparation; no important side-effects have been
encountered (Prescott et al., 1977). Whatever agent
is used, treatment must be started within 10 hours of
ingestion of paracetamol (Prescott, 1978), and in
particularly susceptible patients the time available
for treatment may be further reduced (Scott and
Stewart, 1975). The decision whether to start treat¬
ment depends on knowledge of the plasma para-
cetamolconcentrqtion and the time after ingestion,as
this is the only known guide to the likelihood of
subsequent liver damage (Prescott et al., 1974). In
practice, the observed plasma paracetamol concen¬
tration is interpreted in relation to a 'treatment line'
(Fig. 1). Patients with concentrations above the line
are treated, since they have at least a 60% chance of
developing severe liver damage (AST or ALT > 1000
IU/'l), a 10% risk of acute renal failure, and a 5%
chance of death in hepatic failure (Prescott, 1978).
Simple, rapid, and accurate methods are therefore
\
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Fig. 1 Treatment line for use in cases
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required for the emergency estimation of plasma
paracetamol. Many methods have been described,
and the subject has recently been reviewed by
Wiener (1978). However, some methods which have
become popular on the grounds of simplicity and
speed are non-specific and give rise to serious errors
since they also measure the inactive glucuronide and
sulphate conjugates of paracetamol which are present
in plasma in amounts which may greatly exceed the
concentration of the unchanged drug (Prescott and
Wright, 1973). These metabolites of paracetamol are
very polar and therefore do not interfere with
methods involving extraction of paracetamol into
an organic solvent. However, they are readily
hydrolysed to paracetamol and are thus included in
methods based on colorimetric assay of p-amino-
phenol produced by the acid hydrolysis of para¬
cetamol without prior extraction of the paracetamol.
A comparative study of different methods for the
determination of paracetamol was therefore under¬
taken using plasma from 24 patients admitted with
paracetamol poisoning. The non-specific acid-
hydrolysis methods ofWelch and Conney (1965) and
Wilkinson (1976) were compared with the simple
colorimetric nitration method of Glynn and Kendal
(1975) and a reference HPLC method (Adriaenssens
and Prescott, 1978) which also simultaneously




Blood samples were obtained between 5 and 47
hours after paracetamol overdosage from 24
patients admitted to the Edinburgh Regional
Poisoning Treatment Centre. The plasma was
separated, stored frozen, and subsequently divided
for analysis by each of the methods detailed below.
standards
Paracetamol standards were prepared by serial
dilution of an aqueous stock solution of paracetamol
with horse serum (Wellcome) or pooled human
plasma. The solutions were divided into aliquots and
stored at — 20=C.
Paracetamol glucuronide and sulphate were
obtained from Sterling-Winthrop Laboratories,
Newcastle upon Tyne. Standard solutions of
metabolites were prepared as above in human
plasma.
quality control
Specimens prepared and stored as above were used.
The concentrations were 0-5 mmol/l for the colori¬
metric methods and 0-33 and 1-65 mmol/l for high-





Internal standard (1 ml of2T6mmoI/lN-propionyl-/J-
aminophenol in 0-33 m perchloric acid) was added to
1 ml plasma, mixed, and centrifuged. A 5 /xl sample
of the clear supernatant was injected on to a 100
mm x 4-6 mm ID stainless steel column packed with
Hypersil ODS (Shandon) (5 /aM octadecyl bonded
silica microspheres). The solvent was 0T m KH2PO4:
98% formic acid:propan-2-ol(100:0T : 1-7 v/v/v).
(2) colorimetric nitration method
(glynn and kendal, 1975),
modified by mace and walker (1976))
Aqueous trichloroacetic acid (2 ml of a 0-6 M
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solution) was added to 1 ml plasma, mixed, and
centrifuged. To 2 ml of supernatant were added 1 ml
6 m HCI and 2 ml 1-44 m sodium nitrite (freshly
prepared). After 2 minutes, 2 ml 1-54 m sulphamic
acid were added slowly, followed by 5 ml of 2-5 m
NaOH. The yellow colour was read at 450 nm
against a reagent blank.
(3) colorimetric method of welch and
conney (1965)
The colour reagent was prepared freshly for each
batch by mixing 80 ml 0-2 m NaOH, 10 ml of 9-3 m
phenol, and 10 ml of a mixture of 15 ml bromine
water in 100 ml 1 m Na2CC>3. To 0-5 ml plasma was
added 0-5 ml 10% w/v aqueous trichloroacetic acid
solution. After mixing and centrifugation 0-5 ml of
the supernatant were added to 2 mi 4 m HCI. The
tubes were loosely stoppered and heated at 100~C in
a water bath for 1 hour. After cooling to room
temperature the contents were diluted to 5 0 ml with
water, and 0-5 ml of this solution was added to 5 0
ml colour reagent. The contents of the tubes were
mixed thoroughly and allowed to stand for 40
minutes; the blue colour was read at 620 nm
against a reagent blank.
(4) coi.or1metric method of
wilkinson (1976)
To 0-5 ml plasma was added 4-5 ml 0-33 m perchloric
acid in a conical centrifuge tube. After mixing and
centrifugation, 10 ml of the supernatant solution
was pipetted into a 10 ml tube, loosely stoppered, and
placed in a boiling water bath for 40 minutes. After
cooling, 1 ml 0 1 m o-cresol was added, followed by
2-0 ml 4 m NH^OH solution. The contents were
mixed and the blue colour was read at 615" nm
against a reagent blank.
Results
The precision and accuracy of the HPLC assay have
been reported (Adriaenssens and Prescott, 1978) and
the results obtained for unchanged paracetamol in
specimens from poisoned patients have been shown
to correlate well with a gas chromatographic method
(Howie et ah, 1977). Values obtained by HPLC were
therefore used as reference data. Since the data were
non-Gaussian in distribution the results obtained
using the different methods were compared with
HPLC using the Wilcoxon matched pairs test of
significance.
colorimetric nitration method (glynn
and kendal, 1975)
There was good agreement between the values
obtained using HPLC and the method of Glynn and
Kendal (r = 0-99). The mean values did not differ
significantly (p = 0-9879) and the correlation is
shown in Figure 2. This colorimetric method is
uninfluenced by the presence of paracetamol
metabolites.
Paracetamol (mmol't) byHPIC
Fig. 2 Comparison ofplasma paracetamol
concentrations measured by the colorimetric nitration
method ofGlynn and Kendo! {1975) and the reference
'{HPLC) method: n — 24: r — 0-99; 45'
line; regression line.
colorimetric method of welch and
conney (1965)
In every case the values for 'paracetamol' obtained by
this method greatly exceeded those obtained using
HPLC (Fig. 3). The mean value was about three
times higher and there was considerable variation in
the extent of the overestimate with a maximum dis¬
crepancy of 700% (Tablet (p < 0 0001).
To determine whether hydrolysis of the conjugates
to p-aminophenol was complete, the values obtained
for 'paracetamol' were compared with the sum of the
paracetamol, paracetamol sulphate, and paracetamol
glucuronide concentrations as estimated by HPLC in
each sample. The results (Fig. 4 and Table) shew
close agreement for both the individual values and
the mean value (p > 0-9). These observations con¬
firm complete hydrolysis of paracetamol and its
conjugates to p-aminophenol with this method.
colorimetric method of wilkinson
(1976)
The values obtained for paracetamol were again
\
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HPLC paracetamol (reference) 0-608
Colorimetric nitration (Glynn and Kendal, 1975) 0-603
Perchlorate hydrolysis (Wilkinson, 1976) 0-905







HPLC—total paracetamol and metabolites 1-468
PARACETAMOL (mmol/1) by HPLC 0.00 1.00 2.00
Fig. 3 Comparison ofplasma paracetamol concentrations
obtained using HCl hydrolysis (Welch and Conney, 1965)
with the reference (HPLC) method: n = 24; r = 0-98;
45° line; regression line.
greater than the HPLC values (Fig. 5) (p < 0 0001).
The mean value gave an average overestimate of 76%
(Table) with a maximum error of 423%. When the
paracetamol values obtained by this method were
compared with the sum of the concentrations of
paracetamol, paracetamol sulphate, and paracetamol
glucuronide as determined by HPLC, they were
always lower than the HPLC values for total para¬
cetamol plus metabolites (Table) (p < 0 0001).
These results suggested either incomplete hydro¬
lysis or loss of p-aminophenol. Aliquots of the
perchloric acid mixture were therefore sampled at
intervals during the 40 minute period of hydrolysis
and analysed directly by HPLC. The sample taken
after 10 minutes hydrolysis was of particular interest
since this is the time advocated by Love (1977) in his
modification of this method. The chromatograms
obtained are shown (Fig. 6). Paracetamol sulphate
had disappeared by 10 minutes, but even after 40
minutes hydrolysis both paracetamol and parace-
'<* Total paracetamol and metabolites (mmoi/1) by HPLC
Fig. 4 Compd -r'son ofplasma paracetamol concentrations
obtained using HCl hydrolysis (Welch and Conney,
1965) with total paracetamol and metabolites as
determined by HPLC: n = 24; r = 0-99;
45° line: — regression line.
tamol glucuronide were still present in large amounts.
The actual 'paracetamol' concentration is over¬
estimated to a variable degree as there is only partial
hydrolysis of the conjugates. The results are therefore
even more difficult to interpret than those from a
method which gives complete hydrolysis.
t
Discussion
Wiener (1978) mentioned the problem of non-
specificity of some methods in his review and quoted
the work of White (1976), which indicated that
paracetamol may be overestimated.
This study shows the extent to which methods that
involve a hydrolysis step without prior separation of
paracetamol from its polar conjugates overestimate
paracetamol. The methods of Wilkinson (1976) and
Love (1977) are particularly unsatisfactory since
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Fig. 5 Comparison ofplasma paracetamol
concentrations obtained using perchiorate hydrolysis
(Wilkinson, 1976) and the reference (HPLC) method:
n = 24; r — 0-96;——— 45° line;
regression line.
hydrolysis is incomplete and variable. Although this
serious disadvantage has been pointed out before
(Stewart, 1974; White, 1976) yet another method
with the same shortcomings was recently published
(Plakogiannis and Saad, 1978).
Since the concentrations of paracetamol conju¬
gates in plasma may exceed those of the unchanged
drug in patients with paracetamol poisoning, it is not
surprising that paracetamol may be overestimated by
as much as 700% with non-specific methods. The
highest ratios of conjugates to unchanged parace¬
tamol occur in patients without severe liver damage
(Prescott and Wright, 1973).
In practical terms, such serious errors are ofmajor
clinical significance. Misleadingly high values may
lead to unnecessary treatment with toxic agents such
as cysteamine, and a mistaken impression of the
efficacy of treatment may be gained. Paracetamol
concentrations as high as 7-4 mmc!/l were reported
by Jones and Thomas (1977) and were found on
subsequent enquiry to have been estimated by the
method of Wilkinson (1976). The results of a trial of
cysteamine in patients presenting more than 12 hours
after ingestion of paracetamol could not be inter¬































Pig- 6 High-performance liquid chromatograms showing paracetamol (P) and its glucuronide (C7) ond sulphate (S)
conjugates in plasma before and after hydrolysis in perchloric acid for 10 and 40 minutes. IS = internal standard
O^-propionyl-p-aminophenol).
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using the non-specific method of Welch and Conney
(Smith eta!., 1978; Prescott et a!., 1978a; Gilbertson
eta!., 1978). In another report (Rigby et a!., 1978)
unnecessary charcoal haemoperfusion was carried
out as a result of a misleading high plasma
paracetamol concentration measured by the method
of Welch and Conney.
The proper interpretation of plasma paracetamol
concentrations by the clinician depends on his under¬
standing of published data. This is at present
confusing, not only because of the multiplicity of
units in use (Prescott et a!., 1978b), but also because
of the continuing failure toappreciate the gross errors
introduced by the use of non-specific analytical
methods. Prognostic guides such as the treatment
line in Fig. 1 are useless unless used in conjunction
with accurate plasma paracetamol concentrations.
The failure of some laboratory analysts to appre¬
ciate the problem of non-specificity has been due, in
part, to the use of internal quality control plasma
containing weighed-in paracetamol. Such plasma
contains no conjugates and does not give false high
values with non-specific methods. For the same
reason, non-specific methods correlate well with
specific methods when synthetic, as opposed to
patients', specimens are used (Wilkinson, 1976).
The proper management of paracetamol poisoning
depends on the rapid availability of an accurate
estimate of the plasma paracetamol concentration.
Gas chromatographic and high-performance liquid
chromatographic methods are highly specific and are
among the most accurate by virtue of the use of
internal standards. Unfortunately they are not
always available and not the most convenient for
emergency analysis.
There are two accurate methods currently avail¬
able which may be carried out in small laboratories.
The colorimetric method of Glynn and Kendal
(1975) is not affected by paracetamol conjugates and
correlates well with HPLC as shown above, and with
GLC as reported by Chambers and Jones (1976).
The single point showing a result 107% higher than
the result by the reference method was close to the
origin and probably is a reflection of precision at this
level rather than specificity. The method is subject to
interference by other drugs including salicylate, and
the modification described by Mace and Walker
(1976) should be used if salicylate is present.
The method of Routh et al. (1968) and its modi¬
fication by Gibson (1972) are also adquate for
emergency use in the majority of cases. The latter has
been in use in the Royal Infirmary of Edinburgh for
over seven years and in our hands gives a coefficient
of variation of ±4-8%. The method suffers from
interference from a small group of drugs, of which
the barbiturates and phenylbutazone are the most
troublesome. In our experience, an abnormal UV
scan is obtained in 10% of specimens analysed; but
in only 4% is the interference likely to cause a
significant error.
According to Martin and Powell (1976), the
method ofGlynn and Kendal gives lower results than
the method of Routh et al. (1968). We have not con¬
firmed this and find that the UV method of Gibson
(1972) correlates well with the method of Glynn and
Kendal using samples from patients.
The methods of Routh et a!., Gibson, and Glynn
and Kendal are prone to occasional interference
from other drugs, whereas the methods ofWilkinson
(1976), Love (1977), Welch and Conney (1965), and
Plakogiannis and Saad (1978) consistently over¬
estimate paracetamol. Methods that involve acid
hydrolysis to p-aminophenol without prior separa¬
tion of paracetamol from its conjugates should no
longer be used in clinical chemistry laboratories.
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